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A Col9a3 EXON 3 SKIPPING AS NOVEL MODEL FOR MULTIPLE EPIPHYSEAL 
DYSPLASIA. 
Introduction: Multiple epiphyseal dysplasia (MED) is generally an autosomal dominant 
chondrodysplasia characterised by early-onset degenerative joint disease. Its genetic 
background is complex and heterogeneous and among the mutated genes are those encoding 
for the pro-α chains of the collagen type IX, COL9A1, COL9A2 and COL9A3, where the 
majority of mutations lead to the skipping of a syngenic exon. 
Aim: Reproduce in a mouse model the skip of exon 3 in the COL9A3 gene to understand its 
pathogenic role in relation to MED. 
Material and Methods: By CRISPR/Cas9 technology we generated two mouse lines, one 
carrying a deletion of Col9a3 exon 3 (Col9a3Δex3/Δex3), reproducing the splicing events 
reported in a MED patients group and a Col9a3-null mouse (Col9a3-/-). On the mutant mice, 
we performed skeletal X-ray phenotyping and growth plate analysis, including 
immunohistochemistry and BrdU labelling to monitor proliferation. Ultrastructure of growth 
plate was visualised using Transmission electron microscopy (TEM). Sequential protein 
extraction and Atomic force microscopy (AFM) were used to evaluate growth plate cartilage 
stability, whereas articular cartilage integrity was assessed by destabilisation of the medial 
meniscus (DMM) surgery and during ageing. Bone density and ultrastructure was assessed by 
Microcomputed tomography (μCT). Mutant transcriptomes were obtained by RNAseq. 
Results: The phenotyping of CRISPR/Cas9 generated offspring through DNA and cartilage 
RNA analysis had led to the establishment of two transgenic mouse lines, one splicing as 
predicted (Col9a3Δex3/Δex3) and a second lacking the Col9a3 transcript and collagen type IX 
protein (Col9a3-/-). Both lines are viable, however only Col9a3-/- mice displayed detectable 
phenotypic abnormalities: mild short stature and hip dysplasia, abnormal tibial epiphysis 
morphology and delayed ossification of femoral head in 18-week old mice. A reduced level 
of growth plate chondrocyte proliferation was detected in both mutant mice compared to WT, 
along with softening of the proliferative zone shown by AFM indentation measurements on 
new-born and 6 weeks old animals. Interestingly, both mutant mice exhibited similar 
transcriptome profiles. Only in Col9a3-/- mice immunoblotting of sequentially extracted 
matrilin-3 and COMP proteins revealed different cartilage extractability from controls. 
Articular cartilage integrity seemed not to be affected by either mutation. 
Discussion and conclusion: Analysis confirmed the production of a shorter transcript from 
cartilage of Col9a3Δex3/Δex3mice. However, these mice still produced collagen type IX protein 
and had no overt phenotype apart from reduced chondrocytes proliferation and softer 
proliferative cartilage extracellular matrix. The Col9a3-/- mice had a mild skeletal phenotype 
and express no Col9a3 transcript or protein, resulting in overall more unstable cartilage.  
Both mutant mice will represent an important tool to gain insights on collagen type IX role 
into the matrix. In particular, the Col9a3Δex3/ Δex3 line, by recapitulating human Col9-MED, 











1.1 Bone development 
During embryogenesis bone tissue forms from the mesoderm layer. More specifically 
the axial skeleton derives from the somites, the appendicular skeleton from the lateral plate 
mesoderm, and the cranial neural crest gives rise to the branchial arch and craniofacial bones 
and cartilage. Bone formation, also called osteogenesis, is the transformation of the 
mesenchymal tissue into bone tissue and this can occur through mainly two mechanisms, 
intramembranous or endochondral ossification. Intramembranous ossification is the process 
through which flat bones such as those constituting the skull form. This mechanism involves 
the direct transformation of mesenchymal tissue into bone and starts when proliferating 
mesenchymal cells condense into compact nodules, which gives rise to osteoblasts. As bone 
precursor cells, the osteoblast produce an ECM able to incorporate calcium salt and therefore 
allow for pre-bone matrix calcification. During this process some osteoblasts remain engulfed 
in the calcified matrix they have secreted, becoming bone cells, osteocytes, and bony spicules 
start to radiate while the bone ossifies. A membrane of compact mesenchymal cells 
surrounding the calcified spicules, the periosteum, also deposits osteoid matrix and 
contributes to bone growth (Gilbert 2000).   
Both ossification processes are regulated by various signalling pathways. These include 
members of the bone morphogenetic proteins (BMP), the fibroblast growth factor (FGF) 
groups and the Wnt signalling pathway (Shahi et al. 2017). Moreover, the activation of the 
transcription factor CBFA1, also known as Runx2, is responsible for mesenchymal cell 
transformation into osteoblasts and the activation of bone-specific extracellular matrix (ECM) 
protein genes (Komori 2010).  
Endochondral ossification is the mechanism that allows long bones to develop and grow. The 
stepwise process involves the formation of a cartilage template from aggregated 
mesenchymal cells, which is then replaced by bone (Fig. 1.1). Endochondral ossification 
initiates when mesenchymal cells are induced by paracrine factors to express two 
transcription factors, Pax1 and Scleraxis, which are believed to be activators of cartilage-
specific genes (Cserjesi et al. 1995, Sosic et al. 1997). Subsequently, the mesenchyme cells 
condense and differentiate into chondrocytes, which then proliferate and produce the ECM to 
form the cartilaginous template of the bone. Chondrocytes in the centre of the cartilaginous 
template become then hypertrophic, arrest proliferation and start secreting collagen type X 




promoting the generation of calcium and phosphate ions to permit the mineralisation of 
cartilaginous matrix. Finally, the majority of hypertrophic chondrocytes undergo apoptosis, 
facilitating blood vessel invasion and creating the space for the bone marrow. Blood vessels 
introduce osteoblasts, which produce bone matrix generating the primary ossification centre, 
which extends outwards in both directions to form the metaphysis of the newly formed bone. 
At the bone epiphysis secondary ossification centres form and only a cartilaginous area, 
called epiphyseal growth plate, remains between the primary and secondary ossification 
centres. This area is constituted by ordered chondrocytes organised into zones termed resting, 
proliferative, and hypertrophic and is responsible for longitudinal growth of the newly 
formed bone. In this area chondrocyte differentiation is tightly coordinated to allow 
longitudinal bone growth which continues as long as proliferation of growth plate 
chondrocytes occurs (Burdan et al. 2009). Within the resting or reserve zone, chondrocytes 
are small and uniform. They can be singular or in pairs, if they have divided, and are rich in 
lipid and cytoplasmic vacuoles. Resting chondrocytes proliferate at a low rate and have a 
reduced synthesis of proteoglycan and collagen type II. After the resting zone, the 
proliferative zone is present. Proliferative chondrocytes are flat and organised into 
longitudinal columns which with the immediate surrounding ECM, constitute the chondron. 
Mitotic activity is increased as well as the synthesis of collagen types II and XI. Below the 
proliferative zone is a layer known as the hypertrophic zone whose chondrocytes terminally 
differentiate and become larger. DNA synthesis is reduced and cellular division stops; 
conversely the synthesis of various components of the ECM is increased. Longitudinal 
growth of the skeleton is importantly affected by chondrocytes hypertrophy, as it has been 
reported that a great part of longitudinal growth depends on chondrocytes height, while the 
remaining on matrix synthesis and chondrocytes proliferation. Therefore, the differential 
growth of various bones seems to be related to differences in the size of hypertrophic 
chondrocytes (Ballock and O'Keefe 2003). Notably, the hypertrophic zone is the first zone 
that produces alkaline phosphatase, which by increasing phosphate ions, it allows the process 
of matrix calcification (Burdan et al. 2009).  
While longitudinal growth occurs, a simultaneous bone resorption is carried out by 
osteoclasts forming the endosteum, the fibrovascular membrane that lines the medullary 
cavity of a long bone. This process has the double function of reducing the bone weight and 
creating the space for the bone marrow. At the same time the osteoblasts in the periosteum, 
the membrane that covers the outer surface of all bones, increase the diameter of the bone 




alongside bone resorption, is responsible for a constant bone remodelling which helps 
maintaining the structural integrity of the bone (Rauch 2005). 
Longitudinal growth continues until adult age, after which the cartilage growth plate ossifies, 
fusion between epiphysis and metaphysis occurs and bone growth ceases completely. It is 
worth mentioning that a thin layer of cartilage is present on the surface of the bone epiphyses 
adjacent to the synovial cavity, and it is called articular cartilage. Its function is to facilitate 
joint movement, resist compressive forces and protect the underlying bone. As seen in the 
growth plate, also chondrocytes of articular cartilage follow a pattern of distinct layers 
according to their sub-population of cells and ECM organisation. The superficial zone, 
directly in contact with the joint space, produces a high level of lubricants and provides the 
ability to resist shear stress.  This zone is formed by elongated cells, tightly packed and 
arranged parallel to the joint cavity and they represent a source of cartilage progenitors 
(Kozhemyakina et al. 2015). The middle or transitional zone forms approximately half of the 
total articular cartilage volume and consists of very large and round sparse chondrocytes, 
followed by the deep zone where mostly organized into column-like stacks perpendicular to 
the tissue synovial surface. This zone represents the 30% of the total cartilage and its 
mechanical properties are due to the production of the typical cartilage matrix molecules, 
such as collagen type II and aggrecan (Sophia Fox et al. 2009). Between the deep zone and 
the underlying subchondral bone, is found the last zone called calcified cartilage, which is 
separated from the not calcified tissue by a visible tidemark (Fig. 1.2). In this last zone, cells 
are even larger, entered an hypertrophic state, are active in matrix production and likely 
responsible for interactions with the underlying subchondral bone (Decker et al. 2015).  
Disease- or ageing-driven degeneration of the articular cartilage surface leads to joint pain 






Fig. 1.1 | Endochondral ossification process. (A, B) Mesenchymal cells condense and 
differentiate into chondrocytes to form the cartilaginous model of the bone. (C) Primary centre of 
ossification forms when chondrocytes in the centre of the shaft undergo hypertrophy and apoptosis 
while they change and mineralize their ECM. Blood vessels can invade the empty spaces left by dead 
cells. (D, E) Blood vessels introduce osteoblasts, which bind to the degenerating cartilaginous matrix 
and deposit bone matrix. Secondary ossification centres also form as blood vessels enter near the tips 
of the bone. They are separated from the primary ossification centre by ordered zones of proliferating, 





Fig. 1.2 | The epiphyseal growth plate. Magnified image of a 3-week old rat proximal tibial 
epiphysis section stained with H&E. Indicated is the epiphyseal growth plate, whose structure is 
divided in different zones, which is positioned between the secondary ossification centre and the 
trabecular bone. In addition, the magnified picture of the articular cartilage surrounding the tibial 




1.2 The cartilage extracellular matrix 
In most multicellular complex organisms, cells and an intricate network of 
macromolecules, called the extracellular matrix (ECM), constitute the tissues.  Different 
ECM composition is expressed in different multicellular systems, as a result of the 
independent evolution of multicellularity in distinct lineages. Despite this, the basic functions 
of ECM, such as cell adhesion, cell-to-cell communication and differentiation, remain 
common features (Abedin and King 2010). The ECM in cartilage comprises a variety of 
proteins and polysaccharides that are secreted locally by chondrocytes. Once in the 
extracellular space, they assemble into an organised meshwork in close association with the 
surface of the cell that has produced them.  
Two main classes of extracellular macromolecules form the matrix: proteoglycans and 
fibrous proteins, such as collagen. In addition, glycoproteins, such fibronectin, laminin and 
elastin, have both structural and adhesive functions. Members of both classes come in a great 
variety of shapes and sizes. These molecules are mainly synthesised and secreted by stromal 
cells, such as fibroblasts, osteoblasts and chondrocytes. The proteoglycan molecules in 
cartilage form a highly hydrated, gel-like “ground substance” in which the fibrous proteins 
are embedded. This characteristic is given by the presence of several net negative charges 
that attracts positively charged sodium ions, which recruit water molecules via osmosis. This 
osmotic swelling gives to cartilage elastic properties, including the ability to resist 
compressive forces (Gentili and Cancedda 2009). This network enables the rapid diffusion of 
nutrients, metabolites, and hormones between the blood and the tissue cells. The collagen 
fibres are the main structural protein of the matrix, they contribute to the organisation of the 
matrix conferring it stability and specific mechanical properties according to the collagen 
content (Rozario and DeSimone 2010). Elastin fibres give it resilience. Finally, many matrix 
glycoproteins help cell binding in the appropriate locations, conferring typical structure and 
properties to cartilage. Moreover, cartilaginous ECM is remodelled continuously by a 
combination of synthesis and degradation by matrix metalloproteinases (MMPs) and ‘a 
disintegrin and metalloproteinase with thrombospondin motifs’ (ADAMTSs) proteinase 
family members (Takahashi et al. 2005). 
Considering the possible different nature and composition, the ECM can have many 
functions, such as providing support or regulating intercellular communication and cell 




growth factors, which can be released during altered physiological conditions, leading to the 
activation of a cascade of events affecting cellular functions.  
In addition to the zonal stratification according to structure and composition mentioned for 
growth plate and articular cartilage matrix, within each zone different regions of the matrix 
can be distinguished according to proximity of chondrocytes, composition and collagen fibril 
organization. The pericellular matrix (PCM) immediately surrounds the cell membrane and it 
is a thin layer mainly containing sulphated proteoglycans, glycoproteins and very fine 
collagen fibres tightly packed, forming a dense woven enclosure around the chondrocyte 
(Poole 1997). The major components of PCM are collagen type IX, perlecan, hyaluronan, 
biglycan and other small aggregates. Remarkable is the presence of collagen type VI around 
the chondrocytes (Poole et al. 1992). It is believed that this matrix region may play a role in 
the initiation of signal transduction within cartilage (Eggli et al. 1985). Around the PCM, the 
territorial matrix (TM) is thicker region formed by cross-banded fine collagen fibrils 
organised in a basket-like network surrounding the PCM. This tight organization of fibrils 
confers to this region the ability to withstand mechanical stress, hence giving mechanical 
resistance to the chondrons. Finally, the interterritorial matrix (ITM), is situated between the 
chondrons. It is constituted by thick collagen fibrils, assembled in small groups alternated by 
lerger interfibrillar spaces. The differentiation of matrix in various compartments allows for 
differential distribution and diffusion of metabolites applying a tight zonal control of various 
cartilage pathways (Eggli et al. 1985).  
 1.3 Collagens 
Collagen is the most abundant protein in mammals and in particular in humans account 
for one-third of the total protein content. Collagens represent the major component of 
connective tissues. Twenty-eight different types of collagen have been identified in 
vertebrates so far, constituted by at least 45 different polypeptide chains. Collagens provide 
both structural integrity and functional diversity within tissues and by interacting with 
specific receptors, provide signals (cellular adhesion, differentiation, growth and survival) to 
cells overlaying the collagen scaffold that can alter their behaviour (Mienaltowski and Birk 
2014b). The generic collagen structure is formed by a triple helical assembly of α-chains. A 
different gene can encode each distinct α-chain and the α-chains of one collagen type are 
unique and differ from the α-chains of another collagen type. Collagens molecules can be 




comprising α-chains encoded by different genes of the same collagen type. The primary 
structure of α-chains contains a variable number of conserved Gly-X-Y repetitive motifs 
(where X and Y are often proline and 4-hydroxyproline, respectively), which permit the 
formation of hydrogen bonds between chains (Gordon and Hahn 2010). The formation of a 
triple helix is possible thanks to the presence of the glycine residue, the smallest amino acid 
residue, as it lacks a side chain, and allows sufficient space and flexibility to tightly pack 
three chains in the structure. According to their structural and functional properties, collagen 
molecules can be grouped into seven subfamilies: 
• Fibrillar collagens are mainly present in connective tissues, they provide integrity and 
confer mechanical tensile strength. Collagen type I, II and III are the most abundant 
fibrillar collagens in vertebrates.  
• Network-forming collagens, through the interruption in their triple helical structure, 
they are more flexible and they can associate with each other, forming networks. They 
can also interact with other ECM components giving rise to multi-molecular 
complexes. Collagen type IV is a network forming collagen present in the pericellular 
matrix of normal and osteoarthritic articular cartilage (Foldager et al. 2014). Another 
example is collagen type X, found exclusively in the hypertrophic zone of growth 
plate and basal calcified zone of articular cartilage (Gannon et al. 1991). 
• Fibril-associated collagens with interrupted triple helices (FACIT) are characterised 
by the presence of non-collagenous domains that give flexibility to the molecule. 
FACIT closely interact with the surface of fibrillar collagens and link collagen fibres 
to each other and to other ECM molecules. They are also able to affect the surface 
properties of fibrils as well as fibril packing. Collagens type IX, XII, XIV and XX are 
FACIT collagens. Collagen type IX and type XII also possess covalently attached 
glycosaminoglycan side chains, and for this reason, they are also considered 
proteoglycans. Collagen type XII and XIV are expressed in musculoskeletal 
connective tissues, including tendons and ligaments at various times during 
development, and affect fibre supra-structures and tendon biomechanics (Ansorge et 
al. 2009b, Zhang et al. 2003). The general structure of FACIT collagens comprises 
short collagenous (COL) domains interrupted by non-collagenous (NC) domains with 




space. The two C-terminal domains, NC1 and COL1, are considered to interact with 
other type of collagen fibrils (Mienaltowski and Birk 2014a).  
• Anchoring fibrils are composed of collagen type VII that is a homotrimer flanked by a 
large and a small non-collagenous domains (NC1 and NC2). Collagen type VII 
molecules within the ECM usually dimerise in an antiparallel direction and are 
stabilised through disulphide bonds between the NC2 domains of the two molecules 
forming the dimer.  Many dimers then aggregate to form the basement membranes in 
the stroma of ECM (Chung and Uitto 2010). 
• Multiplexin collagens (types XV and XVIII), are characterised by the central triple 
helical collagen domain interrupted by several non-collagen regions and N- and C- 
terminal domains. Both are found in the basement membrane zones (Rehn and 
Pihlajaniemi 1994). 
• Transmembrane collagens include types XIII, XVII, XXIII, and XXV. These are 
expressed in different cell types and act as cell surface receptors. They have a single 
transmembrane domain with an extracellular C-terminal domain composed by 
collagenous and non-collagenous parts and a cytoplasmic N-terminal domain 
(Mienaltowski and Birk 2014b). Of the transmembrane collagens, collagen type XIII 
is found in musculoskeletal tissues, particularly in myotendinous and neuromuscular 
junctions (Heikkinen et al. 2012, Latvanlehto et al. 2010). 
• Collagen type XXVIII is expressed in peripheral nerves and has the triple helix 
flanked by a von Willebrand factor A (vWFA) structure at both N- and C- terminals 
(Gebauer et al. 2016). 
1.4 Formation of Collagen Fibrils 
After translation, collagen polypeptides have globular propeptide extensions at each 
end and a signal sequence at the N-terminal that is recognised by a signal recognition particle 
on the endoplasmic reticulum (ER) to target them from the ribosomes to the ER. At this level 
molecules are referred to as pre-procollagen (Hulmes 2008). Once in the ER, three post-
translational modifications take place. First, the signal sequence is cleaved to form a 
propeptide. Then hydroxylases add hydroxyl groups to proline and lysine residues to allow 




of glucose or galactose to the hydroxyl groups of lysines. Then the hydroxylated and 
glycosylated propeptides twist and form a triple helix, now called procollagen (Khoshnoodi 
et al. 2006). Consequently, procollagen is delivered to the golgi apparatus for its 
glycosylation and then transported to the extracellular space by secretory vesicles. Once 
outside the cell, the two globular propeptide extensions at both ends of the collagen triple 
helix, are removed by specific N- and C- terminal collagen peptidases, triggering in this way 
fibril formation. Finally, an extracellular enzyme, named lysyl oxidase, transforms the several 
lysines and hydroxylysines amino groups into aldehydes that covalently crosslink each other, 
stabilising the collagen fibrils. The C-propeptide function is to direct the intracellular 
assembly of the procollagen molecule from its three constituent α-polypeptide chains. The 
general model proposed for fibril assembly that occurs in the extracellular space, is a 
concentric model that follows energy minimisation, whose result is a helicoidal organisation 
of collagen where molecules are leaning obliquely to the fibril surface (Hulmes et al. 1981). 
A tight control of fibril diameter and shape (along with heterotypic collagen interactions and 
interactions with other matrix components), is maintained in part by the N-propeptide, which 
is not immediately cleaved. Its presence functions to prevent incorporation into the centre of 
the fibril, thereby forcing all N-termini to the surface of the fibril, preventing further growth 
and limiting fibril diameter. This might provide a mechanism for diameter control for 
heterotypic collagen interactions such as types II/XI and IX in cartilage (Hulmes 2002). 
Fibrils are made by collagen molecules that are staggered with each other creating the typical 
repeating banding pattern. An overview or the main steps of collagen biosynthesis is shown 





Fig. 1.3 | Overview of the steps involved in the production of collagen. After translation, 
procollagen chains undergo a large number of post-translational modifications (hydroxylation and 
glycosilation) that occur in the ER and the Golgi. At this level, the polypeptides are brought together 
by interactions between the C-propeptides and fold to form a rod-like triple-helical domain flanked by 
globular N-and C-propeptides. The removal of the N-and C-propeptides from fully folded procollagen 
only occurs after transport of procollagen from the Golgi stacks to the extracellur space, and results in 
collagen molecules that are then able to assemble into fibrils. Covalent crosslinks occur within and 
between triple-helical collagen molecules in fibrils. (Image source: cellbiology.med.unsw.edu.au/). 
1.5 Cartilage collagens 
Among the collagens specifically expressed within cartilage, we find types II, III, VI, 
IX, X, XI, XII and XIV. Cartilage fibrils are usually referred to as collagen type II which is 
the most abundant of the fibrillar framework, accounting for 90% of the total cartilage 
collagen. Collagen type II disorders comprise a diverse group of clinical phenotypes 




features, whose severity ranges from perinatal severe lethal disorders to milder conditions 
appearing in adulthood (Gregersen and Savarirayan 1993-2019). Collagen type II provides 
tensile strength, is resistant to shearing forces and supports chondrocyte adhesion. However, 
the protein by itself is incapable of forming fibrils of the extensive lengths required in the 
tissues. It is instead always found as macromolecular composites, which include collagen 
type IX and XI (Mendler et al. 1989).  Collagen type IX is a member of the FACIT family 
and it interacts with collagen type II and other components of cartilage ECM (for a fuller 
description see section 1.6 of this chapter). The biogenesis of the heterotypic collagen type 
II/IX/XI macromolecular structure and its functional complexity in cartilage fibrils is not 
fully understood. Overexpression of normal collagen type II in mice leads to a highly 
disorganised growth plate cartilage that contains abnormally wide fibrils with a strong 
banding pattern. This suggests the crucial importance of the correct molar proportions of 
cartilage collagens in fibrillogenesis (Garofalo et al. 1993). In addition, it is believed that 
collagen type XI is essential for the regulation of the lateral fibril growth (Blaschke et al. 
2000). Direct evidence for this concept came from studies of in vitro fibrillogenesis by 
mixtures of soluble cartilage collagens (Eikenberry E. F. 1992). It was found that collagen 
type XI was essential in restricting lateral growth of collagen type II fibrils to a uniform 
width of about 20 nm, typical of cartilage fibrils (Blaschke et al. 2000). Collagen type II is 
known to interact with other ECM component to create a tight network between matrix and 
chondrocytes, aimed to facilitate and improve the stability of the tissue structure. Among its 
direct interactors there are the integrin receptor α10β1 (Camper et al. 1998), the 
proteoglycans fibromodulin and decorin (Hedbom and Heinegard 1993) as well as annexin V 
(Kim and Kirsch 2008), matrilin-1 (Winterbottom et al. 1992), matrilin-3 (Fresquet et al. 
2007) and COMP (Rosenberg et al. 1998). 
Collagen type III is a homotrimeric fibrillar molecule and is present in smaller amount 
compared to collagen type II in adult articular cartilage, where it localises onto the rest of the 
collagen fibril network. Its function seems to be reinforcing weakened collagen type II fibril 
networks in cartilage, as it is often present in sites of healing and repair (Wu et al. 2010). 
Three distinct α–chains constitute the collagen type VI monomers. These monomers 
assemble in an antiparallel direction to form dimers, which then cross-link together to form 
the tetramers that make up collagen type VI microfibrils (Gelse et al. 2003). Moreover, its 
supramolecular assembly in antiparallel dimers and tetramers begins inside the cell. 




called beaded filaments. These microfibrils are localised predominantly to the pericellular 
matrix, bind to both decorin and biglycan (Wiberg et al. 2003) in vitro, and are proposed to 
integrate the cartilage fibrillar network that includes collagen type II (Budde et al. 2005). 
Collagen type VI disorders have a continuum spectrum of overlapping phenotypes 
encompassing Bethlem myopathy at the mild end and Ullrich congenital muscular dystrophy 
(CMD) at the severe end (Lampe et al. 1993-2020).  
Collagen type X is present in the cartilage growth plate and localises in the hypertrophic 
zone. It is a short-chain homotrimeric α1(X)3 collagen that is synthesised exclusively by 
hypertrophic chondrocytes during endochondral ossification. Collagen type X usually 
assembles into a hexagonal mesh-like network (Kwan et al. 1991), but it can also exist as a 
fibril-associated form in foetal cartilage (Schmid and Linsenmayer 1990). Collagen type X is 
a reliable marker for new bone formation in articular cartilage since it facilitates 
endochondral ossification through the regulation of matrix mineralisation and 
compartmentalisation of matrix components (Shen and Darendeliler 2005). Mutations in the 
COL10A1 gene cause Schmid metaphyseal chondrodysplasia (MCDS) (OMIM # 156500). 
COL10A1 pathogenic variants cause collagen type X protein misfolding which leads to 
aggregation within the ER of hypertrophic chondrocytes, triggering ER stress and activation 
of UPR, underlying the development of the MCDS (Rajpar et al. 2009).  
Apart from Collagen type IX, other two members of the FACIT subfamily are expressed in 
cartilage, collagens type XII and XIV. Collagen type XII has been proposed to be involved in 
the regulation of cellular communication during bone formation (Izu et al. 2011). Conversely, 
collagen type XIV is known to regulate fibrillogenesis by regulating the entry of fibril 
intermediates into lateral fibril growth (Ansorge et al. 2009a). Finally, member of the 
collagen fibrillar family, collagen type XXVII localises throughout the growth plate and it is 
believed to play a role in the transition of cartilage into bone (Hjorten et al. 2007). 
During cartilage development spatial and temporal changes occur in the expression of 
different types of collagens. For instance, Collagen types I and III are more abundant in the 
mesenchymal matrix of the developing limb bud. However, when chondrogenesis starts and 
mesenchymal cells condensation occurs, gene expression switches to the production of 
collagen types II, IX and XI (Kosher et al. 1986). In addition, as stated before, the expression 
of collagen type X is specific to hypertrophic chondrocytes of the growth plate. Furthermore, 




one example is the case of collagen type VI, which is more abundant in fibrillar cartilage, 
compared to elastic or hyaline cartilage (Eyre 2002). Finally, an important reduction of 
collagen synthesis occurs once skeletal growth is complete, and at this point 
production/remodelling of the fibril network is active only after injury events. Other factors 
that can alter the abundance and ratio of the components of the fibrillar network are the 
proteolytic and mechanical damages that occur during arthritis-like disorders (Bonnans et al. 
2014). 
1.6 Collagen type IX 
Collagen type IX, a FACIT subfamily member, represents about 1% of the collagenous 
proteins in adult mammalian articular cartilage and 10% in foetal cartilage (Eyre 1991). 
Collagen type IX is found mostly in cartilage, but it also occurs in the eye (vitreum and avian 
cornea), ear (tectorial membrane), and intervertebral disc. It is a heterotrimeric collagen, 
whose structure comprises three α-helical polypeptide chains, α1(IX), α2(IX), α3(IX) 
encoded by three different genes, COL9A1, COL9A2 and COL9A3, respectively. Each 
collagen type IX α chain comprises three collagenous domains (COL1-COL3) separated by 
three shorter non-collagenous domains (NC1-NC3), which add flexibility to the usually rigid 
collagen molecule (Olsen 1997) (Fig.1.4).  
 
Fig. 1.4 | Schematic representation of collagen type IX structure. The molecule contains 
three collagenous domains, COL1, COL2 and COL3, and four non-collagenous domains, NC1-NC4 
(Olsen 1997).  
Two isoforms of collagen type IX are known, a short and a long form. This is due to the 
presence of two transcription start sites at a distance of 20 kilobases with each other in 
COL9A1 which give rise to two α1(IX) variants. mRNA transcripts from the upstream site 
encode a large N-terminus globular NC4 domain of 266 amino acids, whereas the transcripts 




NC4 domain. The long form is prevalently expressed in cartilage, whereas the shorter form of 
the mRNA transcript is mainly found in cornea and the vitreous of the eye. The incorporation 
of either form in the ECM is believed to contribute to the differences in the macromolecular 
organisation of the ECM in cartilage and cornea (Nishimura et al. 1989). It is hypothesised 
that the presence or absence of the amminoterminal region of the α1(IX) chain to act as 
discriminator for ligands, creating different ligands selection in different tissues. More 
specifically, it has been speculated that the amino-terminal globular domain of cartilage 
collagen type IX molecules interacts with the anionic glycosaminoglycan side chains of 
cartilage proteoglycans, providing a molecular link between collagen fibrils and 
proteoglycans. The absence of such a domain in the corneal form of the molecule is 
consistent with the absence of the large aggregating proteoglycans in cornea. The rate of 
transcription of each α1(IX) is not known, however it is believed that these rates depend on 
tissue specific transcription factors level or activity in corneal cells and chondrocytes. It is 
also believed that the ratio between the two transcript types may vary depending on specific 
physiological or pathological conditions. For example, in conditions characterized by 
cartilage degradation such as rheumatoid arthritis, it is possible that chondrocytes may 
contain higher levels of the short (corneal) form of α1(IX) collagen mRNA and that the 
synthesis of collagen IX molecules that lack the amino-terminal globular domain contributes 
to the pathological changes in the cartilage matrix (Nishimura et al. 1989). This hypothesis is 
supported by the observation of the presence of a sequence element in the downstream 
α1(IX) promoter, which is involved in regulation of the collagenase and stromelysin (a matrix 
metalloprotease) genes (Angel et al. 1987). Therefore, it could be speculated that the 
conditions that lead to an increased transcription of these genes also produce increased levels 
of the corneal form of α1(IX) mRNA. 
As member of the FACIT subfamily, collagen type IX molecules are found periodically 
organised along the surface of collagen type II/ type XI fibrils, forming therefore a 
heterotypic structure, with the COL3 domain functioning as mobile hinge to allow the NC4 
domain to project into the perifibrillar space (Eyre et al. 2004) (Fig. 1.5). The COL1 and 
COL2 domains are believed to maintain the correct linear distance between type II collagen 
molecules (Asamura et al. 2005). Additionally, a chondroitin sulphate (CS) 
glycosaminoglycan (GAG), is attached to a serine residue of α2(IX) NC3 domain (Huber et 
al. 1988). Covalent crosslinks connect collagen type IX with collagen type II molecules and 




control the assembly, growth and diameter of the fibrils, a function fulfilled thanks to the 
unprocessed N-terminal non-collagenous domain of collagen type II (Gelse et al. 2003). 
Supporting this, chondrocytes deficient in collagen type IX exhibit fibrils with a larger 




Fig. 1.5 | Supramolecular structure of collagen type IX alongside collagen type II. 
Collagen type IX associates via cross-links with the surface of the collagen type II and XI fibrils in an 
antiparallel direction. The globular NC4 domain and the triple-helical COL3 domain project out from 
the fibril surface whereas the CS-chain, covalently attached to a serine residue of α2-NC3 domain,  
faces down and inserts itself into the macromolecular structure (Muragaki et al. 1996).  
Along with the collagen type II and XI interactions, studies showed that collagen type IX has 
the ability to bind to other non-collagenous components of the ECM such as matrilin-3 
(Budde et al. 2005), COMP (Holden et al. 2001), fibronectin (Parsons et al. 2011), heparin 
(Pihlajamaa et al. 2004), fibromodulin (Tillgren et al. 2009), and various integrins (Sandya et 
al. 2007). These findings suggest collagen type IX to act as a macromolecular bridge between 
collagens fibrils and other matrix macromolecules (Shaw and Olsen 1991). Proteomic 
analysis on cartilage of collagen type IX null mice has given more insights about 
direct/indirect physical or genetic interaction of collagen type IX and other proteins. For 
example, along with higher expression of fibronectin detected in collagen type IX null mice, 
also the TGFβ-induced protein Tgfbi and collagen type XII were increased, while epiphycan, 
a small leucine-rich PG involved in fibril assembly, was reduced in abundance. These 




normal pattern of TGFβ signalling and fibril-assembly in the developing cartilage, as well as 
creating some sort of potential compensation through expression of another FACIT collagens  
(Brachvogel et al. 2013). 
Mice lacking collagen type IX develop non-inflammatory degenerative joint disease with 
pathological changes comparable to some of those seen in human OA, suggesting the 
collagen type IX crucial role in maintaining the mechanical stability of articular cartilage 
(Fassler et al. 1994). Further details about mice carrying mutations in collagen type IX will 
be described in section 1.9.3 Collagen Type IX mice  
1.7 Skeletal dysplasias 
Skeletal dysplasias are an extremely heterogeneous and complex group of rare diseases 
that affect the development, organisation and homeostasis of the skeleton. Among the 
different mechanisms causing skeletal dysplasia, there are the alterations of ECM 
components or the establishment of an intracellular stress which lead as consequence to an 
abnormal change to chondrocyte proliferation and survival. These generalised heritable 
disorders of the bone and cartilage have an incidence of 1.3–3.2 per 10,000. The International 
Skeletal Dysplasia Society, in its latest nosology and classification of genetic skeletal 
disorders, identified a total number of 461 well-characterised phenotypes (Mortier et al. 
2019). In this classification, these genetic disorders have been grouped according to clinical 
and radiological patterns along with the molecular ontology, giving rise to a total of 42 
different groups caused by mutations in 437 genes identified in 425 listed disorders. 
Chondrodysplasias show a broad spectrum of phenotypic severity, varying from some 
disorders associated with mild disability, to others that are lethal at birth. Moreover, great 
variability is also found between chondrodysplasias belonging to the same group, and 
symptoms can sometimes differ between individuals carrying the same mutation. It is 
therefore extremely challenging to understand the causes underpinning the onset of each of 
these disorders and finding an adequate treatment. Moreover, the importance of studying 
skeletal dysplasias relies also on the fact that the knowledge gained by investigating these 
rare disorders can be applied to understanding more general mechanisms of cartilage 
degradation, such as that seen in OA. The focus of this Thesis is to further investigate 




loci with pseudoachondroplasia (PSACH), and a continuum of phenotypic severity, hence 
belonging to the same bone dysplasia group (Table 1.1).   
1.7.1 Multiple Epiphyseal Dysplasia and Pseudoachondroplasia group 
Initially considered as two different entities, MED and PSACH are now classified 
together as a group of skeletal dysplasia comprising a continuum of clinical spectrum, from 
the more severe cases of PSACH to the mild forms of MED, without excluding a certain 
extent of phenotypic overlap between the two.  
Pseudoachondroplasia is an autosomal dominant inherited condition characterised by a more 
severe phenotype than MED.  Patients are usually diagnosed with PSACH early in life, when 
at the onset of walking they exhibit a waddling gait. Among the PSACH clinical findings are 
marked short stature and deformity of the legs, short fingers typical of brachydactyly, loose 
joints, ligamentous laxity and myopathy, but normal facial features, head size and 
intelligence (Briggs and Chapman 2002). Often the joint pain developed during childhood 
progresses into early onset osteoarthritis leading to joint replacement therapy early in life. 
Patients show small and irregular epiphyses, irregular metaphysis, and a delay in the 
ossification of annular epiphyses of the vertebrae upon radiographic analysis.  A milder form 
of PSACH is recognised sharing clinical similarities with MED (Maroteaux et al. 1980).  
Multiple epiphyseal dysplasia is a clinically heterogeneous ostechondrodysplasia whose 
incidence is about 1 in 10,000 people. The disorder is milder than PSACH, but its clinical 
features were initially classified into two kinds of MED, the milder Ribbing type and the 
more severe Fairbank type. The Ribbing type of MED comprises short stature, flat epiphyses, 
and consequently early-onset OA of the hips, whereas the Fairbank type is recognised 
because of the dwarfism, stubby fingers, and small epiphyses of several joints, including the 
hips (Fairbank 1947). Among the symptoms, MED patients suffer from pain and stiffness of 
multiple joints during childhood and adolescence and development of OA in late childhood to 
adulthood. In some patients only radiological evidence of MED or OA have been reported, in 
the absence of joints pain (Oehlmann et al. 1994) and in some forms of MED stature is not 
affected and patients are of normal height. However, MED associated phenotypes are 
extremely variable and sometimes families remain unclassified because their phenotype does 




Only mutations in the gene coding for the cartilage oligomeric matrix protein COMP have 
been reported to cause PSACH (Briggs et al. 1995). However, the genetics of MED is more 
complex. MED can be either dominant or recessive and is more genetically heterogeneous 
since mutations in several genes, the majority coding for ECM components, have been 
identified in patients. The autosomal dominant forms are caused by mutations in COMP 
(COMP) (EDM1; MIM# 132400), matrilin-3 (MATN3) (EDM5; MIM# 607078) and in the 
collagen type IX genes (COL9A1 (EDM6; MIM# 120210), COL9A2 (EDM2; MIM# 120260) 
and COL9A3 (EDM3; MIM# 600969)). The recessive form of MED results from mutations in 
the diastrophic dysplasia sulphate transporter (SLC26A2) (EDM4; MIM# 226900) and rarely 
in mutations in CANT1 (EDM7; MIM# 617719) coding for calcium‐activated nucleotidase 1. 
However, an estimation of the incidence of the dominant and recessive forms is difficult, 
since both forms of this disorder may actually be more common and some people with mild 
symptoms may never be diagnosed. Nonetheless, it is estimated that mutations in COMP are 
responsible for at least half of the cases of MED, followed by SLC26A2 mutations, which 
account for one-quarter depending on ethnicity. The remaining 25% of clinical cases, when 
classified, are due mainly to mutated MATN3, then to a lesser extent mutations in COL9A1, 
COL9A2 or COL9A3 genes (Unger et al. 2008). Nevertheless, for a great portion of MED 
cases, the underlying genetic cause remains still unknown.  
Studies conducted on PSACH and the dominant forms of MED showed that in mice 
expressing the mutant forms of COMP or matrilin-3, ER stress which then affected as 
consequence chondrocyte proliferation and apoptosis, was detected in these mice. From these 
findings, arises the idea that the reduced proliferation and an increased and spatially 
dysregulated apoptosis, probably resulting in disrupted linear bone growth, could be 
considered the common disease mechanism for PSACH and dominant MED bone dysplasia 
family (Briggs et al. 2015). The disease mechanism of MED caused by collagen type IX 
mutations is still unknown and later in this thesis some of the most relevant findings leading 
to possible hypothesis will be discussed. When the recessive form of MED was investigated 
using a Dtdst knock-in mouse with a partial loss of function of the sulfate transporter, 
homozygous mutant mice were characterized by growth retardation, skeletal dysplasia and 
joint contractures. Along with the impaired sulfate uptake leading to a significant cartilage 
proteoglycan undersulfation, the reduced proliferation and/or lack of terminal chondrocyte 
differentiation was also hypothesised to contribute to the reduced bone growth (Forlino et al. 
2005), as similarly considered for the dominant forms of MED. The mechanisms underlying 




CANT1 is localizes to the Golgi and is involved in the synthesis of glycosaminoglycans 
(GAG) and the posttranslational modification of proteoglycans. Nixon et al. demonstrated 
that fibroblasts with impaired CANT1 have reduced GAG synthesis due to the inability of 
CANT1 to transform UDP in UMP (Nizon et al. 2012). Based on this observation, it is 
hypothesised that CANT1-MED results from an indirect effect on normal ECM biosynthesis, 
due to the incorporation of many ECM proteins whose GAG posttranslational modifications 





Table 1.1 | Multiple epiphyseal dysplasia and pseudoachondroplasia disease phenotype 
spectrum and related allelic disorders. Adapted from (Mortier et al. 2019). MIM No.: numerical 
assignment for inherited diseases, genes and functional segments of DNA, as listed in the 





1.7.2 Matrilin-3 in MED  
Matrilin-3 is a protein encoded by MATN3 and is a member of a family of oligomeric ECM 
proteins which share a similar domain structure (Deak et al. 1999). Matrilin-3 structure 
comprises a signal peptide, vWFA domain, four epidermal growth factor (EGF)-like domains 
and a coiled-coil oligomerisation domain (Belluoccio et al. 1998). Matrilin-3 is 
predominantly found as a homotetramer, but it can also oligomerise with matrilin-1 to form 
heterotetramers (Wu and Eyre 1998). While expression of matrilin-1 is exclusively cartilage 
specific, matrilin-3 is expressed in both cartilage and bone (Segat et al. 2000, Klatt et al. 
2000), and more precisely in cartilage it is usually localised in the pericellular and 
interterritorial matrix of all growth plate zones (Klatt et al. 2002). Expressed during the early 
development of the skeleton, matrilin-3 has been proved able to interact with other important 
ECM components such as COMP, collagen type II and the collagenous domains of collagen 
type IX, sometimes in an ion dependent manner (Budde et al. 2005, Fresquet et al. 2007).  
The vast majority of the mutations identified in MATN3 and responsible for MED (EDM5) 
are missense variants localised in exon 2, which encodes for the vWFA domain of the 
protein. Only one mutation (p.Arg70His) has been identified in exon 1, which localises in the 
proximity of the vWFA domain and is believed to have a role in maintaining its structure and 
function (Maeda et al. 2005). Among those mutations of the vWFA domain, about 70% are 
variants affecting the β-sheet of the domain, while the remaining 30% have been identified in 
the α-helices of the same domain (Briggs et al. 1993-2019). In vitro and in vivo studies have 
suggested that these pathogenic variants are responsible for the misfolding of the vWFA 
domain which interferes with correct protein trafficking, eventually resulting in protein 
accumulation in the ER (Cotterill et al. 2005, Leighton et al. 2007, Nundlall et al. 2010, Otten 
et al. 2005). 
Notably, a high intrafamilial MED phenotype variability results from MATN3 mutations 
(Mortier et al. 2001), suggesting a contribution of other modulators to the phenotype of 
EDM5. 
1.7.3 COMP in MED 
COMP is a secreted pentameric glycoprotein of 524KDa (Hedbom et al. 1992) which is 




Cesare et al. 1997, Fang et al. 2000, Maddox et al. 1997). In the epiphyseal growth plate 
COMP is localised in the territorial matrix of resting, proliferating and pre-hypertrophic 
zones.  COMP is a modular protein that belongs to the thrombospondin (TSP) family and its 
structure is organised in a coiled-coil oligomerisation domain, four type II (EGF-like) repeats, 
eight type III (calmodulin-like) repeats and a large C-terminal globular domain (Newton et al. 
1994). Within the ECM, COMP is able to bind to fibrillar and non fibrillar collagens and 
other proteins. Interactions with collagen type I, collagen type II, collagen type IX (Thur et 
al. 2001), fibronectin (Di Cesare et al. 2002), aggrecan  (Chen et al. 2007), matrilins and 
integrins are reported (Fresquet et al. 2008, Mann et al. 2004, Chen et al. 2005). Moreover, 
Posey et al. proposed a role of COMP in regulation of collagen fibre diameter during their 
assembly (Posey et al. 2008a). Mutations in COMP cause PSACH and MED (EDM1). 
Around 85% of PSACH and MED mutations are localised in the T3 repeats, whereas the 
remaining 15% have been reported in the C-terminal domain of COMP (Suleman et al. 2012). 
PSACH-causing mutation are often missense, in-frame insertions/deletions mutations and 
have a dominant negative effect. Studies have shown that consequences of this dominant 
negative effect are identified into retention of mutant COMP into the rRER along with other 
ECM proteins (Hecht et al. 2005), leading to an ER overload response  or alternatively into a 
partial secretion of mutant forms of COMP with potential ECM stability implications, while 
complete knock-out of COMP has no effect. The most common described is the in-frame 
deletion of an aspartic acid residue (p.D469del) from the seventh T3 repeat (T37), which 
accounts for approximately 30% of all PSACH (Suleman et al. 2012).  
MED-causing mutations in COMP are responsible for the most severe and also most 
prevalent form of MED (Unger et al. 2008). Also for MED, COMP mutations are missense, 
insertions or deletions and they have been identified in exons coding for the T3 repeats and 
the C-terminal globular domain, despite the majority of deletions and insertions cause 
predominantly PSACH rather than MED. 
There seem to be a correlation between the site of mutations and severity of the phenotype 
leading to MED or PSACH. It has been reported that missense mutations in the residues of 
T34 and T35 are more likely to result in MED, while mutations in T36–T38 will result in 
PSACH. In addition, it has been demonstrated that in position 473 of COMP, deletion or 
duplication of one or more aspartic acid residues result in either PSACH or MED (Briggs et 




1.7.4 Collagen type IX in MED 
Among the different types of MED, those caused by mutations in the collagen type IX 
genes (EDM2, EDM3, EDM6) are relatively benign. The typical features of COL9-MED 
patients are pain and stiffness mainly in the knee joints, symptoms which tend to appear late 
in patients’ life. The phenotype consists of epiphyseal dysplasia mainly of the knee but also 
of other joints are reported in childhood, with osteochondritis dissecans and osteoarthritis of 
the knee joints in adulthood (Lohiniva et al. 2000). Stature is generally not affected. Notably, 
no effect on sight or hearing is reported in COL9-MED patients, differently from another 
disorder caused by collagen type IX mutations, Stickler syndrome, which will be described in 
section 1.8. 
Surprisingly, all but one mutation reported thus far (Table 1.2) cause splicing defects 
consistently affecting the same region of the collagen type IX protein; the COL3 domain 
(Fig. 1.5). In COL9A2 and COL9A3 the COL3 domain is encoded by exons 2 to 10, and by 
exons 8 to 16 in COL9A1. The mutations reported in COL9A2 and COL9A3 affect only the 
splice acceptor sites in intron 2, splice donor sites in intron 3 and 5′ and 3′ regions of exon 3 
(Bonnemann et al. 2000, Holden et al. 1999, Lohiniva et al. 2000, Muragaki et al. 1996, 
Nakashima et al. 2005, Paassilta et al. 1999, Spayde et al. 2000, van Mourik et al. 1998b). 
When assessed, these mutations cause the skipping of exon 3 during splicing, leading to an 
in-frame deletion of 12 amino acids residues within the COL3 domain. An insertion mutation 
has been reported in exon 8 of COL9A1 gene in MED patients, leading to a complex splice 
pattern involving mainly exons 8 and 10 and causing the deletion of an equivalent region of 
the COL3 domain of collagen type IX. (Czarny-Ratajczak et al. 2001). Of all the MED forms 
described, the least is known about the disease mechanism in the collagen type IX variants. 
During collagen fibril formation, collagen α chains are associated through the C-terminal 
ends of the peptides, followed by triple helix formation that progresses towards the N-
terminus (Engel and Prockop 1991). It is therefore questionable, considering the position of 
the COL3 domain in the whole protein, whether the 12 amino acid deletion is likely to 
prevent the synthesis or assembly of collagen type IX molecules, as suggested by evidence of 
enlargement of ER reported in some patients (Bonnemann et al. 2000). Alternatively, the 
mutations might interfere with the interactions between collagen type IX and other matrix 
collagens, such as collagen type II fibrils. However, in an electron microscopy examination 
of articular cartilage of MED patients with a COL9A2 splicing mutation, no differences were 




appearance and a lack of inclusion bodies (van Mourik et al. 1998a, Muragaki et al. 1996). 
Despite this, the deletion is likely to affect the structure and the putative function of the 
COL3 and NC4 domain in mediating the interactions between the fibrils and other matrix 
components (Douglas et al. 1998, Nakata et al. 1993). Evidence of this was reported in a 
study concerning the characterisation of recombinant matrilin-3, a heterotrimeric protein 
important component of cartilage ECM. In the study, matrilin-3 A-domain was shown to bind 
to the COL3 domain of collagen type IX, but this binding was abolished by the in-frame 
deletion of the 12 amino acids from the COL3 domain of the α3(IX) chain (Fresquet et al. 
2007). However, it is entirely possible that type IX collagen has a matrilin-3 binding site that 
involves all three α-chains, which could explain the reason why all collagen IX mutations 
characterised thus far result in an identical deletion in the COL3 domain, which is likely to 
play an important role in the pathogenesis of MED. 
1.7.5 EDM3 Clinical cases 
COL9A3 was proposed as a new and third locus for MED when in 1999, in a family 
diagnosed with a history of MED where no linkage was found with COMP, COL9A1, or 
COL9A2, the genes at the time known to be MED associated. The clinical spectrum presented 
by this family involved mainly knee joint problems with some individuals also presenting 
limited extension of the hip, but with an overall normal stature. When mutation analysis was 
performed, researchers found an A→T transversion in the acceptor splice site of intron 2 
(A−2IVS2→T) of COL9A3. As a consequence of this mutation exon 3 of COL9A3 was 
skipped and an in-frame deletion of 12 amino acid residues in the COL3 domain of the α3 
(IX) chain was proposed to be generated (Paassilta et al. 1999). This case was similar to the 
MED mutations reported previously in COL9A2 (Muragaki et al. 1996, Spayde et al. 2000, 
van Mourik et al. 1998b).  
The following year Bönnemann et al. described another family diagnosed with autosomal 
dominant MED, whose symptoms were predominantly localised at the knee joints along with 
a mild proximal myopathy. Genetic analysis indicated COL9A3 as the locus where a splice 
acceptor mutation in intron 2 occurred due to a G →A transition (G−1IVS2→A). Similarly to 
the previously reported case, this mutation resulted in an mRNA also lacking exon 3 and the 
corresponding encoded 12 amino acids. When studies were performed on patient epiphyseal 




protein (Bonnemann et al. 2000). Interestingly, in an independent study, muscle weakness 
was also reported in the proband of a MED family with the same G−1IVS2→A mutation 
(Lohiniva et al. 2000). 
Nakashima et al. then identified a novel COL9A3 mutation in 2005 in a family suffering from 
mild dysplasia of the hip, knee and ankle. The patients’ stature was normal, and the OA 
phenotype of the knee was similar to idiopathic OA of age-matched individuals. Mutation 
analysis reported a G+5IVS3→A mutation in the splice donor site of intron 3 of COL9A3. 
RNA analysis confirmed the in-frame deletion of exon 3 as result of this mutation, 
representing the first evidence of a splice donor mutation having the same effect of the 
previously reported acceptor site mutations (Nakashima et al. 2005). 
It is intriguing how all these mutations cause the same molecular mechanism of skipping of 
exon 3, which then conveys a certain variability in the skeletal phenotype for the different 
patients, suggesting a more complex mechanism underlying the disease onset, and/or a role 
for genetic modifiers.  
Interestingly, the only reported exception was a novel mutation in exon 2 of COL9A3 that 
was detected in 2014 in a Korean family diagnosed with MED. The clinical findings involved 
epiphyseal changes predominantly affecting the knee joints, and only mildly other joints such 
as ankle, foot and wrist. Differing from the splicing mutations around exon 3, this mutation 
was a c.104G>A substitution in exon 2 of COL9A3. This missense mutation resulted in a 
substitution of Gly to Asp (p.Gly35Asp) in the “G-X-Y” consecutive sequence of the COL3 
domain in the α3(IX) polypeptide. So, although this mutation was not involving aberrant 
splicing, the change in the amino acid sequence once again affected the COL3 domain. 
Researchers conducted molecular dynamic simulation to analyse the energy state and 
physical movement of the mutant α3(IX) polypeptide. They found that this amino acid 
substitution generated self-aggregation of the polypeptide strand which severely affected its 
interaction with the other strands in the formation of collagen type IX heterotrimer (Jeong et 
al. 2014). 
Looking at the spectrum of COL9-MED mutations reported to date, a common characteristic 
is mutation affecting the COL3 domain, in α1(IX), α2(IX), α3(IX) (Fig. 1.6). Taken together 





Fig. 1.6 | Collagen type IX MED mutations. Schematic representation of Collagen type IX 
molecule and the MED mutations reported to date in COL9A1, COL9A2 and COL9A3 genes. 
NC=non-collagenous domain; COL=collagenous domain; Ex=exon; In=intron. Adapted from (Briggs 





Table 1.2 | Collagen type IX gene mutations that result in phenotypes within the 






1.8 Other collagen type IX disorders 
Mutation in collagen type IX have also been associated with other skeletal disorders 
such as Stickler syndrome recessive type, lumbar disc disease and progressive hearing loss. 
1.8.1 Stickler syndrome recessive type 
Stickler syndrome was first described in 1965 as a heterogeneous disorder affecting 
connective tissue (Stickler et al. 1965). Inter and intra familial variability is known in terms 
of clinical spectrum, hence requiring a combination of clinical and genetic analysis during 
diagnosis. Among the characteristic features are reported hearing losses, problems in the 
palate and facial development, and myopia with occasional retinal detachment. In addition, 
patients sometimes develop hypermobility of the joints and early-onset OA (Hanson-Kahn et 
al. 2018). Autosomal dominant and recessive forms of Stickler syndrome have been reported, 
in most cases caused by mutations in genes coding for cartilage expressed collagens. 
Heterozygous mutations in COL2A1, account for the 80–90% of dominant Stickler syndrome 
cases (Liberfarb et al. 2003). Other dominant cases are due to mutations in COL11A1 
(Majava et al. 2007) or COL11A2, causing a form of Stickler syndrome, which does not 
involve eye defects (Pihlajamaa et al. 1998). Fewer cases of the autosomal recessive form of 
Stickler syndrome have been described, and the vast majority involved homozygous variants 
in the collagen type IX genes COL9A1, COL9A2, and COL9A3. Ten families have been 
reported with homozygous loss-of-function variants in the collagen type IX genes either due 
to insertion of premature stop codons leading to nonsense-mediated decay or removal of the 
N-terminal regions of the collagen alpha chains necessary for chain association (Baker et al. 
2011, Nikopoulos et al. 2011, Faletra et al. 2014, Hanson-Kahn et al. 2018, Van Camp et al. 
2006, Nixon et al. 2019). The clinical spectrum does not seem to differ between variants in 
COL9A1, COL9A2, and COL9A3 and mainly comprises high myopia and hypoplastic 
vitreous, whereas the facial flattening is not as pronounced and none of the cases presented 
with palate abnormalities. Joint dysplasia was also often reported, characterised by 
hypermobility, mild spondyloepiphyseal dysplasia and precocious osteoarthritis and was 
expected considering the importance of collagen type IX in articular cartilage. Although it is 
surprising how patients with homozygous variations in genes for collagen type IX did not 
show a more severe joint involvement compared to patients carrying other recessive or 
dominant variants in other Stickler syndrome associated genes. Such discrepancies could be 




the α1 chain of collagen type IX in cartilage has a large amino-terminal globular domain, 
whereas in vitreous the α1 chain is much shorter and the α2 chain has a very large 
chondroitin sulphate chain attached (Nixon et al. 2019). These differences may be the reason 
for the different penetrance of joint problems versus eye problems, possibly due to some sort 
of redundancy mechanism which takes place in cartilage but not in the vitreous. Compared to 
the dominant form of Stickler syndrome, sensorineural hearing loss was more consistent in 
collagen type IX mutation containing patients. This hearing loss appears to be congenital, 
suggesting that loss-of function mutations might have affected ear development.  
Two other non-collagen genes have also been reported in association to a Stickler syndrome 
phenotype: LRP2, coding for the lipoprotein receptor-related protein-2 or megalin, an 
endocytic receptor which mediates the endocytic uptake of diverse circulating compounds, 
and when mutated causes many major malformations such as craniofacial features, 
developmental delay, intellectual disability, ocular findings, low molecular weight 
proteinuria, and sensorineural hearing loss (Schrauwen et al. 2014); and LOXL3, coding for 
the collagen type II cross-linker enzyme lysyl-oxidase-like 3, plays a role in the formation of 
crosslinks in collagens and elastin, and when deficient is expected to result in collagen defect 
(Chan et al. 2019). 
1.8.2 Non syndromic hearing impairment  
Mutation screening for COL9A3 in non-syndromic sensorineural deafness patients and 
healthy controls has also been reported (Asamura et al. 2005). One identified mutation, which 
appeared recessive, was a homozygous inframe deletion of nine nucleotides at position 541–
549 in exon 11, removing a Gly–Pro–Hypro triplet in the 5′-end of the collagen type IX 
COL2 domain. A second mutation appeared dominant and was a missense mutation, D617E 
(1851 C > A) in exon 31, which locates in the COL1 domain of the protein. Both mutations 
were considered good candidates for the pathogenesis of hearing loss since they were not 
detected in healthy patients or SNP databases and involve highly conserved amino acid 
residues. The hypothesis is that the mutated COL1 and COL2 domains affect the assembly 
and stability of the collagen type IX three-dimensional structure resulting in modifications of 




1.8.3 Intervertebral disc disease (DD) 
Intervertebral disc disease (DD) (OMIM #603932) is the major cause of low back pain 
and it is defined as a degeneration of intervertebral discs with subsequent remodelling of the 
closely attached vertebrae which starts early in life. The degenerative phenotype is believed 
to be caused by the concurrence of genetic and environmental factors, rendering the disease a 
complex condition to treat (Feng et al. 2016). Recent epidemiological studies have 
highlighted genetic inheritance as driving factor for the development of this condition. It is 
still unknown whether the phenotype is due to the strong impact of a specific gene or multiple 
genes that contribute in a synergistic way to the pathogenesis, however it is more likely to be 
a polygene and multifactorial disease. The genes that have been associated to DD are 
COL1A1 (Pluijm et al. 2004), COL11A2 (Solovieva et al. 2006), IL1B or A (Solovieva et al. 
2004), ACAN (Kawaguchi et al. 1999), VDR (vitamin D receptor) (Kawaguchi et al. 2002), 
MMP3 (Takahashi et al. 2001), and CILP (cartilage intermediate-layer protein) (Seki et al. 
2005). Polymorphisms in the collagen type IX genes, COL9A2 and COL9A3 have been 
identified as risk factors for lumbar DD. In a screen conducted in a Finnish population with 
intervertebral DD, a sequence variation, known as the Trp2 allele, in COL9A2, caused a 
glutamine to tryptophan substitution into the protein (Annunen et al. 1999). Subsequently, in 
another study performed on Finnish families, researchers found that the degree of vertebral 
disc degeneration was higher in those individuals carrying the Trp2 variant. A similar 
polymorphism in the COL9A3 gene, causing a substitution of arginine to tryptophan (Trp3 
allele) was described by Passilta et al. In their analysis, they found that in individuals 
carrying at least one Trp3 allele, the risk of lumbar disc degeneration was 3-fold increased 
(Paassilta et al. 2001). However such results were not confirmed in studies carried on other 
ethnic group populations (Seki et al. 2006, Kales et al. 2004), suggesting a variation of the 
genetic risk factors for DD according to ethnicity. Therefore, further investigation and in 
multiple ethnic groups are needed to understand the association of the Trp alleles with DD 
(Wu et al. 2018). Early changes during spine development have been reported in collagen 
type IX null mice. These alterations seemed to develop into disc degeneration defects later in 





1.9 Mouse models for the study of PSACH and MED 
Mutation analysis performed on patients has shown that PSACH and the more severe 
cases of MED were caused by mutations in the same gene COMP. However, MED as 
mentioned before, is genetically heterogeneous, therefore also caused by dominant mutations 
in other genes coding for matrilin-3 and collagen type IX and recessive mutations in 
SLC26A2 and CANT1 genes.  
Having identified the causative genes for these disorders, discovering the mechanism 
responsible for their pathogenesis turned out to be a more difficult challenge, especially when 
considering the low availability of patient tissue that could be studied. Though model systems 
that completely reproduce the human PSACH or MED phenotypes are not available, the 
generation of knock-in mice and some tissue culture models have provided important insights 
about these disease mechanisms. There are many limitations in using cell models for these 
diseases, such as the limited amount of patient chondrocyte materials usually available when 
the severe clinical phenotype requires joint replacement (Zhang et al. 2009). Moreover, the 
maintenance of a chondrocyte-like phenotype in monolayer cultures has been also an issue, as 
primary chondrocytes dedifferentiate in serial monolayer with respect to their morphological 
and biosynthetic phenotype, by changing from a round to a flattened fibroblast-like shape and 
secreting collagen type I instead of the cartilage-specific collagen type II (Zaucke et al. 
2001). Even when 3D cultures are established, despite overcoming this problem, the matrix 
produced by chondrons does not completely mimic the ECM 3D organization usually found 
in vivo, but gradients and defects can occur in material properties, affecting proteins 
deposition and diffusion which will impact on chondrocytes behaviour (Tibbitt and Anseth 
2009). In addition, there is also the fact that results obtained from cultured chondrocytes are 
cross-sectional, missing therefore information about how the disease progresses along human 
development (Posey et al. 2008b). Hence, the utility of mouse models to recapitulate human 
diseases have come into fruition. They represent a valuable source of material for different 
kinds of experiments and are a system that can be monitored and analysed throughout 
development. An important aspect to be taken into account when trying to reproduce this 
kind of skeletal disorders with mouse models is the correct correlation between human and 
mouse. Despite sharing similar bone biology, when comparing the human and mouse skeletal 
phenotype, some of the differences between the two systems might make extrapolation of 




which skeletal development occurs in the two systems. In most mouse strains, the peak bone 
mass is reached at the age of 4-6 months, so unlike humans, bone acquisition and longitudinal 
bone growth continue in mice after sexual maturity, which occurs at 6–8 weeks of age (Jilka 
2013). Thus, from this derives our choice of specific time points when we evaluated the bone 
phenotype of our mutant mice, which will be described in detail into the results section of this 
thesis. Moreover, the difference of posture and patterns of mechanical loading constitutes 
another difference to be considered, with humans being bipedal, the impact on the skeletal 
elements will be different from mice. Both transgenic and knock-in approaches have been 
undertaken in the study of the PSACH-MED disease spectrum and some of them will be 
outlined in this thesis. The phenotype investigated through these mouse models has 
highlighted important aspects of the disease mechanism involving endoplasmic reticulum 
(ER) stress and chondrocyte proliferation, which contribute to the dysplastic skeletal 
phenotype.  
1.9.1 Matrilin-3 mice   
Transgenic knockout mice for matrilin-3 have been generated to better understand the 
role of the protein during skeletal development and in the pathogenesis of MED. When Ko et 
al. generated a knockout mouse line for matrilin-3, null mice were viable, of normal height, 
and without obvious abnormalities in the skeletal phenotype. Histology and ultrastructural 
analyses showed no defects in endochondral bone formation and intervertebral disc 
development. A compensatory effect of structurally and functionally related proteins was 
suspected to account for the absence of an obvious phenotype. However, expression analysis 
did not show compensatory upregulation of other members of the matrilin family. These 
findings suggested that the skeletal phenotype reported in MED disorders due to mutations in 
the MATN3 gene, are more likely caused by the presence of a mutated protein rather than its 
absence (Ko et al. 2004). Likewise, a double knockout mouse for matrilin-1 and matrilin-3 
(Matn1/Matn3) was found with similar normal features. The growth plate was of normal 
height and no change was noticed in any of its zones. The only variation noticed, was 
detected at the age of 7 days, when in double-deficient mice the collagen fibrils of the 
interterritorial matrix were larger in diameter and more densely packed, giving the matrix an 
overall increased density (Nicolae et al. 2007). To the contrary, in a Matn3 null mouse 
independently generated by van der Weyden et al., researchers identified prenatal changes in 




evidence of premature maturation of chondrocytes. These alterations recovered at the time of 
mouse birth and during postnatal development, thus confirming the lack of phenotype shown 
in the previous studies. Nonetheless, these mice were reported with increased bone mass 
density and to be more prone to develop OA (van der Weyden et al. 2006).  
To generate a murine model of MED, Leighton et al. knocked-in the equivalent of an MED 
mutation into the mouse Matn3 gene, substituting a valine with an aspartate (p.Val194Asp) 
mutation in the A-domain of matrilin-3. Homozygous mice reproduced the human phenotype, 
by developing progressive dysplasia and short-limbed dwarfism. The retention of the mutant 
protein in the ER was indicated by the observation of enlarged cisternae of ER within the 
chondrocytes, this triggered a cellular stress as indicated by upregulation of chaperones for 
the unfolded protein response (UPR). Moreover, the organisation of chondrocytes into 
chondrons was disrupted, along with reduced proliferation and spatially dysregulated 
apoptosis in the cartilage growth plate, all of which might have influenced linear bone growth 
and resulted in the short-limbed dwarfism phenotype presented by the mutant mice (Leighton 
et al. 2007). 
1.9.2 COMP mice 
Similarly to matrilin-3 deficient mice, knockout mice for COMP did not show skeletal 
abnormalities and did not reproduce any of the clinical features of PSACH and MED 
patients. The histological evaluation revealed a normal growth plate and no dwarfism or short 
limb phenotype, indicating endochondral ossification similar to WT animals. In addition, no 
evidence of OA was detected in COMP null mice up to the age of 14 months. Normal cell 
morphology and collagen fibrillary network in the ECM were confirmed by ultrastructural 
analysis of growth plate cartilage, articular cartilage, and Achilles tendons. The same 
hypothesis of possible compensation mechanisms expressed by functionally related proteins 
was not confirmed by expression analysis, with no variation in the protein levels of other 
components of the thrombospondin family (Svensson et al. 2002). 
With the purpose to study the role of COMP mutations in the pathogenesis of PSACH, 
transgenic mouse models overexpressing mutated COMP were generated. This mutation was 
an in-frame deletion of 3 nucleotides which resulted in a deletion of a single aspartate at 
position 469 in the protein (D469del) and is known to cause a severe form of PSACH (Deere 




PSACH patients, such as growth retardation in male mice, a disorganised growth plate with 
less densely packed fibrils and increased rate of cell apoptosis, and altered extracellular 
localisation of the mutant COMP in the growth plate. Evidence of enlarged ER cisternae 
suggested probable mutant protein retention. Other features not directly related to PSACH 
were observed, such as sternal malformations and the complete fusion of certain segments of 
the sternum (Schmitz et al. 2008). In the transgenic model for PSACH generated by Posey et 
al. expression of human mutant COMP with the same D469del mutation was induced, with 
the model reproducing the findings of human PSACH growth plate morphology, including a 
disruption of growth plate organisation, chondrocyte retention of mutant COMP as well as 
retention of matrilin -3 and collagen type IX. These have shown to be able to assemble with 
pro-collagen type II to form an intracellular matrix within the rER cisternae where they are 
retained, as previously reported for other PSACH causing COMP mutations (Merritt et al. 
2007). Increased chondrocyte apoptosis in mutant growth plates was also shown by 
immunohistochemistry (Posey et al. 2009). The results obtained through these models 
demonstrated that the PSACH phenotype is caused by the generation, retention and partial 
secretion of the mutant COMP protein, rather than by its absence.  
Using a knock-in approach, the D469del mutation was directly introduced into the mouse 
genome. COMP mutant mice did not display an obvious phenotype at birth, but in the post-
natal period they developed short limb dwarfism. In this mouse model, disorganisation and 
reduced number of columns of chondrocytes in the growth plate and retention of the mutant 
COMP into the ER were confirmed. Chondrocyte proliferation was reduced, and cell death 
was increased and spatially dysregulated. Interestingly, no UPR response was found as the 
cause of the alterations described. Instead expression changes of genes involved in oxidative 
stress, cell cycle regulation, and apoptosis were observed, suggesting that a mechanism of 
chondrocyte stress might be at the base of the pathology induced by a mutant COMP 
(Suleman et al. 2012). 
A model for a mild form of PSACH was generated by introducing p.Thr583Met mutation in 
the C-terminal globular domain (CTD) of COMP (Pirog-Garcia et al. 2007). In these mice 
mutant COMP was secreted into the ECM, and therefore no protein retention was occurring 
in the ER. However, a UPR was detected in combination with increased and spatially 
dysregulated apoptosis. Localisation of COMP, matrilin-3 and collagen type IX were also 
altered. At 9 weeks of age homozygous mice presented with shorter tibiae and hip dysplasia, 




patients. Further phenotypic analysis pointed out that homozygous mice show mild myopathy 
equivalent to PSACH and MED patients. Finally, tendons of mutant mice were lax and weak 
with thicker fibrils, reproducing patients’ joint laxity (Pirog et al. 2010).  
1.9.3 Collagen Type IX mice 
Several studies have investigated the role of collagen type IX in cartilage, and to do so 
transgenic mice harbouring different mutations have been generated. Fässler et al generated 
the first mutant mouse for a collagen type IX gene in 1994. To test the role of collagen type 
IX in the interaction with other fibrils and components of the ECM, using gene targeting in 
ES cells, they generated a mouse lacking both isoforms of α1 of collagen type IX (Fassler et 
al. 1994). Homozygous mice, despite lacking Col9a1 RNA and protein, were viable and did 
not show an obvious skeletal phenotype or shorter stature at birth and early in life. 
Nonetheless, evidence of development of degenerative joint disease predominantly localised 
at the knee of 4-months old homozygous mice were reported to be similar to the human OA. 
A few years later was demonstrated that the lack of type IX collagen in Col9a1−/− mice results 
in age‐dependent OA‐like changes in the knee joints and temporomandibular joint (TMJ) (Hu 
et al. 2006). In 1997, Hagg et al. demonstrated that mice lacking the α1 chain, were a 
functional knockout of collagen type IX protein, although expression of the Col9a2 and 
Col9a3 genes, coding for the other two helices, was unaffected when rib cartilage was 
analysed (Hagg et al. 1997). The use of the Col9a1-/- mice allowed the investigation of 
stability and integration of other structural components within the ECM of cartilage when 
collagen type IX protein is missing, such as matrilin-3 and COMP proteins. Cartilage 
integrity was disrupted in collagen type IX deficient mice as shown by loss of matrilin-3 and 
COMP integration in the cartilage primordium of vertebral bodies and ribs of new-born 
Col9a1-/- mice . In fact matrilin-3 is known to interact directly with collagen type IX, or by 
means of COMP as adapter (Budde et al. 2005), and COMP has been shown to bind directly 
to Matrilin-3 and collagen type IX (Holden et al. 2001, Mann et al. 2004, Thur et al. 2001). In 
a study on adult Col9a1 null mice, the absence of collagen type IX affected bone fracture 
healing as maturation of cartilage matrix was delayed and cartilage abundance reduced at the 
level of the healing callus (Opolka et al. 2007).  
Collagen type IX has been also associated with the pathogenesis of osteoporosis. This derives 




osteoporosis in aged Col9a1+/− mice. In addition, ageing leads to progressive loss of 
trabecular bone and bone deterioration in male and female heterozygous mice (Wang et al. 
2008). In Col9a1 null mice the growth of cartilage was profoundly affected. At birth, and in 
the early stages of post-natal development, mutant mice show broadened tibial condyles and 
shorter long bones. Large hypocellular central regions with consequently altered 
proteoglycan content were found in the tibia epiphysis (Blumbach et al. 2008, Dreier et al. 
2008). Growth plate organisation was severely compromised: proliferative cells appeared 
rounded and lost their typical columnar distribution, whereas hypertrophic cells were 
enlarged, more loosely packed, and surrounded by more ECM. Moreover, the separation 
between proliferative and hypertrophic cells was no longer clear (Fig. 1.7). A reduction of 
proliferation rate was also reported. However, these alterations tended to ameliorate during 
adulthood. Remarkably, staining for collagen binding integrin, showed that β1-integrin levels 
in Col9a1-/- proliferative zones were strongly reduced, in particular in the proximity to the 
described hypocellular region. Whether the reduction in β1-integrin is a direct consequence 
of collagen type IX absence or due to other compromised cell vitality mechanisms remains 
unresolved.  (Dreier et al. 2008). It is worth noting that Col9a1-/- mice develop progressive 
hearing loss. This finding is consistent with collagen type IX being expressed in the inner ear, 
hence its absence affects the structural integrity of the tectorial membrane in the cochlea 
(Asamura et al. 2005, Suzuki et al. 2005). 
The absence of collagen type IX also severely affects the integrity of the cartilage of the 
intervertebral discs. At early stages of post-natal development, Col9a1−/− animals showed 
cellular disorganisation in the vertebral end plate, smaller nucleus pulposus and disturbed 
distribution of other matrix proteins. The change in matrix composition led to reduced tissue 
stiffness and a delay in the development of the vertebral body. (Kamper et al. 2016, Kimura 





Fig. 1.7 | Cartilage growth plate defects in Col9a1-/- mice. Areas of hypocellularity and 
chondrocytes with altered morphology and spatial organization in Col9a1-/- mice. Adapted from 
(Blumbach et al. 2008, Dreier et al. 2008) 
Transgenic mouse models have also been generated to better understand the role of collagen 
type IX in cartilage. A cDNA construct designed to create an in-frame deletion of parts of the 
COL2 and COL3 domains and the whole of the NC3 domain in the central part of cDNA 
encoding the αl (IX) chain, was injected into mice. Cartilage expression specificity was 
provided by collagen type II promoter and enhancer driving expression of the construct. The 
shorter α1 (IX) chain assembled with the endogenous α2 (IX) and α3 (IX) chains to generate 
mutant heterotrimeric collagen type IX. This transgenic mouse phenotype comprised OA like 
changes in the articular cartilage of knee joints, and mild chondrodysplastic features: mild 




pulposus, the appearance of clefts in the annulus fibrosus, associated to herniation of disc 
material and slight osteophyte formation (Kimura et al. 1996, Nakata et al. 1993). 
Interestingly, growth plate abnormalities were detected only in null collagen type IX mice, 
but not in transgenic mice carrying a mutated protein. 
The studies mentioned so far demonstrated the importance in vivo of the presence of the α1 
polypeptide for the trimerisation with the other two polypeptide chains, since its absence 
impairs the formation of the whole collagen type IX heterotrimer. Interestingly, these 
findings were not confirmed by studies performed in vitro, when the mechanism of collagen 
type IX chains selection and assembly was tested using recombinant constructs expressing 
the three human α chains (Jaalinoja et al. 2008, Pihlajamaa et al. 1999). These studies showed 
the capability for α1 (IX) chains to form disulphide bonds with each other, therefore giving 
rise to an homotrimeric helical assembly α1(IX)3 which was also secreted in vitro and could 
function as an alternative collagen type IX molecule. However, in the case of co-expression 
of α1(IX), α2(IX) and α3(IX), the formation of the canonical heterotrimer containing all three 
chains remained the most favourable form of trimer assembly. Neither α2(IX) nor α3(IX) 
procollagen chains were able to generate homotrimers. These findings suggest the possibility 
that α1(IX)3 could compensate for the absence of α2(IX) or α3(IX). When examining Col9a1
-
/- mice, it was confirmed that a similar mechanism of compensation (i.e. the formation of a 
collagen type IX lacking α1 chains) was not possible. 
The consequences of loss of the α2 (IX) were explored in a recent study where a knockout 
mouse for Col9a2 was generated. Homozygous mice (Col9a2-/-) lacked collagen type IX 
protein, indicating that α2(IX) chain is essential for the correct folding of the whole protein. 
Col9a2-/- mice showed defects in skeletal development, as evidence of short limbs, trunk, tail 
and retarded bone growth. Histological analysis showed growth plate defects similar to 
Col9a1-/- mice. Tibial epiphyseal cartilage was wider in knockout mice and a large 
hypocellular region was present in the centre of the proliferative zone. In addition, 
proliferative chondrocytes showed irregular morphology and disruption of columnar 
distribution was noticed in the proliferative and hypertrophic zones. The knockout mice 
exhibited significant reduced auditory function, reproducing the hearing defects reported by 
patients affected by Stickler syndrome. Finally, Col9a2-/- mice showed early onset 
degenerative joint changes, consistent with those observed in Col9a1-/- joints 
(Balasubramanian et al. 2019). Taken together, we can conclude that both α1(IX) and α2(IX) 




knockout of the whole protein. From this we might hypothesise that a knockout of α3(IX) 
would give a similar outcome, however no transgenic mice carrying mutations in Col9a3 
have been described in the literature to date. This will be one of the aspects covered in this 
thesis.  
1.9.4 Combined knockout mice  
Some of the knockout mice for genes of various cartilage proteins did not exhibit an 
obvious skeletal phenotype. Functional redundancy between structurally related proteins was 
assumed to be the reason behind this lack of phenotype, but as stated before, in COMP 
deficient and matrilin-3 deficient mice no change in the expression of related proteins was 
detected (Ko et al. 2004, Svensson et al. 2002). In order to investigate the role of possible 
complementarity between different but related ECM components, combined knockout mice 
for multiple genes were generated. In collagen type IX/COMP double-deficient mice the 
phenotypic abnormalities were similar to the characteristics reported for the functional 
collagen type IX knockout. Increased thoracic spinal curve, shorter limbs and an alteration in 
the bone structure were some of the phenotypic abnormalities in mice deficient in both 
collagen IX and COMP.  Remarkably, along with impaired columnar arrangement and a 
reduction in chondrocytes proliferation, a large uncalcified hypocellular region was found in 
the central region of the growth plate, again as reported for collagen type IX deficient mice. 
Similarly to Col9a1-/- mice,  in the double knockout mice the disorganised appearance of the 
growth plate tended to improve with age (Blumbach et al. 2008). From these observations, it 
seems that the lack of collagen type IX is the predominant contributor to the phenotype of the 
double deficient mice, while the absence of COMP did not cause any specific morphological 
changes. Nonetheless, when matrix protein deposition was assessed, differences were noticed 
in the localisation of matrilin-3 in double deficient mice, indicating a role for COMP in 
matrix deposition. 
To study the role of TSP1, TSP3, TSP5 (COMP), and collagen type IX in the growth plate, 
knockout mouse lines for each of the genes and combinatorial strains were generated. Again, 
from this study, collagen type IX appeared to have a more significant role in growth plate 
stability, although each combined knockout showed some growth plate alterations. The most 
disorganised growth plate was exhibited by TSP3/5/Collagen type IX knockout mice, which 




(COMP) and collagen type IX, mice subjected to exercise develop cartilage degeneration 
(Posey et al. 2008a). 
1.10 Genome editing: CRISPR/Cas9 and Non-homologous end joining 
repair 
In recent years, the development of highly versatile genome-editing technologies has 
given researchers the ability to rapidly and economically introduce sequence-specific 
modifications into the genomes of a broad spectrum of cell types and organisms. The most 
commonly used genome editing technologies nowadays comprise zinc-finger nucleases 
(ZFNs), transcription activator-like effector nucleases (TALENs), homing endonucleases or 
meganucleases, and clustered regularly interspaced short palindromic repeats (CRISPR)-
CRISPR-associated protein 9 (Cas9).  
ZFNs are fusion proteins formed by an array of site-specific DNA-binding domains attached 
to the endonuclease domain of the bacterial FokI restriction enzyme. To cleave a specific site 
in the genome, ZFNs are designed as a pair that recognizes two sequences flanking the site, 
one on the forward strand and the other on the reverse strand. Upon binding of the ZFNs on 
either side of the site, the pair of FokI domains dimerize and cleave the DNA at the site, 
generating a double-strand break (DSB) with 5′ overhangs (Urnov et al. 2010). One potential 
disadvantages in the use of ZFNs is the difficult and extremely time consuming process of the 
assembling of optimized engineered ZFNs domains and the limitation of the target site 
selection (Gupta and Musunuru 2014).  
TALE repeats comprise tandem arrays of 10 to 30 repeats (each repeat is 33 to 35 amino 
acids in length) that bind and recognize extended DNA sequences. TALE repeats have been 
used to create a new type of engineered site-specific nuclease that fuses a domain of TALE 
repeats to the FokI endonuclease domain, termed TAL effector nucleases (TALENs). 
Similarly to ZFNs, TALENs can generate DSBs at a desired target site in the genome 
(Bogdanove and Voytas 2011). TALENs are easier to design and have wider target site 
selection, however a clear disadvantage of TALENs is their significantly larger size 
compared to ZFNs. 
Meganucleases are enzymes able to establish extensive sequence-specific contacts with their 




TALENs, their binding and cleavage domains are not modular, so that the overlap in form 
and function make challenging their use for more routine applications of genome editing. 
The recent discovery of bacterial adaptive immune systems known as clustered regularly 
interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) systems has 
led to the newest set of genome-editing tools. CRISPR-Cas systems use a combination of 
proteins and short RNAs to target specific DNA sequences for cleavage. The bacteria collect 
“protospacers” from invading DNA sequences (for example from bacteriophages), 
incorporate them into their genomes, and use them to express short guide RNAs, which can 
then be used by a CRISPR-Cas system to destroy any DNA sequences matching the 
protospacers during future invasions. The mode of action of this genome editing tool 
comprises two biological macromolecules, the Cas9 protein and a guide RNA, which interact 
to form a complex that can identify target sequences with high selectivity. The Cas9 protein 
is responsible for locating and cleaving target DNA. In its structure the Cas9 comprises six 
domains, REC I, REC II, Bridge Helix, protospacer-adjacent motif (PAM) Interacting, HNH 
and RuvC. The Rec I domain is the largest and is responsible for binding guide RNA. The 
role of the REC II domain is not yet well understood. The arginine-rich bridge helix is crucial 
for initiating cleavage activity upon binding of target DNA (Nishimasu et al. 2014). The 
PAM-Interacting domain confers PAM specificity and is therefore responsible for initiating 
binding to target. The HNH and RuvC domains are nuclease domains that cut single-stranded 
DNA (Nishimasu et al. 2014). In engineered CRISPR systems the guide RNA is a single 
strand of RNA that forms a T-shape comprised of one tetraloop and two or three stem loops, 
and it is engineered to have a 5′ end that is complementary to the target DNA sequence. 
When the artificial guide RNA binds to the Cas9 protein, it induces a conformational change 
converting the inactive protein into its active form. Once the Cas9 protein is activated, it 
stochastically searches for target DNA by binding with sequences that match its protospacer 
adjacent motif (PAM) sequence (Sternberg et al. 2014). A PAM is a two- or three-base 
sequence located within one nucleotide downstream of the region complementary to the 
guide RNA. PAMs have been identified in all CRISPR systems, and the specific nucleotides 
that define PAMs are specific to the particular category of CRISPR system (Mojica et al. 
2009). The PAM sequence in Streptococcus pyogenes for example, the one mostly used in 
genome editing, is 5′-NGG-3′ (Jinek et al. 2012). When the Cas9 protein finds a potential 
target sequence with the appropriate PAM, the protein will melt the bases immediately 




(Sternberg et al. 2014). If the complementary region and the target region pair properly, the 
RuvC and HNH nuclease domains will cut the target DNA after the third nucleotide base 
upstream of the PAM (Anders et al. 2014). Previous studies demonstrated the efficiency of 
the system, as the expression of the Cas9 protein along with guide RNA(s) in mammalian 
cells, results in double strand breaks (DSBs) at target sites with a 20-bp sequence matching 
the protospacer of the guide RNA and an adjacent downstream PAM sequence (Cho et al. 
2013). 
Because target site recognition is mediated entirely by the gRNA, CRISPR-Cas9 has emerged 
as the most flexible and user-friendly platform for genome editing, eliminating the need for 
engineering new proteins to recognize each new target site. Its advantage compared to ZFNs 
and TALENs, which require recoding of proteins using large DNA segments for each new 
target site, is that CRISPR-Cas9 can be easily adapted to target any genomic sequence by 
changing the 20-bp protospacer of the guide RNA. This can be accomplished by subcloning 
this nucleotide sequence into the guide RNA plasmid backbone. The Cas9 protein component 
remains unchanged. This ease of use for CRISPR-Cas9 is a significant advantage over ZFNs 
and TALENs, especially in generating a large set of vectors to target numerous sites or even 
genome-wide libraries (Wang et al. 2014b) . The potential advantage of CRISPR-Cas9 is the 
ability to use multiple guide RNAs in parallel to target multiple sites simultaneously in the 
same cell (Cong et al. 2013). This makes it straightforward to mutate multiple genes at once 
or to engineer precise deletions in a genomic region. The main issue regarding CRISPR-Cas9 
usage however, is the possibility of off-target effects mainly related to the guide RNA 
sequence specificity, demonstrating tolerance of single or multiple mismatches in the 
protospacer (Hsu et al. 2013). Off-target mutations have been reported at higher rate at sites 
where sequences are similar to the on-target sites sequences (Fu et al. 2013), however efforts 
to improve the specificity of CRISPR-Cas9 in mammalian cells are in progress. 
The final goal of the use of such genome editing tools is the creation of DSBs in the genomic 
DNA of the organisms we are trying to modify. Cells repair DSBs using either the 
nonhomologous end joining (NHEJ) repair pathway, or the homology-directed repair (HDR).  
NHEJ repair can occur during any phase of the cell cycle, but occasionally results in 
erroneous repair. On the contrary, the HDR typically occurs during late S phase or G2 phase 
when a sister chromatid is available to serve as a repair template. Importantly, NHEJ is an 
error-prone repair pathway, since the process does not use a complementary template, thus 




The NHEJ repair process requires a nuclease to excise the damaged DNA, polymerases to 
fill-in new DNA, and a ligase to restore integrity to the DNA strands. The precise mechanism 
of NHEJ repair is still under investigation, however the model involves the Ku protein which 
is thought to bind to DNA end and to form a Ku-DNA complex at each end for preparation of 
ligation and recruiting of nuclease, polymerase and ligase activities in any order (Lieber 
2008). The Ku heterodimer has been shown to recruit either directly or indirectly the main 
NHEJ factors, including DNA-PKcs, X-ray cross complementing protein 4 (XRCC4), DNA 
Ligase IV, XRCC4-like factor (XLF), and Aprataxin-and-PNK-like factor (APLF) to DSBs. 
These core NHEJ factors interact with each other to form a stable complex at the DSB (Davis 
and Chen 2013). The DSB ends undergo a step of DNA processing to make them compatible 
for ligation for the terminal step of the NHEJ pathway. The XRCC4 and Ku proteins 
conjugate to recruit specific processing enzymes. After processing, the stabilisation of the 
DNA ends is achieved by the interplay of XRCC4 and XLF with DNA-PKcs and Ku which 
produce a filament able to bridge, protect and stabilise the two regions of broken DNA ends. 
The final ligation and detachment of the NHEJ complex occurs when the DNA ends are 
ligated by the DNA-Ligase IV. XRCC4, XLF, and likely APLF contribute to the process 
while DNA-PKcs gets released after a conformational change, leaving the DSB finally 
repaired (Davis and Chen 2013) . 
1.10.1 Transgenic animal models  
Traditionally, homologous recombination has been used in mouse embryonic stem cells 
to create mouse lines with genetic alterations, such as gene knockouts or knockin. (Smithies 
et al. 1985, Thomas and Capecchi 1987). The main downside of this method has been the 
issue related to the time required for the generation of transgenic animal lines. The most 
eloquent example is in mice, as it takes more than a year to generate a genetically modified 
mouse using homologous recombination. In addition, when the same approach was used to 
modify human cells, the result was not as efficient, and alternative approaches (i.e. antisense 
oligonucleotide and short interfering RNAs) have been used. These techniques have only a 
transient effect and can sometimes have effects also on non-targeted genes (Qiu et al. 2005, 
Wang et al. 2014a). These limitations required more effective methods of gene modification 
to achieve transgenesis in multiple organisms. In recent years, novel genome-editing tools for 
the generation of genetically modified mice have been developed. These tools comprise the 




All three engineered nucleases outlined above have proven effective at producing targeted 
mutations in mouse embryos (Carbery et al. 2010, Cui et al. 2011, Wang et al. 2013, Wefers 
et al. 2013). The efficiency of each system was strongly depending on the nuclease, target site 
in the genome, and amount of RNA injected. However, the highest transgenesis efficiency 
has been demonstrated in experiments where CRISPR/Cas9 was used (Wang et al. 2013). 
Nowadays, CRISPR/Cas9 has become the preferred and elected approach for the generation 
of transgenic animal models, thanks to its incomparable ease of use. A particular advantage is 
that it is possible to obtain knockout animals in the first generation (assuming that the 
targeted gene is not embryonic lethal), dramatically speeding up the time needed to do 
genetic studies in animals. The Cas9 protein and transcribed sgRNA can be directly injected 
into fertilized zygotes to achieve heritable gene modification at one or multiple alleles in 
animal models such as rodents and monkeys (Li et al. 2013, Niu et al. 2014, Wang et al. 
2013) . By bypassing the typical ES cell targeting stage in generating transgenic lines, the 
generation time for mutant mice and rats can be reduced from more than a year to only 
several weeks. Such advance, combined with highly specific editing, has paved the way for 
cost-effective and large-scale in vivo mutagenesis studies in rodent (Fu et al. 2013, Ran et al. 
2013a). Another advantage of this approach is that embryos from any of a variety of animal 
strains can be used; in the case of mice, embryos from an inbred strain can be used to directly 
generate the knockout mice. Similarly, embryos from a strain that already carries genetic 
alterations can be used, relieving the need for many generations of interbreeding to obtain 
mice with multiple genetic alterations. The ability to perform multiplex gene targeting with 
CRISPR-Cas9 is also helpful in this regard.  
Conversely, one outstanding challenge with transgenic animal models generated via zygotic 
injection of CRISPR reagents is genetic mosaicism, partly due to a slow rate of nuclease-
induced mutagenesis. Studies to date have typically relied on the injection of Cas9 mRNA 
into zygotes (fertilized embryos at the single-cell stage). However, because transcription and 
translation activity are suppressed in the mouse zygote, Cas9 mRNA translation into active 
enzymatic form is likely delayed until after the first cell division (Oh et al. 2000) . Because 
NHEJ-mediated repair is thought to introduce indels of random length, this translation delay 
likely plays a major role in contributing to genetic mosaicism in CRISPR-modified mice. To 
overcome this limitation, Cas9 protein and sgRNA could be directly injected into single-cell 
fertilized embryos. The high rate of mutagenic repair by the NHEJ process may additionally 
contribute to undesired mosaicism, due to the risk of introducing indels that mutate the Cas9 




increase the mutagenic activity of NHEJ, a pair of sgRNAs flanking a small fragment of the 
target gene may be used to increase the probability of gene disruption. A similar strategy has 
been adopted for the generation of mutant mice in our project and it will be explained in 
detail in future sections of this thesis work. 
1.11 Splicing mechanism 
Pre-mRNA splicing is the mechanism by which introns are removed from the pre-
mRNA whilst exons are simultaneously joined together, forming a continuous protein-coding 
region (open reading frame, ORF) within the RNA sequence (Matlin et al. 2005). Splicing is 
a highly regulated process performed by a macromolecular complex called the spliceosome. 
This complex is constituted of between 150 and 300 individual proteins (Rappsilber et al. 
2002), together with a group of small nuclear ribonucleoproteins (snRNPs) which consist of 
proteins bound to an RNA component (snRNA), which are crucial in the recognition of the 
splicing sites and the catalysis of the splicing reaction. The core elements of the spliceosome 
are able to recognise specific regions at both 5’ and 3’ ends of the intron called splice sites 
and this recognition mediates the splicing event. The sequence of the 5’ splice site, also 
called donor splice site, comprises a nearly invariant “GU” dinucleotide sequence along with 
less conserved residues downstream. The 3’ end, or acceptor splice site, is characterised by a 
conserved “AG” dinucleotide. Along the sequences at the two sites, the presence of an intron 
is also indicated by a further element, the branch site. This sequence is located 20-50 
nucleotides upstream of the acceptor site and consists of a conserved adenosine typically 
followed by a track of 15–20 polypyrimidine residues.  
The splicing mechanisms is a complex two-step trans-esterification reaction carried out by 
the spliceosome. In the first step, a lariat forms thanks to a nucleophilic attack of the 5’ splice 
site phosphate group by the 3’ hydroxyl group of the branch point adenosine. In the second 
step the free hydroxyl of the detached exon attacks the 3’ splice site, creating two fused exons 
and a lariat intron (Montes et al. 2019).  
1.11.1 Alternative splicing and nonsense-mediated decay. 
While some exons are constitutively spliced into mRNA transcript, others are 
sometimes included and other times skipped, therefore alternatively spliced. Alternative 




messages can be transcribed from one gene, which then can translate into several proteins 
with different sizes and/or functions. The importance of alternative splicing resides also in its 
capability of regulating gene expression by affecting mRNA stability, altering the 
untranslated regions (UTR) or the open reading frame (ORF) of a transcript (Matlin et al. 
2005). Splice variants can thus arise from mechanisms including alternative promoters, 
preferential usage of exons or splice sites, scrambling of exon order and alternative 
polyadenylation. Splice site selection is influenced by the combinatorial effect of cis-acting 
elements (within the RNA sequence) and trans-acting factors. The splice site strength is a cis-
acting element and is influenced by the sequence complementarity between the 5’ and 
3’splice sites with the snRNA component of the spliceosome snRNP. Along with the splice 
site strength, splice site selection is determined by other cis-acting elements, such as splicing 
enhancer and silencer sequences. These sequences can be found in intronic and exonic 
regions and are recognised by many auxiliary RNA-binding proteins (RBPs) which compete 
to either enhance or repress splice site recognition of both constitutive and alternative exons 
(Matlin et al. 2005). Trans-acting factors affecting splicing comprise the relative 
concentration, localisation and activity of RNA-binding proteins, such as members of the SR-
protein family and the heterogenous nuclear ribonucleoproteins (hnRNPs). SR-proteins are 
generally considered enhancers of splicing, whilst hnRNPs are often considered splicing 
repressors. However, the activating or repressive activity of SR-proteins and hnRNPs is 
largely position-dependent (Erkelenz et al. 2013).  
One third of alternative splicing events result in alteration to the open reading frame (ORF) of 
a gene, potentially leading to the generation of premature stop codons (PTCs) within the 
RNA sequence and subsequently targeting the transcript for nonsense-mediated decay 
(NMD) (Lewis et al. 2003). Accurate splicing of the pre-mRNA constitutes a key aspect in 
maintaining normal cellular physiology, and it is estimated that between 15% and 50% of 
human genetic diseases may arise from mutations to splice sites or splicing regulatory 
sequences (Cartegni et al. 2002, Faustino and Cooper 2003). As mentioned, nonsense-
mediated mRNA decay (NMD) is a translation-coupled mechanism that eliminates mRNAs 
containing premature translation-termination codons which have been acquired as 
consequence of mutations or errors during transcription or RNA processing (Brogna and Wen 
2009). Despite its physiological importance is not yet completely understood, NMD is 
thought to serve as an mRNA-surveillance mechanism to prevent the synthesis of truncated 




interactions. In addition, studies involving the inactivation in different species of central 
components of the NMD machinery have highlighted its function in regulation of 
physiological gene expression. These studies led to the suggestion that some alternative 
splicing events had evolved to exploit NMD to achieve quantitative post-transcriptional 
regulation (AS-NMD) (McGlincy and Smith 2008). Two critical steps are recognised in the 
NMD pathway: the PTC recognition and discrimination from natural occurring stops and the 
mechanism by which PTC-containing mRNAs are targeted for fast degradation. Despite 
conservation of the NMD pathway, the nature of the signals and the decay pathway of 
targeted mRNAs vary across species. In mammals the PTC is recognised thanks to the 
crosstalk between the terminating ribosomes and a downstream exon junction complex (EJC), 
a multimeric protein complex deposited by the spliceosome ∼20–24 nucleotides upstream of 
exon–exon junctions. More specifically a stop codon is recognised premature if it is found 
spatially located more than 50-55 nucleotides upstream an EJC (McGlincy and Smith 2008). 
During translation, the ribosome proceeds along the mRNA displacing EJCs, until it reaches 
the stop codon where then a termination complex forms and the mRNA then goes on to direct 
protein synthesis. When an mRNA contains a PTC, it is still recognised by the ribosome as a 
stop codon, but the presence of an exon-exon junction downstream sets the conditions for the 
interaction between the termination complex and the EJC, which activates the NMD pathway. 
The UPF1, UPF2 and UPF3 proteins are core components of the surveillance complex whose 
basic function is conserved in eukaryotes (Conti and Izaurralde 2005), and their deletion or 
silencing results in the stabilization of PTC-containing mRNAs, highlighting their important 
role in the NMD pathway. The model proposed comprises the recruitment of UPF1 by 
translation release factors, and its interaction with the UPF2 and UPF3 proteins bound to the 
downstream EJC. This event facilitates the assembly of an active surveillance complex 
consisting of UPF1, UPF2 and UPF3 and possibly other proteins (Baker and Parker 2004). 
Once an RNA transcript is recognised as aberrant, the enzymes responsible for its 
degradation through NMD are those involved in general mRNA decay. One decay pathway 
for NMD substrates involves removal of the cap structure by the decapping enzymes, which 
expose the body of the transcript to 5′-to-3′ degradation by XRN1 (Muhlrad and Parker 
1994). An alternative pathway, which also contributes to the decay of PTC-containing 
mRNAs, relies on the accelerated deadenylation and 3′-to-5′ degradation by the exosome and 




The human and mouse genomes have similar sequence organization and have most of their 
genes being homologous. Considering the important role of alternative splicing in gene 
regulation, researchers have wondered the conservation of such mechanism between human 
and mouse. From examination of human splice junctions, from a data set containing human 
transcripts from constitutively and alternatively spliced introns and exons, for comparison 
with mouse transcript data sets, researchers obtained a transcript coverage model indicating 
that 74% of constitutive human splice junctions and 61% of alternative human splice 
junctions are conserved in mouse. Therefore it was concluded that many, and probably most, 







1.12 Project aims 
Multiple epiphyseal dysplasia (MED) is an autosomal chondrodysplasia characterised 
by early-onset degenerative joint disease. Among the mutated genes identified in MED 
patients are those encoding for the pro-α chains of the collagen type IX, where the majority of 
mutations are splice site mutations (affecting the syntenous exon 3). Interestingly, all splice 
site mutations reported in COL9A2 and COL9A3 genes, lead to the skipping of exon 3 and 
therefore to the in-frame deletion of 12 amino acids from the COL3 domain of the α-helix. 
The consistency of the splice site mutations reported so far is remarkable and emphasises the 
importance of the COL3 domain in the pathogenesis of MED. The hypothesis is that COL3 
domain might have an important functional role for the protein in the matrix, but what that 
function is and why in the mutated form it causes EDM3 along with the other MEDs, is not 
clear. 
The aim of this project was to address these unresolved questions. The strategy applied was 
to reproduce the skipping of exon 3 of Col9a3 in a C57Bl/6 mouse line, in order to assess the 
molecular consequences of the phenomenon and to obtain a mouse model of EDM3. Using 
CRISPR/Cas9 genome editing technology, we have induced the deletion of exon 3, but our 
strategy led to the generation of two mutant mouse lines, Col9a3Δex3/Δex3 and Col9a3-/-. 
Therefore, the purpose of this thesis project was expanded to address additional related 
questions: 
Col9a3Δex3 
Is the Col9a3Δex3 mouse a model of EDM3? 
What is the role of the COL3 domain in the collagen type IX molecule and how, when 
mutated, does this contribute to the pathogenesis of EDM3? 
Col9a3-/- 
Is the Col9a3-/- mouse a functional knockout of collagen type IX as previously demonstrated 
in Col9a1-/- and Col9a2-/- mice? 
What are the differences and similarities with the previous described knockouts? 
Like deletion of Col9a1 or Col9a2, does the Col9a3-/- recapitulate aspects of Stickler 
syndrome? 
Can we deduce from Col9a3-/- mice further information about the role of collagen type IX 




Chapter 2.   







2.1.1 Commercially available kits 
Commercially available kits used in this study were: Quick Ligation™ Kit (M2200S, 
New England BioLabs, NEB); PureYield™ Plasmid Miniprep System (Promega, 
Southampton, UK); E.Z.N.A.® Tissue DNA Kit (D3396, OMEGA BIO-TEK); ReliaPrep™ 
RNA Tissue Miniprep System (Promega, Southampton, UK); mirVana™ miRNA Isolation 
Kit, with phenol (AM1560, Thermo Fisher Scientific); PHIRE Animal Tissue Direct PCR 
Mastermix Thermo (F170L, Fisher Scientific) DNA-free™ DNA Removal Kit (AM1906, 
Thermo Fisher Scientific); NucleoSpin® Gel And PCR  clean-up (740609, Macherey-Nagel); 
MEGAshortscript™ T7 Transcription Kit (AM1354, Thermo Fisher Scientific);  
MEGAclear™ Kit Purification for Large Scale Transcription Reactions (AM1908, Ambion–
Life Technologies Ltd.). 
2.1.2 Cell culture reagents 
DMEM/F-12 (High glucose, 21331020) and DMEM culture media were both 
purchased from Gibco, Life Technologies Ltd. (Paisley, UK). Foetal bovine serum (FBS), 
Dulbecco’s phosphate buffered saline (PBS), trypsin-EDTA (derived from porcine pancreas), 
L-glutamine, penicillin-streptomycin, and dimethyl sulphoxide (DMSO), were purchased 
from Sigma-Aldrich (Poole, UK). 
2.1.3 Cell lines 
2.1.3.1 HEK 293T 
HEK 293T cells were purchased from the ATCC (293T (ATCC® CRL-3216™)) and 
cultured in DMEM culture media containing 2mM L-glutamine, 100U/ml penicillin, 
100µg/ml streptomycin and 10% (v/v) FBS (DMEM complete). This cell line, originated 
from a foetus, is a highly transfectable derivative of human embryonic kidney 293 cells and 






NIH/3T3 cells were purchased from the ATCC (NIH/3T3 (ATCC® CRL-1658™) and 
cultured in DMEM culture media containing 2mM L-glutamine, 100U/ml penicillin, 
100µg/ml streptomycin and 10% (v/v) FBS. This cell line is a derivative of a mouse 
embryonic fibroblast NIH/Swiss and has proven useful in DNA transfection studies. Further 
details or datasheet available on ATCC website (www.atcc.org/). 
2.2 Methods: Generation and maintenance of mouse model  
2.2.1 CRISPR/Cas9 gRNAs design 
The first step for CRISPR/Cas9 genome editing is the design of the gRNAs, for which 
we used the online tool CHOPCHOP (http://chopchop.cbu.uib.no/) (Montague et al. 2014) 
selecting for mus musculus genome assembly and pasting the region of interest spanning the 
intronic region surrounding the exon 3 boundaries of Col9a3 gene (GRCm38/mm10, Pos.: 
>chr2:180599587-180600578). gRNAs hybridization with the two flanking regions of exon 3 
will trigger double-strand breaks with subsequent deletion of the exon 3. Four gRNAs (Table 
2.1) were chosen from the output list and no potential off-targets were found by searching for 
matches in the mouse genome. 
Table 2.1. | Sequences of the chosen gRNAs obtained using CHOPCHOP. PAM sequences 










#7 GATTCTCTCATCTATACCTGGGG sequence:320 - 48 
#8 GGGCCTGTGGAGACATTGTGGGG sequence:349 - 65 
#10 GGCCTGTGTTGCCCTAGGAGAGG sequence:548 + 65 






2.2.2 In-vitro transcribed gRNAs cloning into viral vector 
2.2.2.1 Lentiviral vector digestion 
5 µg of pLKO.1-puro U6 sgRNA BfuAI large stuffer plasmid (a gift from Scot Wolfe; 
Addgene plasmid # 52628) was digested with 15U of FastDigest BfuAI (NEB) and 3U of 
Fast AP (Fermentas) in 1X FastDigest Buffer containing 1mM DTT. Reaction volume was 60 
µl in total. The digestion was incubated at 37°C for 30 minutes. Inactivation of the enzyme 
was then performed at 65°C for 10 minutes. 
2.2.2.2 gRNAs oligo annealing 
Oligonucleotide annealing was performed using 0.1nM of each oligo per pair (Table 
2.2) in 1X T4 Ligation Buffer (NEB) in a total reaction volume of 10µl. This was incubated 
at 95°C for 5 minutes and then ramped down to 4°C at a speed of 0.1°C /sec. 
Table 2.2. | Forward and reverse sequence of gRNAs oligonucleotides. Oligonucleotide 
sequence in uppercase plus additional sequence for cloning in lowercase. 
Oligo name Sequence 
mCol9a3 g#7 F accgGATTCTCTCATCTATACCTG 
mCol9a3 g#7 R aaacCAGGTATAGATGAGAGAATC 
mCol9a3 g#8 F accgGGGCCTGTGGAGACATTGTG 
mCol9a3 g#8 R aaacCACAATGTCTCCACAGGCCC 
mCol9a3 g#10 F accgGGCCTGTGTTGCCCTAGGAG 
mCol9a3 g#10 R aaacCTCCTAGGGCAACACAGGCC 
mCol9a3 g#11 F accgGTTGCCCTAGGAGAGGCCTG 





2.2.2.3 gRNA cloning and bacteria transformation  
The Quick Ligation kit was used for the ligation reaction. Ligation was conducted using 
50ng of pLKO digested plasmid with 1µl of undiluted oligo duplex obtained after gRNAs 
oligo annealing reaction. 1X Quick Ligase buffer (NEB) and nuclease-free water were added 
to a total volume of 9µl. 1µl of Quick Ligase enzyme (NEB) was finally added before gently 
mixing the reaction by pipetting up and down and centrifuging briefly prior to incubation at 
room temperature (25°C) for 5 minutes.  
2µl of the ligation reaction was gently mixed to 50µl (one vial) of One Shot® Stbl3™ 
Chemically Competent E. coli (Invitrogen C737303) and incubated on ice for 30 minutes. 
Competent cells were then heat-shocked at 42°C for 45 seconds before being placed on ice 
for 2 minutes. 250µl of pre-warmed Super Optimal Broth (S.O.C.) medium (Invitrogen 
15544034) were added to each vial of cells and incubated at 37°C horizontally for 1 hour at 
225rpm in a shaking incubator. Subsequently, the transformation mixture was spread onto 
LB-agar plates containing ampicillin (100µg/ml) and incubated inverted at 37°C overnight. 
The following day individual colonies were selected and incubated in 5ml of LB 
supplemented with 100µg/ml ampicillin (Sigma-Aldrich) at 37°C in an orbital shaker at 
225rpm for 16 hours prior to plasmid purification.   
2.2.2.4 Minipreparation of plasmid DNA 
Plasmid DNA minipreparations were performed using the PureYield™ Plasmid Miniprep 
System according to the kit manufacturer’s recommendation. Plasmid DNA was eluted in 
30µl nuclease-free water and DNA concentration was determined using a NanoDrop ND-
1000 spectrophotometer. gRNA cloning was confirmed by Sanger sequencing (Source 
Biosciences, Nottingham, UK). 
2.2.3 Virus production in HEK 293T cells 
Viral particles were produced in HEK 293T packaging cells which were seeded at 
3.8×106 cells per plate in 10ml DMEM complete in 10cm tissue culture plates and left at 37 
℃, 5% (v/v) CO2 overnight. The following day a mixture of 3 transfection plasmids was 
prepared with 3.15µg of vector, 2.5µg of Packaging vector pPAX2 (Addgene plasmid # 
12260) and 0.63 µg of Envelope vector pCMV-VSV-G (Addgene plasmid # 8454) per dish. 




finally added to the mixture before incubating for 15 minutes at room temperature and then 
adding dropwise to each dish. The third day the media from each dish was replaced with 
10ml of fresh DMEM (plus supplements) with heat inactivated FBS. The viral supernatant 
was harvested at 48, 72, and 96 hours post transfection, centrifuged at ~500g for 10 minutes 
to pellet any cellular material, filtered through a 0.45 μm PES filter, and finally aliquotted 
and stored at -80 ℃ as soon as possible to avoid loss of titre. Cas9 containing viral particles 
were produced by exchanging the pLKO vector for LentiCRISPRv2 (Addgene plasmid # 
52961). Similarly, Green fluorescent protein (GFP) viral particles were also produced by 
exchanging the pLKO vector for pLJM1-EGFP (Addgene plasmid # 19319), as a positive 
control for viral production and transduction (data not shown). 
2.2.3.1 NIH/3T3 cells viral transduction 
NIH/3T3 cells (2×105 per well) were seeded overnight in 3ml of medium in a 6 well-
plate. The following day 500µl of medium was replaced with 500µl of medium containing 
pooled virus (pairs of gRNA virus and LentiCRISPRv2 virus (~165 µl of each)) and 
polybrene (Sigma Aldrich TR-1003) to give a final concentration of 8 µg/ml. The next day 
antibiotic selection for transduced cells was carried on by adding 2µg/ml puromycin (Sigma-
Aldrich) per well and cells were incubated for 2-3 days. Cells transduced with GFP viral 
particles were assessed via fluorescent microscopy. 
2.2.3.2 DNA extraction from transduced NIH/3T3 cells 
Genomic DNA was purified from gRNA-transduced NIH/3T3 cells using E.Z.N.A. ® 
Tissue DNA Kit following manufacturer’s protocol. Briefly, cells were harvested after 
trypsin treatment before adding 25 μL OB Protease Solution and 220 μL BL Buffer followed 
by incubation at 70°C for 10 minutes. 220 μL 100% (v/v) ethanol was added and the entire 
sample was then transferred into a HiBind® DNA Mini Column and centrifuged at maximum 
speed (≥10,000g) for 1 minute. Next, 500 μL HBC Buffer were added to the column and 
centrifugation at maximum speed was performed for 30 seconds. The column was placed into 
a new 2 ml collection tube and 700 μl DNA Wash Buffer added before centrifugation. This 
centrifugation was repeated to remove any trace of ethanol.  The column was then 
centrifuged at maximum speed for 2 minutes to dry and finally DNA was eluted by 





2.2.3.3 Phire PCR 
Polymerase chain reaction (PCR) on cell extracted DNA was carried out using Phire 
Hot Start II DNA. Each 20 μl PCR reaction mix contained 5X Phire Taq buffer, 0.2 mM 
dNTP mixture, 0.4 μl Phire Hot Start II Taq DNA Polymerase (Thermo scientific F-122L), 
and 0.5 µM of each primer (Table 2.3). An Applied Biosystems Veriti™ Thermal Cycler was 
used and PCR conditions are outlined in Appendix B.  
Table 2.3. | Primer sequences used for mouse genomic DNA and cDNA amplification. 
Primers were designed using Primer3. 
Oligo name Sequence 
mCol9a3 F GTGTCACTTGGAGGCTACTGTG 




2.2.4 CRISPR/Cas9 genome editing 
2.2.4.1 Production of gRNAs mRNA 
The T7 promoter was added to the sgRNA templates using PCR amplification. The T7 
promoter sequence, plus 6 bases at the 5' end as an extra ‘landing platform’ for the T7 
polymerase, was added to the forward primer complementary to the gRNA cloned in the 
pLKO vector as shown in Fig 2.1. PCR amplification was performed using as reverse 
complement primer (AAAAGCACCGACTCGGTGCC) for the TRACR region within the 
vector. Using 2ng of DNA plasmid plus gRNA template, PCR was carried out using Q5 Hot 
Start High-Fidelity DNA polymerase (NEB #M0493). Each 100μl PCR reaction mix 
contained 5X Q5 Reaction buffer, 200 μM of dNTP mixture, 1μl of (0.02U/µl) Q5 Hot Start 
Polymerase, and 0.5 µM of each primer. An Applied Biosystems Veriti™ Thermal Cycler 
was used following thermocycling conditions outlined in Appendix B. Purification of 
template was then performed using a Macherey‐Nagel NucleoSpin Gel and PCR clean-up kit 




volume of sample to adjust DNA binding conditions prior to loading on a NucleoSpin® Gel 
and PCR Clean-up Column and centrifugation. Two washes with 700µl of Buffer NT3 were 
then performed before drying the column silica membrane for 1 minute. Elution of DNA in 
water was finally achieved by centrifugation at room temperature for 1 minute.   
 
Fig 2.1. Schematic representation of the designed forward primers structure used for 
gRNAs production. 
2.2.4.2 In vitro transcription (IVT) of Col9a3 #7 and #11 gRNAs 
The PCR amplified T7-sgRNA products (with gRNAs #7 and #11) were used as a 
template for in vitro transcription using the MEGAshortscript T7 kit. In a total volume of 
20µl, 100nM of DNA template were incubated with 7.5 mM of each of the four 
ribonucleotides, 10X T7 reaction buffer and enzyme mix. The reaction was gently mixed 
before incubation at 37˚C for 2 hours. A TURBO DNase treatment at 37˚C for 15 minutes 
was finally performed. 
2.2.4.3 Purification of sgRNA mRNA 
Recovery of sgRNAs was performed using the MEGAclear 3 ™ Kit. The RNA sample 
was brought to 100 µL with Elution Solution and mixed gently. Subsequently, 350 µL of 
Binding Solution Concentrate were added to the sample and mixed before addition of 250 µL 
of 100% (v/v) ethanol. The RNA mixture was passed through a Filter Cartridge by 
centrifugation for 1 min at 10,000g. Two washes with 500 µL of Wash Solution were 
performed and centrifugation continued for 10–30 sec to remove the last traces of Wash 
Solution. The elution of RNA from the filter was obtained by applying 50 µL of RNase free 
water to the centre of the Filter Cartridge and incubation in a heat block set to 65–70°C for 5–





2.2.4.4 Zygote cytoplasm injection of gRNAs into foster mother 
Zygote cytoplasm injection was performed by Dr Colin Miles and Paul Cairns to 
generate both transgenic mouse lines following the Ittner and Götz described procedure for 
pronuclear injection to obtain a transgenic mouse line (Ittner and Gotz 2007).  
Briefly, 10–14 days before the first mating, anesthetised stud males were vasectomized and 
sterility was checked by breeding with females.  
To produce zygotes for pronuclear injection, superovulation was induced in females through 
a first intraperitoneal injection of 5 IU pregnant mare’s serum gonadotropin (PMSG) 
following by 5 IU of human chorionic gonadotropin (hCG), before mating with males. To 
obtain pseudo-pregnant females, females in oestrus (as indicated by a swollen, moist and pink 
vagina) were put together with vasectomised males until they were plugged. For zygote 
preparation, super ovulating females were sacrificed and zygotes harvested with follicular 
cumulus cells, after successive treatments with hyaluronidase (1-2 ul of 10 mg/ml 
hyaluronidase (H3884; Sigma)). 
Preparation of DNA for injection was performed by Professor David Young. 
Transgenic mice were generated by injecting a mix of recombinant Cas9 protein 
(TGEN_CP1, ToolGen, CamBioScience, UK) (final concentration of 40 µg/ul), with two IVT 
guide RNAs (each at 50µg/ul) in standard injection buffer (10mM Tris, 0.1mM EDTA pH 
7.5) into the cytoplasm of fertilised eggs. Zygote injection was achieved thanks to the help of 
a holding capillary to stabilize one zygote in the centre of the plate and injection performed 
when position of the zygote was in the same plane of focus as the opening of the holder, 
ideally facing it with the polar body and the female and male pronuclei aligned horizontally. 
The swelling of the female pronucleus was considered as evidence of DNA injection. After 
injection, about 15-30 injected zygotes were reimplanted into foster mothers. Briefly, an 
anesthetised pseudopregnant female was incised parallel to the dorsal midline, and the ovary 
and attached oviduct and uterus gently pulled out from the fat pad in order to expose the 
infundibulum between the coiled oviduct and the ovary. The reimplantation capillary loaded 
with the injected zygotes arranged in a row was inserted into the infundibulum to slowly 
blow the zygotes inside, before pushing the ovary back into the abdomen and sewing up the 
incision. Reimplanted foster mothers were kept warm until fully recovered and hosted in 




2.2.5 Maintenance  
Mice were housed at the Functional Genomics Unit (FGU) at the Institute of Genetic 
Medicine at Newcastle University, in compliance with the Animals (Scientific Procedures) 
Act 1986 and its associated Codes of Practice. Up to 5 mice were housed together in 
independently ventilated cages (300cm2, 12cm height) to allow enough space for physical 
activity/exercise. All animals had access to food and drinking water ad libitum and were 
subjected to a 12-hour light-dark cycle. When breedings were ended, re-introduction of the 
male breeders to already populated cages was avoided in order to avoid social incompatibility 
issues. The FGU technical staff performed the check and cleaning rota of the cages twice a 
week. Detailed records about each animal used in this study was recorded using the AniBio 
and Softmouse software systems and returns of procedures including severity limits and 
protocols performed annually to the Home Office. Every mouse procedure was performed 
under Project licences n° 60/4525-1 and n° P8A8B649A-1. 
2.2.6 Genotyping  
2.2.6.1 DNA extraction 
Mice were ear-notched at postnatal day 21 and separated into male/female cages after 
the weaning period. DNA was extracted from ear biopsies using the PHIRE Animal Tissue 
Direct PCR Master mix (Thermo-Fisher) following manufacturer’s instructions. Briefly, 20µl 
of Dilution Buffer plus 0.5µl of DNA Release Additive from the Kit were added to each 
sample, these were vortexed and centrifuged (13,000g) prior to subsequent incubations at 
room temperature for 2-5 minutes and at 98°C for 2 minutes. The DNA extracted was finally 
vortexed and centrifuged again before Phire PCR amplification or storage at -20 C until 
required.  The PCR reaction consisted of 8 µL nuclease free water, 2X Phire green master 
mix, 0.5 µM forward and reverser primer (Table 2.3) and 1µL of extracted DNA mixture. 
PCR was performed in an Applied Biosystems® Veriti™ Thermal Cycler following the 
thermal cycle programme in Appendix B. PCR products were examined by agarose gel 
electrophoresis. PCR products in gel loading dye (NEB #B7025S) were loaded, onto a 1.5% 
(w/v) agarose gel in 1XTAE (Tris-Acetate-EDTA) buffer. In order to determine DNA band 
size, a DNA marker BIOLINE Hyperladder 100bp (BIO-33056) was loaded along with PCR 
products. The DNA was electrophoresed at 90 V for ~45 minutes and visualised under UV 




2.3 Methods: Validation of mouse model  
2.3.1 Bone measurements 
3-week old mice were sacrificed by exposure to CO2 and 9-week old mice were 
anesthetised using isoflurane.  X-rays images were acquired as DICOM raw files using the 
Faxitron MX-20 cabinet X-ray system (Faxitron Bioptics) at 23 kV for 5 seconds. Raw files 
were then opened in the Fiji (ImageJ) software and bone measurements (tibia, femur, inner 
canthal distance (ICD), skull and hip angle) were performed using the measure tool (Fig 2.2). 
ICD was measured as a marker of intramembranous ossification, whereas length of the skulls, 
tibiae and femurs as indication of endochondral ossification. Hip development was assessed 
by measuring the angle formed by the tuberosity of the ischium protruding from the Ilium 
line. Average measurements of the right and left tibia, femurs and hip angles were calculated 
per mouse. 
 
Fig. 2.2 | Radiographic analysis of skeletal mice morphology. Conventional scheme of mouse 
bone measurement used for x-ray analysis: the inner-canthal distance (ICD) measured as marker of 
intramembranous ossification whereas skull, femur and tibia length as markers of endochondral 




2.3.2 Quantitative bone morphology by micro-computed tomography (μCT) 
2.3.2.1 Dissection and fixation of bones for μCT 
18-week old male mice were sacrificed by exposure to CO2, subsequently the skin was 
removed from their right legs up to the hip and the head of the femur was dislocated from the 
hip socket in order to remove the limb from the mouse. The foot was cut from the ankle joint 
and the soft tissue removed carefully so as not to disturb knee joint. Legs were then fixed in 
10 % (v/v) neutral buffered formalin (containing 4% (w/v) formaldehyde) overnight before 
being washed twice in PBS and being stored in 70% (v/v) ethanol and water for long-term 
storage, until analysis by μCT. 
2.3.2.2 X-Ray micro-computed tomography (μCT) 
Femurs and tibiae from 18-week old mice were subjected to bone density analysis to 
check their cortical and trabecular bone. All μCT scans were performed using the SkyScan 
1272v2 μCT analysis instrument in the laboratory of by Professor Rob van‘t Hof at the 
Institute of Ageing and Chronic Disease, University of Liverpool (UK). Bone specimens 
were placed in 5ml sample vials filled with 70% (v/v) ethanol and then anchored to the 
rotating stage of the μCT X-ray chamber. For cortical bone density multiple 2D image 
projections of the full height knee were obtained with the following settings: a rotation step 
of 0.4°, an energy filter of 0.50 Aluminium, image format of 2016 x 1344 at a vertical 
position of 33 mm, oversized scan of 57 and a spatial resolution of 9 µm. X-rays were 
obtained at 50 kV and 800 mA. For Trabecular Bone density multiple 2D image projections 
of knees were obtained with a rotation step of 0.3°, an energy filter of 0.50 Aluminium, 
image format of 4032 x 2688 at a vertical position of 46 mm, not applying oversize scanning, 
and with a spatial resolution of 4.5 µm. The scanning protocol was set for each sample stage 
on the machine.  To generate a reconstructed 3D bone image, 2D images for each bone were 
stacked and reconstructed using the NRecon (v1.6.4.1, Bruker) programme selecting the 
region of interest to be reconstructed. Reconstruction was performed with the smoothing 
function on, selecting a ring artefact of 5 and a beam hardening of 38% and with a Gaussian 
smoothing kernel in the advanced options. A dynamic range between 0 and 0.11 was then set 
before starting the process. 3D µCT reconstructions for trabecular bone was performed on the 
region which was 50 slides (225 µm) away from the femoral growth plate in femurs or tibial 




which was 50 slides (450 µm) away from the femoral great trochanter in femurs or the fibular 
notch in tibiae. The images shown in the results section are cross-sectional images of 3D µCT 
reconstructions obtained using the software CtVox for trabecular bone and Dataviewer for 
cortical bone from the median animals of each genotype at similar distance from the 
reference points mentioned. Worth mentioning that our standardised method of analysis and 
imaging did not take into account that one of the genotypes presented shorter long bones. 
2.3.2.3 Bone architecture analysis from 3D μCT images 
Reconstructed 3D bone images were used to analyse bone architecture using the CTAn 
(v.1.16) programme. The volume of interest (VOI) to be analysed was set using the 
Dataviewer programme. In order to analyse trabecular bone, the VOI was set to a depth of 
900 μm, 225 μm from the bottom of the tibial or femoral growth plate. In order to analyse the 
cortical bone of the tibial and femoral shaft, the VOI was set to a depth of 450 μm, from the 
top of the fibular notch of the tibia or from the bottom the greater trochanter crest of the 
femur. Femoral and tibial trabecular and cortical VOIs were then opened in CTan and were 
used as the input with different software macros for cortical and trabecular analysis. The 
macros were written and kindly provided by Professor van‘t Hof.  Reconstruction parameters 
and the selected VOI were kept consistent between all samples. The higher and lower grey 
threshold values corresponding to bone in the macro were set at 70 and 255 for cortical bone 
and at 60 and 255 for trabecular bone respectively. Statistical analysis on the results was 
carried out using the Student’s unpaired t-test comparing the bone structural parameters 
between control and mutant mice. 
2.3.3 Tissue preparation for histological and immunological analysis. 
The mice were sacrificed and dissected removing the skin and part of the muscle, 
before knee joints were collected and fixed. Fixation was performed for 24 hours at room 
temperature or for 48 hours at 4°C in 4% (v/v) formaldehyde (for histological protocols) or in 
a solution of 95% (v/v) ethanol / 5% acetic acid (for immunohistochemical (IHC) protocols). 
After fixation the bones were decalcified in 20 % (w/v) EDTA pH 7.4 (Appendix A) for 1 
week (for mice up to 2 weeks of age) or 2-3 weeks (for mice 3-9 weeks of age), with gentle 




Following decalcification, knee joints were washed with running tap water for 1 hour and 
then transferred in 70% (v/v) ethanol prior to overnight processing in a Thermo Scientific™ 
STP 120 Spin Tissue Processor (Appendix D). Tissue samples were then embedded in 
paraffin blocks in a flat orientation or patella down orientation (for destabilisation of medial 
meniscus (DMM) experiment) and left to set overnight.  
Wax blocks were placed at -20°C prior to sectioning. Legs were sectioned using a Thermo 
Scientific™ HM 355S automatic microtome to 6μm sections (histology and 
immunohistochemistry) or 4 μm (DMM sectioning). Wax sections were fixed onto 
Superfrost® Plus slides (CellPath MBB-0102-54A) at 60 °C on a hot plate for 1 minute and 
left to air dry overnight. During sectioning, sister tissue sections were collected starting from 
the beginning of the appearance of the growth plate and finishing when the growth plate 
started to disappear, to be sure to cover the entire depth of the tissue. An average of 25-30 
slides were collected per sample and they were numbered to be able to recognise the tissue 
depth at which sections were collected. Matching of the slides was carried out by choosing 
those slides with the same or close number for each genotype, representative of each region 
(initial, middle and end region) of the tissue. Matched numbered slides of different samples 
and biological replicates were then processed for staining and imaging showed in this thesis 
work.  
2.3.4 Haematoxylin and eosin (H&E) staining 
Sectioned formaldehyde-fixed joints were dewaxed in xylene and were hydrated in a 
decreasing series (100%, 95%, 75%, 50%) of ethanol and then washed with tap water for 1 
minute. Slides were next submerged in filtered Harris modified haematoxylin for 1.5 minutes 
before being rinsed in tap water for 1 minute. Slides were dipped in 0.5% acid alcohol 
(Appendix A) followed by a water rinse, where needed, to remove excess stain, before a 30 
seconds incubation in Scott’s tap water to enhance nuclear staining. Subsequently, slides 
were stained in filtered alcoholic eosin Y for 30 seconds, and rinsed in water for the same 
time. Afterwards, stained slides went through dehydration in increasing concentrations of 
ethanol (50%, 75%, 95%, 100%) and placed in xylene before being mounted using DPX 
Phthalate-free mounting media (CellPath). Once dry, images were acquired using a DM5500 




morphometric measurements were performed by LAS V4.5 (Leica) and Fiji (Image J) 
software. 
2.3.5 Toluidine blue staining  
Toluidine blue staining of the cartilage growth plate was used to analyse sulphated 
proteoglycans. Formaldehyde-fixed limb specimens were sectioned and dewaxed in xylene, 
then sections were rehydrated to water through a series of decreasing ethanol concentrations 
as described previously. Slides were then incubated in 0.04 % toluidine blue pH 3.75 
(Appendix A) for 2 minutes. To remove excess stain, slides were rinsed twice in water before 
being incubated in a Nuclear Fast Red solution for 50 seconds to counterstain the nuclei. 
Sections were then rinsed twice in tap water and were dehydrated in 75 % and 100 % ethanol 
for 3 minutes for each incubation, and finally placed in xylene before being mounted using 
DPX Phthalate-free mounting media (CellPath). Once dry, sections were imaged using a 
DM5500 B bright field microscope (Leica). 
2.3.6 Safranin-O – Fast Green staining 
This method is used for the detection of cartilage, mucin and mast cell granules on 
formalin- fixed paraffin-embedded tissue sections. The cartilage and mucin will be stained 
orange to red and the nuclei will be stained black in a green background corresponding to 
cytoplasm. The method is recommended as a semi-quantitative scoring system following 
DMM surgery. Two independent and blind scorers assessed cartilage damage eight-weeks 
post-DMM surgery (see 2.3.13 Surgical destabilization of the medial meniscus (DMM)). 
Briefly, slides were dewaxed and rehydrated as described in section 2.3.4. Slides were stained 
with Weigert’s iron haematoxylin working solution (SIGMA-Aldrich, Poole, UK) for 10 
minutes and then briefly washed under running distilled water. Slides were then quickly 
dipped in 0.5% acid alcohol to remove excess hematoxylin and then rinsed in running tap 
water to stop the reaction. Slides were then placed in 0.06% (w/v) Fast Green solution 
(SIGMA-Aldrich, Poole, UK) for 5 minutes and then quickly rinsed in 1% (v/v) acetic acid 
solution (SIGMA-Aldrich, Poole, UK) for no more than 10-15 seconds. Slides were then 
stained in 0.1% (w/v) Safranin O solution for 5 minutes before being transferred to 95% (v/v) 




Finally, slides were placed twice in xylene for 10 minutes each, before mounting in DPX 
Phthalate-free mounting media and left overnight at room temperature to dry. 
2.3.7 Picrosirius red staining 
Picrosirius red staining was used to visualise collagen fibres (Appendix E.3). The 
reaction of the dye with collagen fibres is able to enhance their birefringence under polarised 
light, collagen fibrils then appear red, orange, yellow, or green depending on their thickness, 
going from red to green as thickness decreases. For picrosirius red staining paraffin sections 
were de-waxed and hydrated through a series of decreasing ethanol concentrations up to 
distilled water as previously described. Nuclei were then stained with Harris modified 
haematoxylin for 20 minutes and excess stain removed by washing in running tap water for 
20 minutes. Picrosirius red stain was then applied to sections and incubated for 1 hour. 
Sections were then washed in two changes of 0.5 % (v/v) acidified water before dehydration 
through three changes of 100 % ethanol. Slides were finally immerged in xylene prior to 
mounting with DPX Phthalate-free mounting media. The staining was visualized at 20X 
magnification using transmitted polarised light with a Leica DM2700 P polarising 
microscope kindly available from Dr Cees van der Land at the School of Natural and 
Environmental Sciences, Geosciences Institute. 
2.3.8 Immunohistochemistry 
Three-week-old mice were sacrificed and their right legs harvested, fixed, decalcified, 
embedded and sectioned as described in section 2.3.3 Tissue preparation for histological 
and immunological analysis.. Sections were dewaxed in xylene and dehydrated through a 
decreasing gradient of ethanol before two washes in water and re-equilibration in PBS. 
Sections were pre-treated with 0.2% (w/v) bovine hyaluronidase in PBS and incubated at 
37°C in a humidified chamber for 45 minutes for epitope unmasking. They were then 
incubated in 0.5% (v/v) Triton™ X-100 (Sigma) for 5 minutes and with 5μg/ml proteinase K 
in PBS for 5 minutes at room temperature, washing with PBS in between each step. Blocking 
was conducted with a 0.6% (v/v) goat serum (Vector Laboratories Ltd., UK), 1% (w/v) 
bovine serum albumin (BSA, Fisher Scientific) solution in PBS for 1 hour at room 
temperature. Sections were then incubated overnight at 4 °C with primary antibodies diluted 




room temperature with secondary antibodies diluted in 1% (w/v) BSA. Antibodies were then 
removed with a final wash in PBS before mounting in Fluoroshield Mounting Media with 
DAPI (ab104139 Abcam). Antibody dilutions are listed in Appendix C. 
Slides were imaged on a Zeiss AxioImager with Apotome (IGM, system 3) microscope, at 
20X and 40X magnification selecting the DAPI and corresponding AlexaFluor™ filter sets 
on the ZenPro microscope associated software. Exposure times were set on negative control 
sections for equivalent antibodies (Appendix C, Fig.C1).   
2.3.9 Bromodeoxyuridine (BrdU) labelling assay 
For the detection of proliferative cells a 5’-bromo-2’-deoxyuridine (BrdU) labelling 
assay was performed on 3-week-old mice tissue sections. Mice were intraperitoneally 
injected with 0.01mL/g BrdU (Amersham RPN201) labelling reagent. Two hours post-
injection, mice were sacrificed by exposure to CO2 and right limbs were fixed for 
immunohistochemistry, decalcified, processed, embedded and sectioned as previously 
described.  
BrdU positive cells were detected by immunohistochemistry. 6μm sections were dewaxed in 
xylene and dehydrated through a decreasing gradient of ethanol. To unmask antigens, slides 
were incubated in 4M HCl for 15 minutes. Slides were then neutralised in 0.1M borate buffer 
pH8.5 (Appendix A) for 5 minutes and then washed in PBS before blocking with 4% (v/v) 
donkey serum (AbD Serotec) (diluted in PBS) for 20 minutes at room temperature or 
overnight at 4°C. Incubation with anti-BrdU primary and subsequently secondary antibodies 
(Appendix C) was performed following an immunohistochemistry protocol as described in 
section 2.3.8 Immunohistochemistry. Slides were mounted using the Fluoroshield 
Mounting Media with DAPI and allowed to dry in a dark box overnight. Images of sections 
were acquired using a Zeiss AxioImager with Apotome (IGM, system 3) microscope at 20X 
magnification using the DAPI and AlexaFluor™488 filter sets using the tiles and stitching 
functions of the ZenPro software for higher imaging resolution. Exposure times were set on 
negative controls which were sections not probed with anti-BrdU antibody. 
Raw images were viewed in Fiji (ImageJ), colour channels were split and images were 
converted to grey-scale. BrdU positive cells were counted using the Watershed Segmentation 
algorithm on the Fiji program and expressed as a percentage of total cells within the 




and analysed using a Student’s unpaired t-test carried and statistical significance was given as 
p < 0.05. 
2.3.10 Analysis of gene expression 
2.3.10.1 RNA extraction from mouse tissue 
Femoral head caps and xiphoids were dissected from 3-week old mice and snap frozen 
in liquid nitrogen and stored at -80 °C until further use. Total RNA was extracted by 
disrupting the frozen tissue using a Satoris Mikrodismembrator S, shaking for 1 minute at 
2000 rpm. Briefly, the frozen tissue was placed in a cooled stainless steel vial containing a 
cooled stainless steel ball and frozen BL + TG buffer according to sample weight, supplied 
by the ReliaPrep™ RNA Tissue Miniprep System (Promega). RNA was then extracted from 
the powder obtained after tissue disruption using the ReliaPrep™ RNA Tissue Miniprep 
System according to manufacturer’s instructions. Resulting RNA was eluted in 15µl RNase-
free water and its concentration assessed using the NanoDrop ND-1000 spectrophotometer. 
2.3.10.2 Reverse Transcription and cDNA amplification  
For reverse transcription to 1µg of tissue extracted RNA, nuclease-free water was 
added to 9µl final volume and 0.1µg/µl random hexamers pd(N)6 (Integrated DNA 
Technologies, IDT) were added and heated to 70°C for 5 minutes. The samples were then 
placed on ice. To the cooled samples a mixture of 0.25mM dNTPs (Bioline), 4µl of 5X First 
Strand Buffer, 10mM DTT, 1 µl (200 U) Moloney Murine Leukaemia Virus (M-MLV) 
reverse transcriptase (all ThermoFisher Scientific) and water was prepared for a total reaction 
volume of 20µl. Reverse transcription was performed at 42°C for 1 hour. The cDNA obtained 
was immediately used for PCR amplification following the protocol in section 2.2.3.3 Phire 
PCR and PCR cycling programme in Appendix B, or stored at -20°C for future use. 
2.3.10.3 Isolation of rib primary chondrocytes 
Mice at the age of 1 week were sacrificed by cervical dislocation, skinned and the chest 
internal organs removed in order to separate their thoracic cages. Once the sternum was 
removed, ribcages were cut and opened along the spine, cleaned from the bone marrow, and 
placed in warm PBS to keep moist, until all dissections were completed. Each ribcage was 




medium (DMEM) (Sigma-Aldrich) at 37°C for 75 minutes, vortexing every 15 minutes. Then 
in a Petri dish under the microscope, single ribs were separated and cleaned from muscle and 
fibrous tissue, cartilage harvested and digested with 2 mg/ml collagenase type II at 37°C for 3 
hours, vortexing every 30 minutes. After incubation, cartilage was mechanically 
disaggregated by pipetting and released chondrocytes filtered, washed in PBS, and pelleted.  
2.3.10.4 RNA isolation from primary chondrocytes  
RNA was isolated from ribs primary chondrocytes using mirVana™ miRNA Isolation 
Kit according to manufacturer’s protocol. Briefly, about 400µl of Lysis/Binding Buffer 
solution were added to each cell pellet according to estimated cell number and vortexed 
vigorously to obtain a homogenous lysate. Afterwards, organic extraction was carried out by 
adding 1/10 volume of ‘miRNA Homogenate Additive’ to the cells, mixing by inverting the 
tubes several times, and incubation on ice for 10 minutes. A volume of Acid-
Phenol:Chloroform, pH 4.5, (#AM9720, Thermo Fisher Scientific) equal to the initial lysate 
volume was added, vortexed and samples centrifuged for 5 minutes at 10,000g at room 
temperature to separate the aqueous and the organic phases. The aqueous phase was 
recovered to a fresh tube. For final total RNA isolation, 1.25 volumes 100% ethanol were 
added to the aqueous phase, thoroughly mixed by vortexing, loaded onto a kit Filter Cartridge 
which was quickly centrifuged at 10,000g. The filter was then washed three times, first with 
miRNA wash solution 1, then miRNA wash solution 2 and finally wash solution 3, before 
and elution via centrifugation (10,000g for 30 seconds) into a fresh collection tube with 50 µl 
of pre-heated (95˚C) nuclease-free water. RNA was stored at -80 ˚C until further use.  
2.3.10.5 RNA sequencing 
RNA sequencing was carried out on RNA isolated from costal primary chondrocytes. 
The extracted RNA was initially subjected to a DNase treatment step using the DNA-free™ 
DNA Removal Kit (# AM1906, Thermo Fisher Scientific) in order to avoid genomic DNA 
contamination.  RNA integrity was checked on an Agilent Technology Bioanalyzer and 
samples with a RNA integrity number (RIN) ≥ 8 (Appendix E.1) were considered for 
subsequent sequencing library preparation. Sequencing libraries were prepared from total 
RNA using the Illumina TruSeq Stranded mRNA library preparation kit following 
manufacturer's instructions. Briefly, the Poly-A containing mRNA molecules were purified 




fragmented into small pieces using divalent cations under elevated temperature. Cleaved 
RNA fragments were copied into first strand cDNA using reverse transcriptase and random 
primers in the presence of Actinomycin D to prevent spurious DNA dependent synthesis. 
Second strand cDNA synthesis followed using DNA polymerase I and RNase H where the 
incorporation of dUTP in place of dTTP quenched the second strand during amplification. A 
further step of 3’-blunt end adenylation prevented the fragments from ligating to each other 
during the adapter ligation reaction. A corresponding single 'T' nucleotide on the 3' end of the 
adapter provided a complementary overhang for ligating the adapter to the fragment in order 
to prepare the double strand cDNA for hybridisation onto a flow cell. PCR enrichment of 
DNA fragments was conducted before final cDNA library preparation. Sequencing was 
performed on an Illumina NextSeq 500 platform (following manufactures instructions) 
yielding ~12 million 75 bp single reads per sample. Four samples were sequenced for each 
biological condition (n = 4). Read QC was performed using FastQC and summarised using 
MultiQC (Ewels et al. 2016). All samples passed QC. Transcripts were quantified using 
Salmon (Patro et al. 2017) in quasi-mapping mode to mouse genome build GRCm38/mm10 
and summarised to gene level using the tximport package in R. Batch effects were estimated 
using the RUVs method from the RUVSeq package (Risso et al. 2014), the factors of 
unwanted variation were adjusted in the differential expression analysis model. 
Normalisation and differential expression analysis were performed using the DESeq2 
package using default settings (Love et al. 2014). An FDR threshold of 0.05 was used to filter 
significant differentially expressed genes. Sequencing was performed by the Genomics Core 
Facility, Newcastle University, and bioinformatics by Dr Kat Cheung within the 
Bioinformatics Support Unit. 
2.3.10.6 Sequential protein extraction 
Three-week old mice were humanly sacrificed and their cartilage was dissected by 
dislocation of femoral head from the acetabulum of the hip joint and subsequent removal of 
cartilaginous femoral head cap. Five biological replicates per genotype were used, 
comprising both femoral heads from each mouse pooled together and immediately snap-
frozen in liquid nitrogen and stored at -80°C until protein extraction step. In the first step of 
protein extraction, femoral heads were dissected into small pieces with a scalpel before being 
transferred into a pre-weighed clean Eppendorf and weighed. The first round of extraction 




NaCl, 50mM Tris-HCl, pH 7.4) per weight in mg of tissue. The following day, samples were 
centrifuged for 5 minutes at 13,000g at 4°C and the supernatant collected in 100 µl aliquots, 
and stored at -80°C. Pellets from each sample were then resuspended in an appropriate 
volume of pre-chilled Buffer II (1M NaCl, 10mM EDTA, 50mM Tris-HCl, pH 7.4), vortexed 
vigorously, and incubated at 4°C on a rotating mixer overnight. The next day the same 
procedure as previously was performed, samples were centrifuged for 5 minutes at 13,000g at 
4°C, the supernatant collected in 100 µl aliquots, and stored at -80°C. The pellet from this 
centrifugation was resuspended in cold Buffer III (4 M GuHCl, 10 mM EDTA, 50 mM Tris, 
pH 7.4), vortexed, and kept rotating overnight at 4°C. The following day samples were 
centrifuged at 13,000g at 4°C for 5 minutes and the supernatant removed in 100 µl aliquots 
and stored at -80°C. Ethanol precipitation of proteins was carried out adding 1.4ml of 96% 
(v/v) ethanol to each 100 µl aliquot and mixing gently before overnight incubation at 4°C. In 
the morning, samples were centrifuged at 4°C for 15 minutes at maximum speed and 
supernatant collected with help of a syringe. 1ml of wash solution made of 96% (v/v) ethanol 
with Tris-buffered saline (9:1 ratio) was added to pellets, vortexed to let them dissociate from 
wall of tube and incubated for 1 hour. Two more centrifugation cycles were carried out at 
max speed for 15 minutes (at 4°C) and the supernatant completely removed with a syringe to 
let the pellet air dry. Pellets were finally resuspended in 60µl of water and kept at -80°C until 
immunoblotting analysis. 
2.3.10.7 SDS-polyacrylamide gel electrophoresis and immunoblotting 
Sequential protein extracts were analysed by western blotting. Briefly, to 20μL ethanol 
precipitated proteins, 5X Laemmli sample buffer (all buffers are given in Appendix A) was 
added, this included 10% (v/v) β-mercaptoethanol when reducing conditions were applied. 
Samples were immediately loaded (if under non-reducing conditions) or denatured at 95°C 
for 5 minutes before being loaded into a 4-12 % NuPAGE® Bis-Tris precast gel (Invitrogen 
#NP0335BOX) alongside a Precision Plus Protein™ dual colour protein marker (Biorad 
#1610374). Electrophoresis was performed in NuPAGE MOPS SDS-PAGE running buffer 
(Invitrogen # NP0001) for 2 hours at 100 V. Electroblotting of proteins was carried out onto a 
Polyvinylidene difluoride membrane (PVDF) membrane in 1X Towbin transfer buffer 
overnight at 80mA at 4°C. Blocking for one hour in a 5% (w/v) solution of semi-skimmed 
powdered milk in PBS-T was carried out to prevent non-specific binding of antibody to the 




primary antibody in a 5% (w/v) BSA/TBS-T solution at 4°C. The following day the primary 
antibody solution was removed from the membrane and the membrane washed three times 
for 10 minutes in 1X TBS-T. The membrane was incubated at room temperature with a 
species appropriate horseradish peroxidase (HRP)-conjugated secondary antibody in a 5% 
(w/v) powdered milk/TBS-T solution for 1 hour. After secondary antibody incubation, the 
membrane was washed 3 times for 10 minutes in TBS-T to remove excess of antibody before 
being developed using Amersham ECL-advanced western blotting detection reagents 
(#RPN2106) and imaged using an Azure Imaging System. Primary and secondary Antibodies 
dilutions are outlined in Appendix C. 
2.3.11 Atomic Force Microscopy (AFM) 
Atomic Force Microscopy was performed on growth plate cartilage. Newborn and six-
week old mice were euthanized and their hind limbs collected after peeling off their skin, 
embedded in optimal cutting temperature (OCT, CellPath) tissue freezing medium and snap-
frozen in liquid nitrogen. The following steps of tissue processing, AFM measurements and 
analysis, were performed by Dr. Attila Aszodi and Bastian Hartmann at the Clinic for 
General, Trauma and Reconstructive Surgery Ludwig-Maximilians-University in Munich, 
Germany.  
Cryo-sectioning: Samples were sectioned to 20 μm-thickness using a Leica Cryostat CM1950 
(Leica Biosystems GmbH, Nussloch, Germany). In order to preserve the morphology of the 
undecalcified leg, before each cut, a transparent one-sided adhesive tape was placed on the 
sample and a transparent double-sided adhesive tape was placed on a microscope slide. After 
cutting the tape side of the section was attached to the chilled microscope slide via the 
double-sided adhesive tape. Samples were stored at -20°C until AFM measurements.  
AFM measurements: Immediately before the measurement, the slide was taken out of the 
freezer and left at room temperature for 10 minutes. PBS was applied to the section and the 
tissue was given 5 minutes to equilibrate. AFM measurements were performed using a 
NanoWizard® I (JPK Instruments AG, Berlin, Germany). An overview force map on a 
square area of 30 × 30 μm containing 30 × 30 force-indentation curves was made to identify 
the location of the interterritorial matrix (ITM) and the cells. Three maps (3 × 3μm with 25 × 
25 force-indentation curves) were made on the ITM. Parameters of the force curves were: a 




Camarillo, CA, USA) with a nominal spring constant of 0.1N/m. Two slides per animal were 
measured and three animals for each genotype and age were examined. 
Data processing: AFM curves were analysed using the JPK Data Processing software (JPK 
Instruments AG, Berlin, Germany). To obtain the stiffness value (Young’s modulus), the 
Hertz-Sneddon-model for a pyramidal tip was fitted on each force-indentation curve. All 
Young’s moduli of each genotype (three maps per slide; two slides per mouse; three mice per 
genotype) were merged to one distribution (histogram). Finally, a bimodal distribution was 
fitted on the histograms to obtain the peak values using Igor Pro software V. 6.3.7 
(WaveMetrics Inc., Lake Oswego, OR, USA). 
2.3.12 Transmission Electron Microscopy (TEM) 
Transmission Electron Microscopy (TEM) was used to visualise cartilage ECM 
structure. Seven-day old pups were sacrificed by cervical dislocation and their tibia dissected 
by cutting the lateral and medial collateral ligaments and the two cruciate ligaments in order 
to detach the femur and leave the meniscus intact. As much soft tissue as possible was 
removed from the tibial epiphysis and metaphysis prior to fixation in 2% (w/v) 
glutaraldehyde in sodium cacodylate buffer at 4°C (provided by the EM unit) for a minimum 
of overnight, but up to two weeks incubation. Subsequent protocol steps were performed by 
staff at Newcastle University Electron Microscopy Research Services. A secondary fixation 
was performed with 1% (w/v) osmium tetroxide to preserve the lipid content and add contrast 
to the tissue. Tissue samples were then dehydrated through an increasing gradient of acetone 
before being impregnated in increasing concentration of resin in acetone prior to final 
embedding in 100% resin at 60°C for 24 hours. Semi-thin survey sections of 0.5μm were cut 
and stained with 1% toluidine blue in 1% borax to visualise the growth plate. Ultrathin 
sections of approximately 70nm were then cut using a diamond knife on either an RMC MT-
XL or Leica EM UC7 ultra microtome. The sections were stretched with chloroform to 
remove compression and mounted in pioloform-filmed copper grids. The tissue sections were 
then stained with 2% aqueous uranyl acetate and lead citrate. The grids were examined at the 
Electron Microscopy Research Services Unit, using a Hitachi HT7800 transmission Electron 




2.3.13 Surgical destabilization of the medial meniscus (DMM) 
DMM surgery and post-surgery mice checks were performed by Dr Dimitra Tsompani 
and Hua Lin in the Functional Genomic Unit (FGU) at the Institute of Genetic Medicine of 
Newcastle University. 
In the pre-operation step, male mice at 10 weeks of age were used for the DMM surgery. 
Each mouse was anaesthetised separately using isoflurane (2.5-3.5%) 1L/min O2 and then 
placed in a recumbent position applying the mask to their head. The left knee was shaved, 
and the area disinfected with chlorohexidine solution (ECOLAB, MN, USA). The animal was 
weighed and checked for any possible infection. Subcutaneous injection of buprenorphine 
(0.15ml, 3μg/ml solution) was then performed.  
During operation, a small vertical incision in the skin just left of the knee joint was made 
using a scalpel, avoiding the patella ligament region. With curved scissors the incision was 
then enlarged and blood vessels were cauterised to avoid bleeding. The fat tissue was 
removed with a scalpel/scissors pealing back and avoiding blood vessels, which when 
necessary were cauterised. Once the medial collateral ligament and the patella ligament were 
recognised, a small vertical incision was made (large scalpel) down to the side of the patella 
ligament and extended to the left. The fat pad was cleared with two fine forceps to expose the 
medial meniscus with the white medial meniscotibial ligament (MMTL) lying horizontal 
extending towards and behind the patella region. Throughout the surgery, any veins were 
cauterised to avoid bleeding. Using a small scalpel blade an incision of the medial meniscus 
was made, then the skin flaps were held together with forceps and clipped. The clips were 
checked later that day and every day post-surgery up to removal seven days post-surgery.  
In the post-operation, the animals were located in clean cages and the cages placed at 27°C 
until the animals regained consciousness. The following day a further dose of pain relief 
(buprenorphine, 0.15ml, 3μg/ml solution) was subcutaneously injected to all operated mice 
which were closely monitored thereafter to ensure successful recovery.  
At the end of the experiment, eight weeks post-surgery, the animals were euthanised using 
CO2 or by cervical dislocation and both knee joints harvested and fixed in formalin solution, 
overnight at room temperature with rotation, before decalcification in 20 % (w/v) EDTA pH 




embedded in patella down orientation and cut as described in section 2.3.3 Tissue 
preparation for histological and immunological analysis..  
For each DMM joint, 100 serial 5µm-sections were collected on 25 slides, each slide with 4 
‘sister sections’ in order to cover the whole interesting region. Then only 6 slides (Slide 1, 5, 
10, 15, 20 and 25) were selected from each joint and Safranin-O staining, as described, was 
performed to visualise DMM damage. DMM damage scoring (Table 2.4) was carried out by 
different blind researchers, who scored the MFC and MTP throughout 6 slides (24 sections in 
total, each section presents a different level) for each DMM joint. The four maximal scores 
from each site for each scorer were chosen to calculate the mean of 4 maximal MFC or MTP. 
For MCF+MTP summed score, the two means together for each scorer were added and then 
combined different scorers’ data to get a mean for each site or parameter (ie. MFC, MTP, and 
summed score MFC+MTP). The histological images shown in the DMM results represents 
the sections for each genotype which were associated with the highest score during analysis, 





Table 2.4. | The recommended semi-quantitative scoring system for assessing cartilage 
damage on DMM mouse joints. Adapted from (Glasson et al. 2010)  
Grade Osteoarthritic damage 
0 Normal 
0.5 Loss of Safranin-O without structural changes 
1 Small fibrillations without loss of cartilage 
2 
Vertical clefts down to the layer immediately below the superficial 
layer and some loss of surface lamina 
3 
Vertical clefts/erosion to the calcified cartilage extending to <25% of 
the articular surface 
4 
Vertical clefts/erosion to the calcified cartilage extending to 25- 50% 
of the articular surface 
5 
Vertical clefts/erosion to the calcified cartilage extending to 50- 75% 
of the articular surface 
6 








Generation of Col9a3Δex3 and Col9a3-/- mouse models using 





3.1 Introduction: Genome editing strategy to generate the mutant mouse 
line. 
As mentioned, Col9-MED patients whose mutations involve the Col9a3 gene, have the 
recurrent skipping of exon 3 as result of aberrant splicing events. The reason for mutations 
being clustered around exon 3, in a 32-exon long gene, and how the loss of this exon is linked 
to the disease is unknown. 
In our attempt to unravel this, we aimed to generate a mouse to model the disease mutations 
and ideally the disease phenotype reported for the patients. Here we will describe the strategy 
used to generate the genetically modified mouse, carrying the deletion of exon 3 in Col9a3 
gene as found in the Col9-MED subgroup of patients. CRISPR/Cas9 technology was applied 
in order to induce two-double strand cleavage with the concomitant excision of the genomic 
region encompassing Col9a3 exon 3.  
The procedure employed involved the following steps:  
• Designing of gRNAs whose sequences were complementary to the intronic 
regions flanking the exon 3 boundaries of Col9a3 mouse gene.  
• In vitro verification of designed gRNAs in a mouse fibroblast cell line to 
select the efficient gRNA pair able to induce efficient deletion. 
• Zygote cytoplasm injection of CRISPR/Cas9 machinery: in vitro transcribed 
functional gRNAs along with recombinant Cas9 protein. 
• Genotyping of the first transgenic offspring (F0) obtained after CRISPR/Cas9 
injection. 
• Screening of F1 mutant mice to select the deletion mutation more 
representative of those reported in Col9-MED patients and establishment of 




3.2 Designing of CRISPR/Cas9 genome editing system to target Col9a3 
exon 3 for deletion.  
In order to use the CRISPR/Cas9 genome-editing tool to generate our transgenic mice, 
gRNAs were designed whose sequences were complementary to the intronic regions 
spanning the intron-exon boundaries of exon 3 of Col9a3 gene. gRNAs targeting the exon 3 
boundaries of mouse Col9a3 were designed using the web tool CHOPCHOP ((Montague et 
al. 2014)) using the genomic region >chr2:180599587-180600578 (mm10 coordinates and 
centred around the 36 bp of exon 3) as input. A list of ranked (GC content and minimal off-
targets) gRNAs were generated, with four gRNAs finally selected with the least number of 
off-targets (Fig. 3.1): #10 and #11 mapping precisely in position 548 and 555 on the sense 
strand of the genomic region, and gRNA #7 and #8 respectively in position 320 and 349 of 
the antisense strand. 
 
Fig. 3.1 | Position of the four gRNAs designed and chosen to be used for CRISPR/Cas9 
genome editing. CHOPCHOP bioinformatic tool view of gRNAs #7, #8, #10 and #11 and their 






3.3 Functional testing of the in silico-designed gRNAs in a mouse 
fibroblast cell line. 
The chosen in silico-designed gRNAs were subsequently tested for efficacy to select 
the pair that most likely was able to induce the desired deletion. Professor David Young 
kindly contributed to the design and the functional testing of the gRNAs. Each individual 
gRNA was cloned into pLKO.1 puroU6 viral vector and viral particles produced in 
HEK293T cells. A Lenti-Cas9-GFP vector provided the Cas9 protein complex. A mouse 
fibroblast cell-line (NIH 3T3) was transduced with various gRNA viral particle combinations 
(one up and downstream of exon 3) and the lenti-Cas9-GFP virus (Fig.3.2).  
After transduction, extracted DNA from each cell line was used as template for PCR 
amplification to assess gRNAs efficiency, using PCR primers outside of the region to be 
deleted. Gel electrophoresis of the PCR amplicons coming from transduced fibroblasts 
confirmed gRNA pair #2 (highlighted by a yellow rectangle in Fig. 3.2) as the most efficient 
in generating the double strand cleavage and repair (presumably by non-homologous end 
joining repair (NHEJ)). The excision of the region encompassing exon 3, was indicated by 
the appearance of an amplicon smaller that the ‘wild-type’ region. All gRNA combinations 
produced low levels of the predicted cleavage size however, none appeared as efficient as 
gRNA pair #2. From this result gRNAs of pair #2 were selected to generate the desired 
deletion in vivo. The exact location of gRNA#7 and #11 with relative PAM sequence, exon 3 
to be removed and PCR primers are presented in Fig. 3.3. Given the location of the gRNAs 





Fig. 3.2 | gRNA pair-viral transduction experimental plan and agarose gel 
electrophoresis of PCR products of mouse fibroblast DNA after transduction.  The four 
gRNA pairs used to transduce mouse fibroblast prior to PCR amplification of extracted DNA. 
Highlighted in the yellow rectangle the gRNA pair showing relatively efficient deletion compared 
with the other pairs. Lane: MM, molecular marker; Empty vector, PCR product from cells transduced 
with empty pLKO virus (negative control); gRNAs pair #1, #2, #3, #4 corresponding respectively to 






Fig. 3.3 | CRISPR gRNAs cleavage sites for exon3 deletion. Partial sequence of mouse 
chromosome 2 showing the sequence of the 2 gRNAs #7 and #11 (underlined) in the intronic regions 
flanking exon 3 (red). Predicted sites of cleavage by Cas9 protein (arrow heads), located between 
gRNA and the three nucleotides called PAM sequence (5’-NGG-3’; blue box). Exon 4 is depicted in 
green. Highlighted in yellow are the PCR primer locations used to verify effective deletion. 
3.4 In vitro transcription and in vitro validation of gRNAs 
From previous studies, a higher efficiency in gene targeting was reported when in vitro 
transcribed gRNAs were injected (Ran et al. 2013b). Therefore, we in vitro-transcribed the 
previously verified functional gRNAs #7 and #11 (2.2.4.2 In vitro transcription (IVT) of 
Col9a3 #7 and #11 gRNAs). Briefly, the gRNA linked with TRACR was amplified by PCR 
from the corresponding pLKO vector. The 5’ PCR primer used in the amplification included 
the T7 RNA polymerase binding sequence (TTAATACGACTCACTATA). The 3′ (reverse) 
primer was complementary to the 3′ region of the TRACR sequence. After purification the 
approximately 120 nt amplicon was used directly in the in vitro transcription (IVT) reaction. 
For the IVT, after optimisation we found that the addition of two extra guanosine nucleotides 
directly at the 5′ of the gRNA sequence improved transcription by T7 polymerase. Similarly, 
addition of several nucleotides upstream of the T7 sequence also increased the efficiency of 
RNA production, presumably aiding the binding of the polymerase to its target sequence. The 




region, as amplified above, in an in vitro restriction digestion reaction with recombinant Cas9 
(Fig 3.4).  
Table 3.1 | List of Oligonucleotides. For the gRNA oligonucleotides the lower case bases are 
required for cloning into the restriction digested pLKO.1 vector. For the IVT oligonucleotides the 





mCol9a3 g#7 F accgGATTCTCTCATCTATACCTG 
mCol9a3 g#7 R aaacCAGGTATAGATGAGAGAATC 
mCol9a3 g#8 F accgGGGCCTGTGGAGACATTGTG 
mCol9a3 g#8 R aaacCACAATGTCTCCACAGGCCC 
mCol9a3 g#10 F accgGGCCTGTGTTGCCCTAGGAG 
mCol9a3 g#10 R aaacCTCCTAGGGCAACACAGGCC 
mCol9a3 g#11 F accgGTTGCCCTAGGAGAGGCCTG 
mCol9a3 g#11 R aaacCAGGCCTCTCCTAGGGCAAC 
Genomic PCR   
mCol9a3 PCR F GTGTCACTTGGAGGCTACTGTG 
mCol9a3 PCR R CCCAGTAACAGACCACTGCATA 
IVT  
3GT7 mCol9A3-7 F atgcatTTAATACGACTCACTATAGGGATTCTCTCATCTATAC 
3GT7 mCol9A3-11 F atgcatTTAATACGACTCACTATAGGGTTGCCCTAGGAGAGGC 







Fig. 3.4 | In vitro test restriction digestion using IVT gRNAs and recombinant Cas9.  
After PCR amplification, the purified Col9a3 amplicon (115 ng) was incubated with 
recombinant Cas9 (500 ng; ToolGen) and the IVT gRNAs (350 ng) at 37°C for 1 hr, followed 
by agarose electrophoresis. In lane 1-4 the intact amplicon of 538bp is visible. gRNA #7 only 
cutting should result in a band of 117bp and gRNA #11 in a band of 364bp. A complex 
digestion pattern can only be observed in lanes 5-7 where all required components of the 
reaction are present.  
3.5 Mouse zygote cytoplasm injection of in vitro-transcribed gRNAs  
To generate the transgenic mice carrying the deletion of exon 3 of Col9a3, we adopted 
the direct zygote cytoplasm injection approach. In collaboration with Dr. Colin Miles and our 
animal colony manager Paul Cairns, the in vitro-transcribed gRNAs were injected into the 
cytoplasm of mouse donor zygotes along with recombinant Cas9 protein, following the Ittner 
and Götz stepwise procedure for pronuclear injection (Ittner and Gotz 2007). The zygotes 
used for injection were F1 of a mixed C57BL/6 and CBA/ca strain background since F1 
zygotes have proved to have higher viability after injection (Ittner and Gotz 2007). The 
injected donor zygotes were then transferred into recipient foster mothers to obtain the first 




3.6 First generation of transgenic mice (F0) obtained after CRISPR/Cas9 
zygote cytoplasm injection. 
The F0 mice obtained herein were the first CRISPR/Cas9-edited mice to be generated at 
Newcastle University therefore it was deemed important to fully evaluate the efficacy of 
pronuclear injection and whether our CRISPR/Cas9 system/strategy was effective. From the 
nineteen F0 pups of first litter we extracted (ear-notch) DNA and performed PCR 
amplification using the same primers we previously used to assess the deletion efficiency of 
the different gRNA pairs. The PCR analysis showed eight out of nineteen pups were positive 
for a deletion (Fig. 3.5). Moreover, two of these positive mice, #8 and #17 (in yellow circle in 
Fig. 3.5) appeared near-homozygous for a deletion event, although each allele clearly 
contained a differing deletion. Thus, our zygote cytoplasm injection procedure and 
CRISPR/Cas9 system appeared highly effective at generation of transgenic deletion mice. 
From Sanger sequence analysis of the purified deletion PCR products from each of the 
positive mice, we were able to confirm the efficacy and specificity of the gRNAs. No exon 3 
was detected in any of the (putative deletion) amplicons purified, when their sequences were 
aligned with the Col9a3 WT gene. Furthermore, Sanger sequence alignment of all the alleles 
containing the deletion, confirmed to some extent the heterogeneous repair (evident by the 
agarose gel electrophoresis; Fig. 3.5), due to the error-prone Non-Homologous End Joining 
(NHEJ) pathway to repair double-strand breaks. Thus, in total we generated over 10 differing 
Col9a3Δex3 alleles, with each mouse therefore representing a potential unique founder. In 
addition, Sanger sequences of these amplicons often gave poor results downstream of the first 
predicted CRISPR gRNA cleavage site, suggesting that each founder mouse was chimeric for 





Fig. 3.5 | Genotype of the first transgenic mice (F0). A. Gel electrophoresis showing the PCR 
product used to genotype the first litter of transgenic mice obtained after CRISPR/Cas9 injection. 
DNA extracted from mouse ear-notch at 3 weeks. From the PCR, eight mice resulted positive for the 
deletion, since a second smaller amplicon was visible. Two mice, #8 and #17 (yellow circle in the 
picture), appeared near-homozygous for a deletion. Transduced NIH/3T3 mouse fibroblast DNA and 
WT C57BL/6 DNA were used respectively as positive and negative control. MW, molecular weight 
ladder. B. BLAT alignment with UCSC Genome Browser of mouse deletion PCR products following 
Sanger sequencing. DNA from lower bands was sequenced using the mCol9a3 PCR F primer to test 
for deletion. Alignment of only those sequences with low level of chimerism is shown.  
Since our Sanger sequencing had suggested some level of chimerism, we crossed all eight 
positive mice for the deletion with pure C57BL/6 mice to quantify and eventually select those 
where the mutation was also in the germline. 
After crossing with pure WT, the different F1 litters were genotyped. PCR amplification and 
Sanger sequencing from ear-notch DNA showed that mice number #6, #8, #10, #11, #12, #17 
and #19 could be considered different founders of different Col9a3Δex3 lines (Fig. 3.6 A). 
Mouse founder #7 failed to produce any Col9a3Δex3 allele containing offspring. The two 
potentially homozygous founders #8 and #17 were bred with the same WT counterpart in the 
same cage and thus different deletion alleles appeared in their litter genotype. Founder line 




Alignment of the Sanger sequenced deleted alleles confirmed the absence of exon 3 from all 
founders, with each founder generating differing alleles due to the error-prone NHEJ 
mechanism (Fig. 3.6 B; Fig. 3.7A and Fig.3.7B).  
 
 
Fig. 3.6 | Genotype of F1 of transgenic mice indicated which founder had a germline 
mutation. A. Gel electrophoresis of genotyping PCR products from mice born from initial founders 
crossed with WT (C57BL/6) animals (F1). Offspring from different founders indicated by different 
colours. All founders expect #7 gave at list one litter member showing heterozygosity for the exon 3 
deletion. Lane MW, molecular size marker; positive controls: lane 1= C57BL/6 DNA; lane 2= 
CBA/ca DNA; lane 3= NIH/3T3 DNA B. BLAT alignment with UCSC Genome Browser of mouse 
deletion PCR products following Sanger sequencing. A representative mouse from each founder was 
sequenced using the mCol9a3 PCR F primer: 36F for founder #10; 41F for founder #6; 50F for 






Fig. 3.7A | Sanger sequences of F1 mice shows the heterogenous DNA repair after 
deletion by CRISPR/Cas9.  Chromatograms of Sanger sequences of Fig. 3.6B showing the region 
in the deletion proximity Arrows indicate the deleted region after CRISPR/Cas9 cutting. Dots indicate 














Fig. 3.7B | Sanger sequences of F1 mice shows the heterogenous DNA repair after 
deletion by CRISPR/Cas9.  Chromatograms of Sanger sequences of Fig. 3.6B showing the region 
in the deletion proximity Arrows indicate the deleted region after CRISPR/Cas9 cutting. Dots indicate 











3.7 cDNA and protein analysis confirmed the generation of Col9a3𝜟ex3/𝜟ex3 
and Col9a3-/- mutant mouse lines.  
Having identified genetically differing founders and confirmed that the mutations were 
germline and specific for deletion of exon 3 of Col9a3, we examined the molecular 
consequences of each independent mutation event, with the purpose of determining which 
founder line best recapitulated the splicing events resulting in exon 3 skipping detected in 
MED (EDM3) patients.  
RNA analysis, initially of the two founders presumed to be homozygous for the deletion (F0 
#8 and #17), was performed to assess whether a transcript of Col9a3 which lacked exon 3 
would be produced. Mice were sacrificed and RNA extracted from xiphoidal cartilage, 
reverse transcribed to cDNA, and PCR amplification performed using forward and reverse 
primers present in exon 1 and 5 of Col9a3, respectively.  Both presumed ‘homozygous’ 
deletion founder mice produced only one PCR product, shorter than the WT amplicon and 
which Sanger sequencing confirmed to be lacking the 36 nucleotides of exon 3 (Fig.3.9). We 
could detect exon 2 spliced directly to exon 4, as no exon 3 was available to form the 








Fig. 3.8 | cDNA analysis of #8 and #17 founder mice revealed the expected splicing 
event. A. Gel electrophoresis following RT-PCR amplification of region spanning from exon 1 to 5 
of Col9a3 transcript. #8 and #17 founders’ cDNA bands are shorter than WT founder #1 and C57BL/6 
cDNA. B. UCSC BLAT alignment of Sanger sequences obtained using a forward primer 
complementary to exon 1 of Col9a3 transcript. #8 (8F) and #17 (17F) showed identical sequence at 
exon 2 and 4 regions, but no exon3 when aligned with C57BL/6 (Bl6F) sequence (red square), 





Fig. 3.9 | Sanger sequencing of #8 and #17 founder mice cDNA showed the precise 
deletion of exon 3. Sanger sequences obtained using a forward primer complementary to exon 1 of 
Col9a3 transcript. #8 and #17 showed identical sequence at exon 2 and 4 regions, but no exon3 when 
aligned with C57BL/6 (WT) sequence, proving that the 36 nucleotides of exon 3 are skipped in both 
mutant mice. 
Along with the analysis of the two homozygous founders’ mRNA, we examined offspring of 
each of the positive founder mice lines to determine if all the different mutations we had 
generated by CRISPR/Cas9 were producing the same exon 3 skipping spliced transcript, 
again using xiphoidal RNA. PCR amplification results showed that the heterozygous 
descendants from both founders #6 and #12 presented the expected exon skipping and WT 
transcript (note: additional and higher sized products were confirmed to be a PCR 
heteroduplex artefact, Fig 3.10 (Anglani et al. 1990). Interestingly, mice originating from 































founders #10 but especially #11, surprisingly only produced one PCR band corresponding to 
the WT transcript (Fig. 3.10). From this, we inferred that no stable transcript was produced 
from founder #10 nor #11 mutated alleles.  
Therefore, from the RNA screening of the different lines, we could summarise the generation 
of two groups of alleles which were germline: founders #6, #8, #12 and #17 whose deleted 
allele resulted in the predicted splicing event giving a shorter but still detectable Col9a3 
transcript lacking exon 3, that we called Col9a3𝜟ex3; lines #10 and #11 where the mutated 
allele produced an unstable Col9a3 transcript, thus null allele, denoted as Col9a3-/+. Note that 
for convenience, we adopted the Col9a3𝜟ex3 nomenclature throughout this thesis to indicate 
homozygous Col9a3𝜟ex3/ 𝜟ex3 mutation. We decided then to proceed the analysis and breeding 
of founder #17 to establish the Col9a3𝜟ex3 line and founder #11 for the Col9a3-/-. 
 
Fig. 3.10 | cDNA analysis performed on F1 mice unravelled the consequences of allele 
variability generated by CRISPR/Cas9. Gel electrophoresis of cDNA amplification of region 
spanning from exon 1 to 5 of Col9a3 transcript of F1 heterozygous mice offspring from initial 
founders (indicated by colour). A smaller product compared to WT size amplicon, hence 
corresponding to a shorter transcript was detected from mice 42 and 67, descendants of founders #6 
and #12, respectively. Only a WT sized amplicon was detected for heterozygous mice 40 and 60, 
offspring of breeding’s of founders #10 and #11, respectively. WT and ΔEx3 amplicon sizes are 
indicated in base pairs (bp). The larger products, obvious from mouse 42 and 67 were determined to 
be a PCR heteroduplex artefact. This was confirmed by mixing equal amounts of cDNA from WT 





Subsequently, we examined the effect on protein expression of the change in transcript 
splicing. Protein was therefore extracted from femoral heads of a representative mouse with a 
shorter Col9a3 transcript and one lacking the genetically altered Col9a3 transcript, both 
compared to a WT mouse. No specific antibody recognising the collagen α3(IX) chain was 
available when this project started, therefore we used an antibody, kindly provided by 
Professor Frank Zaucke (Orthopedic University Hospital Friedrichsheim, Frankfurt, 
Germany) which recognises the NC4 domain of the collagen α1(IX) of collagen type IX 
heterotrimer. By Western blot analysis we were able to detect collagen α1(IX) protein, and 
therefore presumably collagen type IX heterotrimer, in WT and Col9a3ΔEx3/ΔEx3 mice. 
However, we were unable to detect collagen α1(IX) in the protein extracted from the mouse 
lacking Col9a3 transcript expression. This implies that the lack of Col9a3 transcript and 
subsequent loss of collagen α3(IX) chain impairs the formation of all potential collagen type 
IX trimer. 
We also analysed RNA-seq performed on both homozygous Col9a3 mutant lines 
(Col9a3𝜟ex3/𝜟ex3 and Col9a3-/-) compared to WT mice (Chapter 5) to visualise the expression 
and splicing of Col9a3.  These results were as anticipated by the RT-PCR findings. 
Essentially, for Col9a3𝜟ex3/𝜟ex3 mice the expression level of Col9a3 was almost identical to 
WT mice (average TPM 3063 ± 276 vs. 3090 ± 558, respectively). Further, for the 
Col9a3𝜟ex3/𝜟ex3 mice, Col9a3 exon 2 spliced directly to exon 4 using the GT/AG donor and 
acceptors as predicted. However, approximately 6% of transcripts also skipped exon 4, with 
exon 2 splicing directly to exon 5. Other than this, there was no evidence of aberrant 
donor/acceptor usage. However, for the Col9a3-/- mice, very low read numbers for Col9a3 
were detected and aligned, especially for exon 1 and 2 (with <0.4% of WT reads), which was 
maximally approximately 1.1% of the WT level. An aberrant novel exon was also detected 
for these mice, located between WT exon 4 and 5, which may represent an alternative first 
exon. Approximately 30% of the Col9a3 transcripts would be predicted to start or contain 
this novel exon (gold line – Alt. exon – Fig. 3.11). These data, in line with the already 
described cDNA and protein analysis, were further evidence for the generation of a novel 
knockout mouse for Col9a3. 
We could therefore conclude that our attempt at a creation of a Col9-MED mouse line was 
successful at the genomic level. We generated a mouse line exhibiting the deletion of exon 3 
and a shorter Col9a3 transcript, however we were unable to observe any effect on the α3(IX) 




protein, putatively a knockout for collagen type IX was considered an opportunity to deepen 
our phenotypic analysis, by comparing WT, Col9-MED and Col9-null mice. Furthermore, by 
assessing the consequences of Col9a3-/- mutation, we questioned whether possible 
overlapping phenotypic features or findings could be unraveled when comparing our mice to 
previously reported Col9a1-/- and Col9a2-/- mice.  
 
 
Fig. 3.11 | RNA and western blotting analysis confirmed the generation of two Col9a3 
transgenic mouse lines: Col9a3𝜟ex3/𝜟ex3 and Col9a3-/-. A. RNA and protein were extracted from 
of 3-week old femoral heads of homozygous mutant and WT mice. Gel electrophoresis of cDNA and 
Western blot of protein probed with antibody against α1 (IX), showed that Col9a3Δex3 mice produced 
a Col9a3 transcript lacking exon 3, but normal collagen type IX protein. On the contrary, Col9a3-/-  
mice were almost completely lacking the transcript and α1 (IX) polipeptide. (Image of full blot in 
Appendix E, Fig. E4.B). Sashimi plot from RNA-seq data showing the number of reads covering the 
col9a3 exon 1 to exon 5 region confirmed the expected splicing event and the consequences of loss of 
exon3 in Col9a3Δex3 mice (blue plot). Aberrant splicing between exon 2 and 5 was apparent for 
approximately 6% of transcripts. Col9a3-/- mice were almost entirely lacking the transcript especially 
for the initial exons. Interestingly, an alternative cryptic exon (Alt. exon; gold line) was apparent, 




3.8 Mutation analysis of Col9a3𝜟ex3/𝜟ex3 and Col9a3-/- sequences as result of 
CRISPR/Cas9 activity. 
Having achieved our aim in obtaining the transgenic line that replicates the genomic 
result of selected human MED mutations, we questioned the mechanism underlying the 
generation of two different lines of mice when using the same genome editing system to 
mutate the Col9a3 gene. Our genome-editing strategy clearly generated a wide-range of 
mutated alleles in the F0 offspring even when utilising the same Cas9 and pair of gRNAs, 
though all induced mutations did result in the deletion of exon 3 of Col9a3. However, the 
cellular response to the various alleles clearly gave differing outcomes, evident when 
analysing extracted RNA and protein. Comparison of the DNA sequences encompassing the 
CRISPR/Cas9 deleted regions of the two alleles therefore was conducted in order to further 
elucidate the two different mutant lines chosen to be further phenotyped. (Fig. 3.12). We 
could identify the region corresponding to the Cas9 mediated double-strand break sites in-
between the gRNAs and their PAM sequence. When comparing the sequence from the 
Col9a3-/- and Col9a3𝜟ex3 mice the latter contained an additional 5 bases (AACTG) around the 
cleavage/repair site for gRNA#11, for which the AA was non-templated and therefore 
presumably added during the error-prone NHEJ repair mechanism. Since these five 
nucleotides are the only detected difference in the alleles between the two transgenic mice, 
we must assume that these are sufficient to stabilise the transcript in the Col9a3𝜟ex3 animals. 
On the contrary, we hypothesized that in Col9a3-/- animals those missing five nucleotides 
might have created a new cryptic splice site leading to a potential unstable Col9a3 transcript. 
We therefore performed in silico analysis of the region around the deletion in both mutant 
sequences, using the Human Splice Finder bioinformatics tool (HSF 3.1), able to recognise 
consensus sequences for potential splice sites (Desmet et al. 2009). The analysis result 
showed that the potential splice sites for that region were only partially the same between the 
two regions. According to HSF analysis, the Col9a3-/- sequence showed an additional 
potential acceptor splice site which instead was not present in the Col9a3𝜟ex3 sequence (Fig. 
3.13). This observation further supported our hypothesis of the formation of an unexpected 
splice site probably leading to an aberrant splicing and possibly nonsense-mediated decay of 





Fig. 3.12 | Differing deletion in the genomic sequence of Col9a3𝜟ex3/𝜟ex3 and Col9a3-/- mice 
following CRISPR/Cas9 mediated cleavage and NHEJ-mediated repair. Alignment of 
Sanger sequence chromatograms obtained using a primer complementary to the upstream intronic 
region flanking the exon 3 of col9a3 gene. Location of gRNAs (red lines) with their PAM sequences 
(NGG; black lines) are indicated. Col9a3𝜟ex3/𝜟ex3 and Col9a3-/- differed in their deletion of exon 3 with 
the former having an additional 5 nucleotides, AACTG (black rectangle), of which the AA were non-
templated. 
 
Fig. 3.13 | Potential additional acceptor splice site in Col9a3-/- sequence. Human Splice 
Finder sequence analysis graph showing the potential acceptor and donor splice site in Col9a3𝜟ex3 and 
Col9a3-/- genomic sequences. The presence of a potential further acceptor splice site in position 23 is 
shown in Col9a3-/- sequence (red square), but it is not reported in the same position in 
Col9a3𝜟ex3sequence.  
























In this first chapter, we described the strategy and procedure used to generate our 
mutant mice.  One mutant was able to produce the Col9a3 transcript, but lacked exon 3 
(Col9a3𝜟ex3/𝜟ex3 or  Col9a3𝜟ex3 in this thesis) and a second mouse which was almost null for 
the Col9a3 transcript and also lacked collagen type IX protein (precisely α1(IX)), which we 
termed Col9a3-/-. We created our mutant mice using the CRISPR/Cas9 genome editing 
system. Our choice was driven by the speed, efficacy and simplicity of this recent genome-
engineering technology. We chose to use ‘wild-type’ Cas9, which uses HNH and RuvC 
nucleases to cleave both strands of the DNA. When a double strand break is induced, the cell 
double strand break machinery is activated and cells will go through the non-homologous end 
joining repair pathway, which will result in insertions or deletions disrupting the targeted 
locus. Cas9 can also be engineered with an inactive nuclease domain to create a ‘nickase’ 
version of the enzyme which introduces single-strand cleavages. The use of such nickases, 
either singularly, or in pairs, can reduce off-target effects (Ran et al. 2013a) and when 
combined with a repair template, prove more versatile in inserting specific mutations or 
specific DNA sequences. However, such ‘homology-directed repair’ occurs with low 
efficiency compared to the NHEJ methods of repair.  
To generate a mouse recapitulating the splice sites mutations of Col9-MED patients, which 
result in exon3 skipping, the simplest approach was deemed to induce two double strand 
breaks in the intronic regions flanking exon 3. We therefore designed gRNAs complementary 
to the intronic regions flanking exon3 of Col9a3 gene, which were initially tested for 
cleavage efficiency in a mouse fibroblast cell line. Subsequently, the in vitro verified 
functional gRNAs, were in vitro transcribed and in collaboration with Dr. Colin Miles and 
Paul Cairns, they were injected into the cytoplasm of mouse donor zygotes along with 
recombinant Cas9 protein, following a published protocol (Ittner and Gotz 2007). The 
genotyping result of F0 showed a remarkable eight out of a total litter of nineteen pups to be 
positive for the deletion, with a suggestion that several were potentially homozygous. This 
result was considered positive not only because it demonstrated that the CRISPR/Cas9 
system designed was efficient in mice, but also that the cytoplasm injection procedure 
performed in our lab had a good success rate. Our data and experience confirmed previous 
reports surrounding the efficacy and efficiency of generating genetically modified mice using 




insertional mutagenesis (Kool and Berns 2009) or by gene-targeting methods (Capecchi 
2005), both of which were costly, time-consuming and prone to failure. A series of studies 
then demonstrated that the induction of double strand breaks (DSB) in DNA can trigger 
genome editing by HR-mediated recombination. Moreover, it was shown that insertions or 
deletion mutations (indels) via the error-prone NHEJ repair pathway were obtained when a 
homologous repair template was not provided during induced double-strand breaks (DSBs). 
Therefore, alternative methods based on nucleases were developed to achieve genome editing 
through DSBs. Among these, meganucleases (Smith et al. 2006) zinc finger nucleases (ZNFs) 
(Urnov et al. 2005) or transcription activator-like effector nucleases (TALENs) (Christian et 
al. 2010), have been used to generate mutant mice, but such systems are complex and 
generally have low efficiency (Hsu et al. 2014). The type II RNA-guided endonuclease Cas9 
instead, has the advantage in that its specificity is provided by a simple gRNA 
complementary to the region to be mutated, without the need to modify proteins. The method 
is therefore easy to use, more efficient and specific. In addition, to generate transgenic 
animals, Cas9 protein and transcribed sgRNA can be directly injected into the fertilized 
zygotes, without going through the typical step of ES cells targeting. This decreases 
considerably the time needed for generation of the mice and with it the associated costs, 
another reason why we opted for CRISPR/Cas9 editing as our mutagenesis strategy to 
generate our mice.  
Sanger sequencing of all the alleles positive for the deletion on gel electrophoresis, confirmed 
that the shorter amplicons were missing exon 3 and the proximal intronic regions, confirming 
CRISPR/Cas9 efficiency and specificity, but also the variability of the sequences carrying the 
mutation. This variability is almost certainly due to the stochastic pattern of NHEJ repair that 
occurs after a double-strand break. Since these were the first CRISPR/Cas9 mutant mice 
generated in our facility, we deemed it important to determine the true efficiency of our 
mutation. Therefore, we bred the mutant animals with pure C57BL/6 mice to ensure that even 
if the mutant F0 were chimeric, the deleted allele was present in the germline. From these 
matings, each of the six mice whose unique mutation/allele was inherited was considered at 
this point a founder of a new mouse line. To identify a mutant line carrying the deletion 
which recapitulates the human MED situation, we analysed the cartilage (xiphoid) mRNA of 
these lines. Interestingly, RT-PCR of the Col9a3 region spanning exon 3 showed that some 
lines produced the anticipated spliced transcript (Founder #6, #8, #12 and #17) whilst no 




heterogeneous repair that occurred after Cas9 cleavage had also fortuitously generated a 
Col9a3 null mutation.  We therefore proceeded to screen the mutant lines for the expression 
of collagen type IX protein. No specific α3(IX) antibody was available for our study, but a 
specific antibody recognising the NC4 domain, in essence the α1(IX) of collagen type IX, 
was able to detect ‘normal’ levels of the protein in mice homozygous for the deletion allele 
Δex3. However, mice lacking Col9a3 transcript showed no α3(IX) protein. Such observation 
confirmed the generation of a knockout line for Col9a3 gene, but also that this deletion might 
have affected overall collagen type IX stability.  
In the attempt to understand the genetic rationale for the two differing consequences of the 
mutations generated, we examined the region of Col9a3 that was directly targeted and edited 
by CRISPR/Cas9. From sequencing of the various alleles it was apparent that the deletion in 
Col9a3𝜟ex3 allele terminates five nucleotides upstream than for the Col9a3-/- allele. A short 
sequence of AACTG, different from the canonical GCCTG, was indeed found in the intronic 
region surrounding the deletion in Col9a3𝜟ex3 mice, but not in Col9a3-/- animals. The non- 
templated AA were a probable result of the NHEJ repair mechanism. We might predict those 
five base pairs to be relevant in discerning the two mutant lines, however the link between the 
sequence mismatch described and the actual detection of either a shorter or absent Col9a3 
transcript remains unclear. 
We could speculate that the five base pair deletion difference contributed in Col9a3-/- 
genomic sequence to the formation of a possible new cryptic splice site leading to an unstable 
transcript. This in turn would trigger the non-sense mediated decay pathway (NMD), a 
cellular monitoring mechanism targeting mutant mRNAs for degradation (Hug et al. 2016). 
However surprisingly, as it will be described in Chapter 5, the genes involved in the NMD 
pathway resulted downregulated in both mutant mice in costal chondrocytes RNA. When we 
compared the two mutant genomic regions for potential splice sites, our in silico analysis 
indeed predicted the presence of an additional splice site only present in the Col9a3-/- deletion 
region. Nonetheless, our hypothesis remained theoretical and taking into account that no full 
gene sequencing was performed, we could not exclude the possible presence of other 
mutations generated by possible unspecific gRNAs pairing in regions outside of those 
targeted. 
In conclusion we successfully used the CRISPR/Cas9 genome editing system to generate a 
Col9a3𝜟ex3 mutant mouse line which reproduces Col9-MED patients genetic defect. We also 




type IX protein. The deep phenotyping performed on both mutant mouse lines will be 






- Our designed CRISPR/Cas9 genome editing system was efficient and specific both in 
vitro and in vivo  
- Two mouse lines were generated as a result of the heterogeneous NEHJ repair 
mechanism after Cas9 cleavage. 
- A Col9a3𝜟ex3 mouse, mimicking the MED situation and able to produce a transcript 
lacking exon 3, but presumably not affecting collagen type IX protein assembly, was 
successfully generated. 
- A Col9a3-/- mouse, null for Col9a3 transcript and collagen type IX protein was 






Chapter 4.   
Bone phenotypic analysis of mice with altered or absent  






Patients diagnosed with MED due to exon 3 skipping mutations in the gene encoding 
the α3 polypeptide of collagen type IX molecule (OMIM#600969), present a relatively mild 
phenotype when compared to those diagnosed with other MED-causing mutations (eg. 
COMP and MATN3). Orthopaedic and radiologic evaluation of EDM3 patients have shown 
abnormalities involving mainly the pelvic girdle and the lower limbs. Previous studies 
showed evidence of flat and mildly dysplastic hips, flat and irregular knees and ankles, but 
overall normal stature (Bonnemann et al. 2000, Jeong et al. 2014, Nakashima et al. 2005, 
Paassilta et al. 1999, Lohiniva et al. 2000). It is still unknown how collagen type IX splice 
site mutations, and consequently the skipping of exon 3, can result in such clinical findings. 
Long bone formation relies on endochondral ossification, where an initial cartilaginous 
scaffold is replaced by bone, leaving a layer of cartilage, named epiphyseal growth plate, 
through which post-natal longitudinal bone growth occurs. Considering this mechanism and 
taking into account the EDM3 clinical findings, our hypothesis was that collagen type IX, an 
important component of the cartilage ECM, may have a direct or indirect role in bone 
formation, development and/or homeostasis.  
We therefore assessed the Col9a3Δex3 mice for their potential use as a model for Col9-MED, 
starting with an evaluation of their skeletal phenotype. The Col9a3-/- mouse was used as 
constant comparator in all the phenotypic analysis.  
In this chapter the bone phenotype of our mutant mice was explored exploiting two main 
techniques: x-ray morphometric analysis and micro-computed tomography (µCT). The main 
purpose was to test for similarities between the skeletal features of Col9a3Δex3 mice and 
EDM3 patients. In addition, the comparison between our two mutant mice could help to 
unravel if an ECM containing a mutated collagen type IX would result in a similar or 
different bone phenotype compared to a matrix lacking collagen type IX. Together, these data 





4.2 Radiographic analysis of Col9a3Δex3 and Col9a3-/- mice.  
4.2.1 X-ray analysis of hind limbs and hips. 
The skeletal morphology of Col9a3Δex3 and Col9a3-/- mice was assessed by analysis of 
whole-body x-ray images.  Observations at birth did not indicate any obvious morphological 
or size difference in any of the mutant mice compared to WT. For this reason, we opted to 
evaluate later stages of post-natal bone development. Radiographic images were taken from 
animals at 3 weeks, corresponding to the weaning age, and at 9 weeks, the stage in which 
mice reach sexual maturity and their bone growth drastically slows (Jilka 2013).  An initial 
evaluation of heterozygous Col9a3Δex3/+ and Col9a3+/- mice compared with their WT 
littermates identified no differences in size or bone morphology, hence from this stage, only 
homozygous mice were phenotyped further. Radiographic images of the dorsal view of 3- 
and 9-week old female and male animals showed that Col9a3Δex3 and Col9a3-/- skeletal 
phenotypes were not influenced by sex. Therefore for the full radiographic analysis only the 
gender whose highest number of mice was available at the moment of data collection was 
used, in order not to require more animals, in compliance with the 3Rs principle (Flecknell 
2002). 
From whole-body radiographs, at 3-weeks of age, the height of female homozygous 
Col9a3Δex3 mice was the same size as their female WT littermates, whereas Col9a3-/- mice 
were shorter in size overall (Fig. 4.1). The radiographic investigation applied, was based on 
the measurement of established skeletal parameters previously used in the assessment of 
mouse models of other skeletal dysplasias. The length of the femur and tibia were markers of 
endochondral ossification. The extent of the angle formed by the protrusion of the tuberosity 
of the ischium from the ilium was analysed as a marker of general hip development and 
potential dysplasia. At 3 weeks of age both mutant mice showed tibias on average 
significantly shorter compared to WT, which were respectively 96% for Col9a3Δex3 and 89% 
for Col9a3-/- (Fig. 4.2A). When we measured the femur length, only Col9a3-/- mice presented 
a significant reduction at 3 weeks, as their femur was 91% of WT length. When mice reached 
skeletal maturity at 9 weeks of age, both Col9a3Δex3 and Col9a3-/- male animals had 
significantly shorter femurs at 95% and 85% the length of WT bones, respectively. Only male 





Upon examination of the hip angle of mutant mice, we detected a strongly wider average hip 
angle in Col9a3-/- mutant mice. Measurements showed a 2-fold increase in the angle of 3-
week old female mice and 8-fold increase in 9-week old male Col9a3-/- mice angle compared 
to WT (Fig. 4.2A-B). This observation suggested the Col9a3-/- mice hip to be dysplastic, as 
morphologically evident in Fig 4.1. Although in Col9a3Δex3 mice we detected a slight increase 
in hip angle this was not statistically relevant compared to that of WT littermates at 3 weeks 
of age. Moreover, Col9a3Δex3 hip angle values were equal to WT in 9-week old mice. 
Interestingly, along with the dysplasia of the hip, in Col9a3-/- mice we observed a broadened 
tibial condyle and metaphysis (red circle in Fig. 4.1) which was consistent in 9-week animals 
of the same genotype. No such phenotype was observed at any age for the Col9a3Δex3 mice. 
 
Fig. 4.1 | Radiographic images of WT, Col9a3Δex3 and Col9a3-/- skeletal phenotype. 
A. Representative X-ray images of 3 week old female mice (dorsal view). B. close-up of 3-week old 
hips and right legs. The extent of alteration of the hip angle and the tibial condyle are indicated in red. 
Col9a3-/- mice displayed irregular and wider tibial epiphyses and hip dysplasia (assessed by hip angle) 
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3 8.35 ± 0.18 8.31± 0.30 7.59 ± 0.32*** 




3 12.51 ± 0.41 12.01± 0.61* 11.19± 0.34*** 





3 7.50 ± 1.75 8.43 ±1.71 16.71± 1.71*** 
9 1.62 ± 0.66 1.67 ± 0.62 13.21 ±3.67*** 
 
Fig. 4.2 | Morphometric analysis of femurs, tibia and hip angle in WT, Col9a3Δex3 and 
Col9a3-/- mice. A. Tibia and femur bone lengths and hip angle were measured at 3 weeks of age in 
female mice (WT N=9; Col9a3Δex3 N=11; Col9a3-/- N= 10) and 9 weeks of age in male mice (WT 
N=9; Col9a3Δex3 N=11; Col9a3-/- N= 9) of all 3 genotypes. B. Table showing the average values and 
statistical significance of femur, tibia and hip angle measurements. SD = standard deviation; *p<0.05, 





4.2.2 Morphometric analysis of the skull. 
According to the literature, no cranio-facial abnormalities have been reported in EDM3 
patients. However, loss of function recessive mutations in the COL9A3 gene have also been 
associated with Stickler syndrome. Like MED, Stickler syndrome is a genetically 
heterogeneous disorder with a highly variable clinical spectrum. Among the clinical findings 
of Stickler syndrome caused by loss of function mutations in COL9A3 gene are high myopia, 
hearing loss and mid-face hypoplasia (Faletra et al. 2014). We therefore, assessed the x-rays 
of the skull of mice of all three genotypes to identify any relevant morphological changes due 
to the Col9a3 mutations carried by our mice. The morphology of Col9a3Δex3, Col9a3-/- and 
WT mice skulls was evaluated at 3 and 9 weeks on mice dorsal radiographs. The bones that 
form the skull originate from different processes according to their position. Endochondral 
ossification is the mechanisms through which the cranial base and caudal cranial vault are 
formed, whereas intramembranous ossification is at the base of the craniofacial and rostral 
cranial vault development (Percival and Richtsmeier 2013). 
Following established guidelines for the assessment of mouse models for genetic skeletal 
diseases, two parameters were taken into account: the inner canthal distance (ICD) measured 
as a marker of intramembranous ossification; and skull length as indication of endochondral 
ossification in the skull (Fig.4.3). The ICD was similar for all genotypes at both ages 
examined. In contrast, the skull length was influenced by genotype, but only significantly in 
Col9a3-/- mice. The average skull length of Col9a3-/- female mice at 3 weeks of age and in 
male mice at 9-weeks was 92.8% and 89.4% of the average value measured in WT 
littermates, respectively (Fig. 4.4A-B). Although the Col9a3Δex3 mice showed a small 







Fig. 4.3 | Radiographic images of skull parameter comparison in WT, Col9a3Δex3 and 
Col9a3-/- mice. Representative skull x-ray dorsal view images of 3-week old female mice. The 
horizontal and vertical red lines represent ICD and skull length respectively. White dashed lines are 
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Age 
(Weeks) 




3 6.73 ± 0.26 6.78 ± 0.14 6.77 ± 0.15 





3 18.09 ± 1.01 17.97 ± 0.26 16.79 ± 0.58** 
9 21.25 ± 1.44 20.93 ± 0.60 19.01 ± 0.53** 
 
Fig. 4.4 | Morphometric analysis of the skull in WT, Col9a3Δex3 and Col9a3-/- mice. 
ICD and skull lengths were measured at 3 weeks of age in female mice (WT N=9; Col9a3 Δex3N=11; 
Col9a3-/- N= 10) and 9 weeks of age in male mice (WT N=9; Col9a3 Δex3N=11; Col9a3-/- N= 9) of all 3 
genotypes. A. The average ICD and Skull length of homozygous Col9a3Δex3 and Col9a3-/- mice is 
shown. B. Table showing the mean values and statistical significance of femur, tibia and hip angle 





4.3 Col9a3Δex3 and Col9a3-/- mice differ in their bone ultra-structure. 
To investigate the effects on bone phenotype following deletion of exon 3 of Col9a3 
gene or the ablation of collagen type IX protein, we performed µCT analysis on mice of all 
three genotypes. We performed the analysis on adult long bones, using femurs and tibiae 
from 18-week old male mice. The two types of bone tissues are cortical and trabecular, which 
differ in structure and function.  Cortical bone is compact and constitutes the outer part of 
bones where its function is to provide protection and support but also to be a calcium 
reservoir for the functioning of all body organs. The outer surface of cortical bone is called 
the periosteum, and its inner surface endosteum, which is the perimeter dividing cortical from 
trabecular bone. The trabecular, also called cancellous bone, is a spongy type of bone made 
by a porous network of thin columns of bone forming the trabeculae. It is primarily found at 
the end of long bones and in the interior vertebrae. It harbours blood vessels and bone 
marrow.  
3D reconstruction of scanning images with a resolution of 4.5 µm allowed for visualisation of 
the trabecular structure of the distal femurs and the proximal tibiae. For cortical bones, we 
analysed the femur and tibia shafts, whose structure was 3D reconstructed from scanning 





4.3.1 Trabecular analysis of femurs in adult mice. 
Trabecular analysis showed no difference in the total volume (TV) and bone volume 
(BV) of the region of interest in Col9a3Δex3 femurs, but these parameters were significantly 
increased (by 35% and 23%, respectively) in Col9a3-/- mice compared to WT controls (Fig 
4.5 and Table 4.1). Interestingly, when the ratio of the segmented bone volume to the total 
volume (BV/TV) was evaluated, a significant 19% decrease in Col9a3Δex3, but no relevant 
change in Col9a3-/-, was observed. The mean thickness of trabeculae (Tb.Th) was reduced 
only in Col9a3-/- femurs at 89% of WT femoral Tb.Th. The measure of the average number of 
trabeculae per unit length, called trabecular number (Tb.N), and the mean distance between 
trabeculae, trabecular separation (Tb.Sp.) were both significantly changed in Col9a3Δex3.  
While we measured a 16% increased trabecular separation in Col9a3Δex3 mice when compared 
to WT, their trabecular number was significantly reduced to 80% of WT mean values, 
suggesting a less compact trabecular bone (Fig. 4.5). No difference was observed in Col9a3-/- 
mice for these variables. The trabecular pattern factor (Tb.Pf.) as well as the structure model 
index (SMI), which defines the plate- versus rod-like characteristic of the trabecular bone 
structure, were not altered compared to the mean value of WT in both mutant mice. The final 
parameter analysed was an index that measures the degree of connectivity of trabeculae 
normalised by TV, the connectivity density (Conn. Dn.). Col9a3Δex3 trabecular connections 
were significantly less dense with mean values corresponding to 76% of mean control values. 
The findings, in relation to Tb.N and Tb.Sp. values, suggest a less structured trabecular bone 






Fig. 4.5 | Trabecular morphometry of femurs of 18-week old mice. A. Morphometric 
analysis of trabecular bone from femurs of 18-week old male WT (N=13) Col9a3Δex3 (N=10) and 
Col9a3 -/- (N=9) mice. Data of the graphs, relating to Col9a3Δex3 and Col9a3 -/- mice are shown as 
percentage of change compared to WT measurements. Data are shown as means ±SD (standard 
deviation). Statistical analysis (Col9a3Δex3 or Col9a3 -/- vs WT) : *p<0.05, **p<0.01, ***p<0.001, two 
tailed t-test. B. Cross-sectional images of 3D µCT reconstructions using CTVox software of femurs 





Trabecular analysis of the femur (18-weeks) 
 WT (n=13) Col9a3Δex3(n=10) Col9a3-/-(n=9) 
TV (mm3) 2.27 ± 0.26 2.38±0.21 3.07±0.27*** 
BV (mm3) 0.45±0.08 0.39±0.14 0.55±0.12* 
BV/TV (%) 19.76 ± 3.05 16.03 ± 4.77* 17.86 ± 3.19 
Tb.Th (µm) 61.34±4.43 61.80 ±4.37 54.95±4.11** 
Tb.Sp (µm) 184.92±17.37 215.68±30.46** 184.52±15.54 
Tb.N (mm) 3.22±0.39 2.57±0.65** 3.24±0.51 
Tb.Pf (1/mm) 19.51±2.81 21.17±5.27 19.99±4.36 
SMI 2.18±0.19 2.22±0.31 2.05±0.20 
Conn.Dens. 
(1/mm3) 
392.78±90.05 298.33±85.60* 370.49±68.96 
 
Table 4.1. | µCT analysis of trabecular bone in femurs of WT, Col9a3Δex3 and Col9a3-/- 
male mice at 18 weeks of age. Data obtained from µCT trabecular parameters measurements in 
femurs and used to generate the graphs in Fig. 4.5. Data are shown as means ±SD (standard 






4.3.2 Trabecular analysis of tibiae in adult mice. 
The same analysis performed on mice femurs, was also performed on tibiae to assess 
their trabecular structure (Fig. 4.6 and Table 4.2). As reported for the femur, in Col9a3-/- 
tibiae we measured an increase in trabecular TV, which was 32% higher than WT.  
The BV in Col9a3Δex3 tibiae was 68.5% of the WT and 18% higher, but not statistically 
significant, in Col9a3-/-. Consistently with the trabecular femur results, in tibiae from 
Col9a3Δex3 the BV/TV was significantly decreased to 65.6% of the mean control BV/TV.  
Trabecular thickness (Tb.Th) was reduced in Col9a3-/- tibiae by 10% and unchanged in 
Col9a3Δex3 mice. The remainder of the trabecular variables were significantly changed only in 
Col9a3Δex3 compared to WT. We observed an increment of trabecular separation and pattern 
factor in Col9a3Δex3 tibiae, whose mean values were respectively 28.6% and 23.7% higher 
than WT mean Tb.Sp. and Tb.Pf. Moreover, the trabecular number and connectivity density 
were 66.5% and 65% of WT, respectively, and significantly decreased. As mentioned 
previously, the structure model index (SMI) defines the trabecular structure and was set to be 
0 for perfect plates and 3 for perfect rods. In Col9a3Δex3 femurs, we measured a 14% increase 
in the SMI mean value, thus indicating a more “rod-like” structure than “plate-like” 






Fig. 4.6 | Trabecular morphometry of tibia of 18-week-old mice. Morphometric analysis of 
trabecular bone from tibiae of 18-week old male WT (N=13) Col9a3Δex3 (N=10) and Col9a3 -/- (N=9) 
mice. A. Data of the graphs, relating to Col9a3Δex3 and Col9a3 -/- mice are shown as percentage of 
change compared to WT measurements. Data are shown as means ±SD. Statistical analysis 
(Col9a3Δex3 or Col9a3 -/- vs WT): *p<0.05, **p<0.01, ***p<0.001, two tailed t-test. B. Cross-sectional 
images of 3D µCT reconstructions using CTVox software of tibiae from the median animals of each 
genotype, taken 50 slides (225 µm) away from the tibial growth plate. Note the obvious altered 
trabecular bone architecture and low bone volume, connectivity, and the rod-like appearance in 






Trabecular analysis of the tibia (18-weeks) 
 WT (n=13) Col9a3Δex3(n=10) Col9a3-/-(n=9) 
TV (mm3) 1.88 ± 0.22 1.93 ± 0.24 2.48 ± 0.11*** 
BV (mm3) 0.32 ± 0.05 0.22 ± 0.09** 0.38 ± 0.08 
BV/TV (%) 17.13 ± 1.95 11.24 ± 4.21*** 16.17 ± 1.80 
Tb.Th (µm) 55.84 ± 3.94 54.72 ± 3.01 50.54 ± 3.58** 
Tb.Sp (µm) 182.94 ± 15.25 
235.41 ± 
43.20*** 
184.69 ± 16.76 
Tb.N (1/mm) 3.07 ± 0.25 2.04 ± 0.71*** 3.01 ± 0.55 
Tb.Pf (1/mm) 22.53 ± 2.80 27.87 ± 5.52** 23.85 ± 5.39 
SMI 2.02 ± 0.14 2.29 ± 0.29** 1.93 ± 0.22 
Conn.Dens. 
(1/mm3) 
194.48 ± 29.37 
126.55 ± 
37.66*** 
197.37 ± 41.15 
 
Table 4.2. | µCT analysis of trabecular bone in tibiae of WT, Col9a3Δex3 and Col9a3-/- 
male mice at 18 weeks of age. Data obtained from µCT trabecular parameters measurements in 
tibiae and used to generate the graphs in Fig. 4.6. Data are shown as means ±SD. Statistical analysis 





4.3.3 Cortical analysis of the femur in adult mice. 
For cortical bone evaluation, 3D and 2D parameters were considered (Fig 4.7 and Table 
4.3). From the 3D analysis, the ratio of the segmented bone volume (BV) to the total volume 
(TV) of the region of interest, BV/TV, was significantly reduced in cortical bone of Col9a3-/- 
femurs. No genotype specific difference in cortical thickness (Cort.Th) was observed in 
femurs. From the 2D analysis the following variables were extrapolated: the total cross-
sectional area inside the periosteal envelope, tissue area (T.Ar.); the periosteal perimeter 
(P.Pm); the endocortical perimeter (E.Pm); and the mean polar moment of inertia (MMI), a 
parameter which describes the resistance of cortical bone to torsion, so an indication about 
cortical bone stiffness.  
In Col9a3Δex3 femoral cortical bone, the only significant change was in the periosteal 
perimeter, which was increased by 5.5%. For all the other variables, mean values equivalent 
to WT controls were observed. In contrast, Col9a3-/- mice showed a relevant increase in tissue 
area, periosteal, and endosteal perimeters, of 18.1%, 11.1% and 18.7% as compared to WT, 
respectively, resulting in an overall wider bone. Col9a3-/- femurs were also determined to be 
stiffer compared to WT, with their MMI measuring 38% higher than the mean control value. 
An overall wider bone diameter was observed in the femurs of both mutant mice, but which 





Fig. 4.7 | Cortical morphometry of femurs in 18-week old mice. A. Morphometric analysis 
of cortical bone from femurs of 18-week old male WT (N=13) Col9a3Δex3 (N=10) and Col9a3 -/- (N=9) 
mice. A. Data of the graphs, relating to Col9a3Δex3 and Col9a3 -/- mice, are shown as percentage of 
change compared to WT measurements. Data are shown as means ±SD. Statistical analysis 
(Col9a3Δex3 or Col9a3 -/- vs. WT): *p<0.05, **p<0.01, ***p<0.001, two-tailed t-test. B. Cross-
sectional images of 3D µCT reconstructions obtained using the software Dataviewer of femurs from 






Cortical analysis of the femur (18-weeks) 
 WT (n=13) Col9a3Δex3(n=10) Col9a3-/-(n=9) 
TV (mm3) 1.95±0.22 2.05±0.19 2.39±0.07** 
BV (mm3) 0.90±0.07 0.94±0.06 1.01±0.04* 
BV/TV (%) 46.05±2.26 46.25±2.56 42.21±0.98** 
Cort. Th (µm) 222.77±11.05 221.60±10.68 219.50±7.69 
T.Ar (mm) 2.17±2.17 2.28±0.21 2.56±0.27** 
P.Pm (mm) 5.73±0.29 6.05±0.29* 6.37±6.37*** 
E.Pm (mm) 4.65±0.42 5.38±1.28 5.52±0.73** 
MMI (mm4) 0.57±0.11 0.66±0.09 0.78±0.13*** 
 
Table 4.3. | µCT analysis of cortical bone in femurs of WT, Col9a3Δex3 and Col9a3-/- male 
mice at 18 weeks of age. Data obtained from µCT cortical parameters measurements in femurs and 
used to generate the graphs in Fig. 4.7. Data are shown as means ±SD. Statistical analysis (Col9a3Δex3 





4.3.4 Cortical analysis of tibiae in adult mice. 
Interestingly, we observed different results from cortical bone analysis in adult tibiae. 
In contrast with the changes measured in femoral cortical bone, in the tibial cortical bone the 
genotype did not affect either 3D or 2D parameters, with the exception of cortical thickness 
in the Col9a3-/- mice (Fig. 4.8 and Table 4.4), which was significantly reduced (95.7% of the 
average WT value). Mean values equal to WT were exhibited for all other cortical parameters 
in Col9a3Δex3 and Col9a3-/- mice. 
 
Fig. 4.8 | Cortical morphometry of tibiae in 18-week old mice. A. Morphometry analysis of 
cortical bone from tibiae of 18-week old male WT (N=13) Col9a3Δex3 (N=10) and Col9a3 -/- (N=9) 
mice. Data of the graphs, relating to Col9a3Δex3 and Col9a3 -/- mice, are shown as a percentage change 
compared to WT measurements. Data are shown as means ±SD. Statistical analysis (Col9a3Δex3 or 
Col9a3 -/- vs. WT): *p<0.05, **p<0.01, ***p<0.001, two tailed t-test. B. Cross-sectional images of 3D 
µCT reconstructions obtained using Dataviewer software of femurs from the median animals of each 





Cortical analysis of the tibia (18-weeks) 
 WT (n=13) Col9a3Δex3(n=10) Col9a3-/-(n=9) 
TV (mm3) 1.02±0.09 1.00±0.08 0.98±0.10 
BV (mm3) 0.67±0.06 0.67±0.06 0.64±0.05 
BV/TV (%) 66.12±1.42 66.60±2.29 65.11±2.39 
Cort. Th (µm) 268.94±13.16 269.13±14.65 257.56±10.28* 
T.Ar (mm) 1.13±0.11 1.11±0.09 1.10±0.11 
P.Pm (mm) 4.10±0.20 4.05±0.17 3.99±0.20 
E.Pm (mm) 2.39±0.13 2.35±0.15 2.34±0.19 
MMI (mm4) 0.19±0.03 0.18±0.03 0.17±0.03 
 
Table 4.4. | µCT analysis of cortical bone in tibiae of WT, Col9a3Δex3 and Col9a3-/- male 
mice at 18 weeks of age. Data obtained from µCT cortical parameters measurements in tibiae and 
used to generate the graphs in Fig. 4.8. Data are shown as means ±SD. Statistical analysis (Col9a3Δex3 







4.3.5 Bone phenotypic analysis of the femoral head and tibial subchondral 
bone. 
During bone µCT analysis we also assessed other anatomical regions of the long bones 
under investigation, including the femoral head of the proximal femurs and the subchondral 
bone of tibiae in both mutant and WT mice. 
From µCT reconstructed images of the proximal femoral epiphysis, we observed a variability 
in bone composition according to genotype. This finding was of interest when it was 
compared to our µCT observations on the distal femoral epiphysis described in the previous 
section. At 18 weeks, the proximal femoral epiphysis of Col9a3Δex3 male mice presented all 
the characteristics of a fully mature bone, comparable with WT animals. The proximal 
cancellous bone was fully calcified and fusion between epiphysis and metaphysis had 
occurred, in conjunction with complete physeal resorption (Fig. 4.9). In addition, the 
cancellous bone appeared similar to WT with no evidence of reduced trabeculae density or 
altered trabecular space, somewhat different from what we observed in the distal femur. 
Surprisingly, the Col9a3-/- proximal femoral epiphysis showed an important morphological 
change in its cancellous bone composition.  Col9a3-/- epiphysis appeared still in a mineralised 
cartilaginous state, where a distinct layer of articular cartilage was not yet reduced in 
thickness. Formation of trabecular bone was not observed, but a clear separation of epiphysis 
from metaphysis was still present. These features are usually associated with a physeal 
senescence state during the postnatal development of the murine proximal femoral physis 
(Cole et al. 2013). Hence, Col9a3-/- mice were at an earlier stage in the proximal femur 
development process compared to Col9a3Δex3 and WT mice, whose proximal epiphysis were 






Fig. 4.9 | µCT analysis of proximal femoral epiphysis. Coronal (top) and trans-axial view 
(bottom) of µCT reconstructed images of proximal femoral epiphysis from 18-week old male WT, 
Col9a3Δex3, and Col9a3-/- mice. Difference in the developmental state of epiphysis indicated by black 
arrow.  
The evaluation of tibial subchondral bone in 18-week old male mice highlighted another 
interesting morphological change in both mutant mice lines. In Col9a3Δex3 there was a lower 
level of trabecular bone, with reduced presence of trabeculae, which were also thinner than 
those forming the subchondral bone of WT mice (Fig. 4.10). This observation was in line 
with the data from the trabecular morphometry on tibial cancellous bone, findings confirmed 
by the coronal view of Col9a3Δex3 tibia, where an overall decrease of trabecular bone was 
observed in the region below the physis. Col9a3-/- subchondral bone resembled the structure 
of that of the WT mice, showing similar sclerotic regions in the lateral condyle, typical of 
C57Bl/6 background mice (personal communication from Professor Rob Van ‘T Hof, 
University of Liverpool). More trabecular bone was visible in both metaphysis and epiphysis 
in Col9a3-/- tibia, as already stated. Moreover, looking more carefully at the subchondral plate 
of both Col9a3Δex3 and Col9a3-/- mice, we noted a thinner bone in the medial and lateral tibial 
plateau compared to WT in Col9a3Δex3 mice (black stars in Fig. 4.10), but not obvious change 
in the subchondral plate of Col9a3-/-  mice. However, in both mutant mice, the tubercles of 
the intercondylar eminence were lost, giving an overall less defined subchondral plate when 





Fig 4.10 | µCT analysis of tibial subchondral bone. Coronal view of µCT reconstructed images 
of proximal tibial epiphysis and metaphysis from 18-week old male Col9a3Δex3, Col9a3-/- and WT 
mice. Note the reduced subchondral cancellous bone in Col9a3Δex3, along with medial and lateral tibial 





In this chapter we described the skeletal phenotype of our novel mutant Col9a3-/- and 
Col9a3Δex3 mice. The aims of this chapter were essentially two: to verify the presence of 
possible commonalities between the skeletal defects of Col9a3Δex3 mice with EDM3 cases 
caused by similar exon 3 skipping mutations in COL9A3; to compare the consequences at the 
bone level of the two Col9a3 mutations generated, using other collagen type IX knockout 
mice as a point of reference. Radiographic evaluation was performed on homozygous mice at 
two different time points during post-natal development, at a young age (3 weeks), and at 9 
weeks, corresponding to the age of skeletal maturity (Jilka 2013). Radiographic analysis 
showed that the majority of the skeletal abnormalities were detected in Col9a3-/- mice. The 
Col9a3Δex3 skeletal phenotype was characterised by normal stature, with no skull abnormality, 
and no overt morphological changes – with the exception being a shorter femur length 
measured in 9-week old animals. At 3 weeks of age these mice had a reduced tibia length 
however, this growth delay was recovered when skeletal growth was complete at 9 weeks. 
Col9a3Δex3 mice did not display a hip dysplasia often detected in mouse models of skeletal 
dysplasia disorders. Therefore, from radiographic analysis, we could not detect any striking  
skeletal abnormality, similarly to some EDM3 patients’ clinical data. EDM3 patients are 
indeed classified in the mildest part of the spectrum of skeletal abnormalities associated with 
chondrodysplasias. 
On the contrary, the Col9a3-/- phenotype was characterised by overall shorter stature, shorter 
tibiae and femurs (at both 3 and 9 weeks of age), and abnormal wider tibial epiphysis 
compared to WT animals. The hip angle was significantly larger at 3 weeks compared to WT, 
with the difference even more pronounced when mice reached skeletal maturity. Not 
surprisingly, many of the features described about the Col9a3-/-  mice phenotype, are shared 
with the knockout mouse for Col9a1 gene (Col9a1-/-) and Col9a2 (Col9a2-/-), mutations 
leading in both mice to a functional knockout of collagen type IX. Dreier R. et al. described 
the Col9a1-/- mouse phenotype to be characterised morphologically by a reduction in length 
and increased width in all long bones analysed (including the tibia and femur), along with 
broadened tibial condyles (Dreier et al. 2008).  These commonalities between Col9a1-/- and 
our Col9a3-/- mouse, further confirmed our mouse as a valuable Col9a3 knockout, which 





Moreover, the evidence of a shorter skull length, but unaltered intercanthal distance, detected 
in Col9a3-/- mice, suggests that ablation of collagen type IX could affect directly or indirectly 
endochondral ossification in the development of the skull. 
Along with the assessment of bone morphology by radiography, we further investigated long 
bones microstructure of our mutant mice using µCT. The trabecular and cortical bone were 
analysed in the femur and tibia of adult male mice by µCT.  In Col9a3Δex3 mice, the same 
trabecular pattern was observed in 18-week old femurs and tibiae when compared to their 
age-matched WT littermates. The reduced ratio of bone volume per tissue volume, trabecular 
number and connectivity density, along with increased space between trabeculae, detected in 
femurs and tibiae, indicated Col9a3Δex3 mice to be characterised by a low trabecular bone 
phenotype, relative to their WT littermates. In addition, their tibiae structure model index, 
suggested a “rod-like” structure of trabeculae. The conversion from plate elements to rod 
elements is frequently associated to age- or disease- related degeneration of cancellous bone 
that leads to a more fragile bone, as often seen in osteoporosis. What was immediately 
apparent for Col9a3-/- mice instead, was their higher total tissue volume, indicating their long 
bones to have a larger average diameter than the WT average. Interestingly, their trabecular 
thickness mean value was lower compared to WT in both femur and tibia. There are 
contradictory hypotheses in the literature about the correlation between bone volume and 
trabecular thickness, often reporting how thicker trabeculae are more likely to be associated 
to high volume fractions (Macdonald et al. 2011, Beresheim et al. 2018). However, Waarsing 
et al. showed in rats how this relation could be reversed due to ageing, as they demonstrated 
that trabecular thickness increases with decreasing volume fraction when a mechanism of 
bone degradation is triggered. Their hypothesis suggested that the variation noticed could be 
due to compensatory mechanisms aimed at maintaining bone strength despite microstructure 
changes (J.H. Waarsing 2004). The same hypothesis could be applied to our data. We might 
speculate that the decreased trabecular thickness could be a compensatory response for a 
larger bone, which with thicker trabeculae, would become overly compact and heavy. 
Previously, from μCT analyses conducted on lumbar bones of females and males Col9a1-/- 
mice at 8-10 weeks of age, Wang et al. showed how homozygous females had a more 
pronounced trabecular bone phenotype caused by Col9a1-/- mutation than homozygous male 
littermates. In Col9a1−/−females the lumbar bone volume fraction, trabecular thickness and 
connectivity density were significantly decreased and trabecular spacing increased, showing a 




trabecular analysis performed on Col9a3-/- males, also in Col9a1−/− males, the genotype 
seemed not to have a relevant influence on trabecular bone, since only the connectivity 
density was significantly lower. However, with ageing, both female and male heterozygous 
(Col9a1+/−) mice displayed a significant loss of trabecular bone (Wang et al. 2008). 
Conversely, in another study, similar findings to our Col9a3-/- mice were found in Col9a1-/- 
animals vertebral bodies. They showed higher TV and initially reduced BV/TV, which then 
returned to normal by the age of 10 months (Kamper et al. 2016).  
Cortical analysis did not show overt changes in Col9a3Δex3 mice, apart from an increased 
periosteal perimeter in 18-week old femurs. In Col9a3-/- mice the pattern of cortical changes 
recorded in femur was completely consistent with a bone characterised by a wider diameter. 
In fact, a reduction in the bone volume to tissue volume ratio, along with the increased tissue 
area, periosteal and endosteal perimeters were measured in Col9a3-/- femurs. As a 
consequence of the increase in periosteal diameter, the mean polar moment of inertia was 
increased, indicating that the Col9a3-/- mice would be less prone to fragility fracture than WT. 
In Col9a3-/- tibiae only the cortical thickness was significantly lower, leaving all the other 
parameters equal to WT. Such a result could be explained inferring the same hypothesis 
suggested for trabecular bone. We could speculate that the bone, being larger, adapted its 
cortical thickness to be less heavy while at the same time maintaining its supportive function.  
The evaluation of the tibial subchondral bone confirmed the low trabecular bone phenotype 
of Col9a3Δex3 mice and a commonly less defined subchondral plateau in both mutant mice. 
The analysis of the proximal femoral epiphysis by µCT revealed that while in WT and 
Col9a3Δex3 mice calcification, resorption of the physis, and epiphyseal fusion were complete 
(as expected in male mice at the age of 18 weeks), in Col9a3-/- mice maturation of proximal 
femurs was delayed. Col9a3-/- femoral head cartilage was still in the senescent state, 
calcification had been initiated, but the physis was still preventing epiphysis and metaphysis 
fusion. This observation was unexpected, considering that no indication of delayed 
ossification was noticed from µCT images of Col9a3-/- distal femur and tibia. Additionally, it 
is worth noticing that the proximal femur of the Col9a3Δex3 mice did not show evidence of a 
lower trabecular bone phenotype, unlike for their Col9a3Δex3distal femur and proximal tibia. 
Therefore, we could observe different bone microstructure in distinct regions of the same 
bone. These findings confirm that bone morphology and microarchitecture are genetically 




In conclusion, our observations suggested that the potential presence in the ECM of a 
mutated collagen type IX affects long bone development or homeostasis differently when 
compared to its total absence from the ECM. However, the mechanism by which this 
differential outcome takes place is not clear. 
In the next chapter we will analyse aspects of bone development by examining the tibial 
growth plate phenotype and the cartilage proteome of Col9a3Δex3 and Col9a3-/- mice, 







- Radiological findings did not indicate remarkable skeletal abnormalities in Col9a3Δex3 mice, 
which recall some EDM3 patients’ phenotype. 
- Col9a3-/- reproduced (radiologically) the Col9a1-/- and Col9a2-/- mice phenotype. 
- Col9a3Δex3 mice showed a reduced trabecular bone but normal cortical bone phenotype, 
whereas long bones in Col9a3-/- mice were characterised by a stiffer cortical bone with a 
wider diameter. 
- The regulation of bone development and homeostasis differs in distinct bones and in their 
different anatomical sites, adding mechanistic complexity. From our data, we suggest that 
collagen type IX has a role in the complex mechanism of bone regulatory pathways; 













In Chapter 4 we described the bone phenotype of Col9a3Δex3 and Col9a3-/- mice, with 
radiological analysis showing that morphological defects were more predominant in Col9a3-/- 
mice. Analysis of the bone micro-structure identified different changes between Col9a3Δex3 
and Col9a3-/-, suggesting that each mutation affected bone development, homeostasis, or both 
mechanisms differently.  To further unravel this observation, we performed phenotypic 
analysis of cartilage tissue in the mutant mice, in order to identify tissue morphological 
changes that could help to explain the origin of the observed bone defects. In a previous 
study, cartilage biopsies from MED patients lacking exon 3 of COL9A3 due to a G to A 
transition in the splice acceptor site of intron 2 in the gene, showed chondrocyte and cartilage 
matrix abnormalities. MED chondrocytes were found with intracytoplasmic inclusions, 
enlarged rough endoplasmic reticulum (rER), containing electron-dense and –lucent material, 
likely to be retention of abnormally processed matrix proteins. An accumulation of lipids was 
observed in the cytoplasm and rER for some epiphyseal cartilage biopsies (Bonnemann et al. 
2000). Unfortunately, there is a small number of reported studies performed on tissue from 
MED patients with collagen type IX mutations and this is probably due to low availability of   
patients’ biopsy samples. Nonetheless, previous works conducted on Col9a1-/- and Col9a2-/- 
mice described evidence of growth plate anomalies. These included, altered columnar 
distribution of chondrocytes, loss of clear distinction between different zones, reduced 
number of cells in the epiphyseal middle region at early stages of development, along with 
altered integration of other matrix proteins (Balasubramanian et al. 2019, Blumbach et al. 
2008, Budde et al. 2005, Dreier et al. 2008).  
Given the above, for our study a deep analysis of the epiphyseal growth plate was performed, 
at different stages of development and using a variety of different investigation methods. 
Light microscopy and transmission electron microscopy were used to visualise growth plate 
structure and chondrocytes morphology and ultrastructure. By immunohistochemistry (IHC), 
we assessed the presence and localisation of selected matrix proteins in addition to 
quantifying chondrocyte proliferation. Finally, in the attempt to explain the reasons 
underlying the bone and cartilage findings observed in the mutant mice, we performed RNA-
sequencing on their chondrocytes mRNA with the purpose to identify possible gene 





5.2 Analysis of Col9a3Δex3 and Col9a3-/- murine growth plate  
5.2.1 Histological analysis of growth plate structure 
In order to analyse the epiphyseal growth plate architecture, tibiae from female mice at 
3-weeks of age were collected and processed for histology. Tissue sections were subjected to 
Haematoxylin and Eosin (H&E) staining to visualise the general tissue structure. 
Haematoxylin specifically stains cell nuclei blue, and eosin stains the extracellular matrix 
(ECM) and cytoplasm pink. Using H&E we were able to visualise chondrocyte arrangement 
throughout the different zones constituting the growth plate, in both mutant mice and their 
WT littermates. Going from the epiphyseal to the diaphyseal side, in WT tibial sections, we 
could recognise a defined resting zone with its reservoir of small and circular chondrocytes, 
the proliferative zone whose flattened chondrocytes were arranged in regular columns 
parallel to the axis of the bone, and finally the mature and enlarged chondrocytes of the 
hypertrophic zone. From morphometric analysis, both mutant mice exhibited a total height of 
the growth plate comparable to WT controls. No visible difference was detected in the 
organisation of chondrocytes in Col9a3Δex3 growth plate zones compared to WT (Fig. 5.1), 
although their relative height was changed, with the proliferative zone reduced by 15% and 
the hypertrophic zone 9% larger (when measured relative to the total growth plate height) 
(Fig. 5.2). In Col9a3-/- mice, the spatial organisation of chondrocytes in the different growth 
plate zones was impaired. The separation between resting and proliferative zone was lost and 
proliferative chondrocytes were no longer flat and organised in columns, but were instead 
rounded and randomly clustered. In addition, the neat distinction between proliferative and 
hypertrophic zone was hard to determine, as some proliferative cell invasion within 
hypertrophic region was noted. For this reason, we measured a 15% higher proliferative zone 
and 20% narrower hypertrophic zone in homozygous mice for Col9a3-/- mutation (Fig. 5.2); 
however, the lack of precise separation between the two regions made morphometric analysis 
difficult. Col9a3-/- hypertrophic chondrocytes had no obvious anomaly in their shape, apart 
from some sporadic cell enlargement. Larger intercellular spaces surrounded hypertrophic 






Fig. 5.1 | Tibial growth plate architecture in 3-weeks old mice. H&E staining of tibial growth 
plates from 3-week old WT, Col9a3 Δex3 and Col9a3-/- female mice. Representative images from three 
mice per genotype, from twelve sections/mouse. RZ= Resting zone; PZ= Proliferative zone; HZ= 







Fig. 5.2 | Tibial growth plate morphometric analysis. Measurements of the different zones of 
the tibial growth plate at 3-weeks of age (N=3). A. Graph of measurement of whole growth plate 
height. B. Graph of proliferative zone height expressed as percentage of total growth plate height. C. 
Graph of hypetrophic zone height expressed as percentage of total growth plate height. Two tailed T-






5.2.2 Ultrastructural analysis of growth plate chondrocytes 
A more detailed analysis of chondrocytes morphology in the different zones of growth 
plate was performed using transmission electron microscopy (TEM). Cartilage tissue was 
collected from 7-day old tibiae and processed for TEM by researchers at the Electron 
Microscopy Research Services of Newcastle University.   
In the resting zone of Col9a3Δex3 cartilage, chondrocytes displayed enlargement of their 
endoplasmic reticulum (ER) possibly caused by low level protein retention. However, some 
enlargement was also observed in the ER of WT resting chondrocytes (Fig 5.3). Col9a3-/- 
resting chondrocytes were irregular in their morphology and occasionally surrounded by a 
more dispersed fibril organisation, with regions almost devoid of fibres, indicating a less 
compact pericellular matrix (Fig. 5.3).  
Col9a3Δex3 proliferative chondrocytes, as previously stated in the histology analysis, showed 
an overall organisation similar to WT with some cells having a less defined morphology. In a 
few examples, chondrons were less compact, showing a loose, spread chondrocyte 
arrangement (black rectangle in Col9a3Δex3 Fig. 5.4). In Col9a3-/- proliferative zone, the 
distribution of cells was uneven, with regions devoid of chondrocytes. Chondrocytes were 
smaller, with an altered morphology, and their arrangement in chondrons was affected (Fig. 
5.4). Evidence of ER enlargement was present in Col9a3Δex3 and Col9a3-/- proliferative 
chondrocytes. A clear pre-hypertrophic region was visible in WT growth plate, but in both 
mutant mice this defined region was lost. In Col9a3Δex3 mice cells appeared to progress 
directly into hypertrophy, whereas Col9a3-/- pre-hypertrophic chondrocytes showed an 
abnormal morphology, more rounded with loss of the normal columnar arrangement (Fig. 
5.5). 
In Col9a3Δex3 hypertrophic chondrocytes there was some evidence of enlarged ER with 
protein retention. In Col9a3-/- mice glycogen granules were present in chondrocytes (Fig.5.6). 
In addition, between the resting and proliferative zone in both mutant mice (but not in the 
WT) we detected a region lacking all the tissue characteristics typical of growth plate, with 
no normal chondrocytes and an unusual matrix morphology. The overall characteristic was of 
a region where severe tissue degeneration occurred, within which necrotic nuclei were 
detected, along with collagen fibres in an irregular meshwork (Fig. 5.7). This degeneration 





Fig. 5.3 | Ultrastructure of the resting zone in the tibial growth plate. 
Electron micrographs of cartilage from 1-week old mutant mice compared to a WT control (N=1). 





Fig. 5.4 | Ultrastructure of the proliferative zone in the tibial growth plate. 
Electron micrographs of cartilage from 1-week old mutant mice compared to a WT control 
(N=1). Black arrow indicates ER enlargement. Scale bar = 10μm, higher magnification scale 






Fig. 5.5 | Ultrastructure of the pre-hypertrophic zone in the tibial growth plate. Electron 
micrographs of cartilage from 1-week old mutant mice compared to a WT control (N=1). Higher 
magnification images taken from equivalent regions. Black arrow indicates ER enlargement. Scale bar 





Fig. 5.6 | Ultrastructure of the hypertrophic zone in the tibial growth plate. 
Electron micrographs of cartilage from 1-week old mutant mice compared to WT control (N=1). ER= 






Fig. 5.7 | Alteration of tissue morphology in Col9a3Δex3 and Col9a3-/- tibial growth plate. 
TEM images displaying unorganised regions putatively due to tissue degeneration. Note: cells 
undergoing necrosis (black arrows) and an array of ordered collagen fibrils being engulfed within the 





5.2.3 Growth plate abnormalities during early development in mutant mice. 
TEM findings suggested that a more severe phenotype could be exhibited by the growth 
plate at earlier post-natal developmental stages. Therefore, further histological investigation 
on mutant and WT 1-week old tibial epiphysis was needed to confirm the presence of the 
tissue degeneration observed by TEM. 
Unfortunately, because of breeding problems no Col9a3Δex3 samples were available, at the 
time of writing, to perform tissue analysis at 1 week, which therefore only compared Col9a3-
/- mice with their WT littermates. Subsequently the analysis was integrated by adding the 
tissue sections of 1-week old Col9a3Δex3 mice. H&E and Toluidine blue stainings were 
performed on the tibial proximal epiphysis and femoral distal epiphysis growth plates 
sections. Stainings showed Col9a3-/- mice to have a large hypocellular central region, which 
was absent in WT (Fig. 5.8 C, F, I, N). This hypocellular region was localised along the 
whole growth plate height. Starting just below the future secondary ossification centre, 
extending along the resting and proliferative zones and then being engulfed into the 
hypertrophic zone, it finally protruded into the metaphyseal newly formed trabecular bone, 
conferring on the hypertrophic zone an unusual V-shaped morphology. The peripheral tibial 
epiphysis did not show an alteration in chondrocyte density, but only in their distribution. The 
typical columnar organisation of the proliferative zone was profoundly impaired, and 
chondrocytes appeared more rounded and randomly arranged, sometimes following the 
mediolateral axis rather than the proximodistal. Interestingly, no evident broadening of the 
Col9a3-/- tibial condyle was observed at this age. Toluidine blue staining was used as an 
indication of the proteoglycan content in the growth plate. In none of the samples (N=3) a 
change in the intensity of toluidine blue staining was noticed, hence no alteration in the 
proteoglycans abundance or distribution could be observed. However, the possibility of 
overexposure of sections during a not yet fully optimised staining protocol cannot be 
excluded. Indication of cell-free areas were also detected in Col9a3Δex3 tibial sections, mainly 
localised at proliferating region of the growth plate, although not as severe as in Col9a3-/- 
mice (Fig. 5.8 B, E, H, M). Toluidine staining confirmed no change in the proteoglycan 
distribution and abundance also in Col9a3Δex3 tibiae. 
The same cartilage defect was observed also in Col9a3-/- femurs, where an even more 
pronounced central region was completely devoid of cells and was surrounded by smaller and 




height compared to WT. Hypertrophic chondrocytes were enlarged and their spatial 
distribution was profoundly disturbed by the partial invasion of the hypocellular region. The 
presence of a defined circular fold in the tissue section in the middle of the cell-free area, 
suggested that these morphological changes might have affected the mechanical stability of 
the tissue, becoming more fragile and looser. More obvious cell-free areas were also 
recognised in Col9a3Δex3 femurs compared to tibiae, localised in the central proliferating 
region of the growth plate and slightly invading the lower hypertrophic zone (5.9 B, E, H, 
M). Furthermore, we noticed alterations of the secondary ossification centres in both mutant 
mice (5.10). Col9a3-/- mice were found with disrupted secondary ossification centres in 
femurs (5.10 C, F), due to the cell free areas,  and delayed secondary ossification centre in 
tibia (5.10 I, N) whose chondrocytes appeared smaller and at an earlier stage of 
differentiation compared to WT (red circles in Fig. 5.10). Interestingly, from Col9a3Δex3 
sections of both tibiae and femurs (Fig.5.10 E, M), we could notice larger chondrocytes 
showing a hypertrophic phenotype compared to those visualised in WT and Col9a3-/- 
sections. This finding suggested a possibly premature differentiation of chondrocytes and 






Fig. 5.8 | Analysis of tissue defects in 1-week old tibial proximal epyphisis. H&E (A-F) and 
Toluidine blue staining (G-N) of 1-week old tibial growth plates from Col9a3-/- and WT animals. 
Hypocellular regions indicated by arrowheads. Representative images of analysis of three mice per 





Fig. 5.9 | Analysis of tissue defects in 1-week old femoral distal epiphysis. H&E (A-F) and 
Toluidine blue staining (G-N) of 1-week old femoral growth plates from Col9a3-/- and WT animals. 
Representative images of analysis of three mice per genotype. Hypocellular regions indicated by 





Fig. 5.10 | Secondary ossification centre alterations in Col9a3Δex3 and Col9a3-/- mice. H&E 
staining of 1-week old femoral distal epiphysis and tibial proximal epiphysis. Secondary ossification 
centres indicated by red circles in low magnification pictures. Representative images of analysis of 





5.2.4 Collagen type IX localisation in tibial growth plate 
Collagen type IX localisation in the tibial growth plate was assessed using IHC. 
Sections of tibiae collected from 3-week old female mice, were probed with a collagen type 
IX antibody recognising as epitope the NC4 domain of α1(IX) helix (Fig. 5.11). In Col9a3Δex3 
tibial epiphysis, the fluorescence signal corresponding to collagen type IX was weaker than 
control. In addition, at higher magnification, the signal detected in WT growth plate was 
predominantly localised in the inter-territorial matrix, surrounding the chondrocytes arranged 
in columns. Interestingly, Col9a3Δex3 mice showed collagen type IX to be more localised at 
the pericellular matrix and reduced in the inter-territorial matrix. In the proliferative zone of 
Col9a3Δex3 mice, intracellular staining was observed increased, suggesting a certain level of 
retention of the ‘mutant’ protein within the resident proliferative chondrocytes. In Col9a3-/- 
growth plate, the presence of collagen type IX was strongly reduced within the matrix, and 
the weak staining detected, was mainly exhibited by the irregularly distributed chondrocytes, 







Fig. 5.11 | Collagen type IX abundance in the tibial growth plate of WT and mutant 
mice. 3-week old tibiae sections (N=3) were probed with an antibody against the α1 chain of collagen 
type IX. Images were taken at 20X (scale bar = 100μm ) and 40X (scale bar = 50μm) magnification 
























5.2.5 Localisation of Collagen type IX interactors in the ECM. 
Col9a3Δex3 and Col9a3-/- mutations might affect the localisation and retention of other 
ECM proteins into the matrix. For this reason, the localisation and abundance of other 
important ECM structural proteins, known to directly interact with collagen type IX, was 
assessed in 3-week old tibial growth plates (Fig. 5.12).  
Matrilin-3 staining did not indicate any relative change in abundance throughout the different 
zones in both mutant growth plates. Nonetheless, matrilin-3 localisation appeared more 
pericellular, with some intracellular retention, in Col9a3Δex3 mice compared to WT animals. 
Staining for matrilin-3 in Col9a3-/- mice was distributed throughout the growth plate and was 
equally dispersed into the matrix and within proliferating cells. However, the highly altered 
chondrocyte morphology and organisation and the general impaired growth plate of the 
Col9a3-/- line made the exact localisation difficult to determine. 
The intensity of staining for another collagen type IX interactor protein, COMP was only 
slightly reduced in Col9a3Δex3 tissue, but not in Col9a3-/- growth plates. 
When staining for the hypertrophic marker collagen type X was performed, we visualised a 
more extended fluorescent signal in Col9a3Δex3 growth plates, indicating a larger hypertrophic 
zone than in WT controls, confirming our previous growth plate morphometric analysis. 
Reduced abundance, along with a disorganised staining pattern of collagen type X was 







Fig. 5.12 | Localisation of some extracellular matrix proteins in tibial growth plates. 
Immunofluorescence staining was performed by probing 3-week old tibiae sections (N=3) 
with antibodies specific for matrilin-3, COMP and collagen type X. Images were taken at 40X 
(scale bar = 50μm) magnification and exposure time was set on negative control sections (Appendix 






5.2.6 Mutated or absent α3(IX) affects chondrocytes proliferation 
Proliferation of chondrocytes was analysed in the proliferative zone of the tibial growth 
plate at 3 weeks of age using a BrdU (5-bromo-2’-deoxyuridine) in vivo assay.  
Bromodeoxyuridine is a synthetic nucleoside that is an analog of thymidine. The assay is 
commonly used to detect proliferating cells in living tissue by exploiting the capability of 
BrdU to be incorporated into the newly synthesized DNA of replicating cells (during the S 
phase of the cell cycle, when DNA is replicated), substituting for thymidine during DNA 
replication. Col9a3Δex3, Col9a3-/- and WT mice were injected with BrdU solution and their 
legs harvested two hours post-injection. BrdU positive cells were detected by 
immunohistochemistry using a specific anti-BrdU antibody and analysis was performed on 
nine matched sections per mouse (N=3, Fig. 5.13 A) in order to cover the entire growth plate 
depth. The number of cells undergoing mitosis were expressed relative to the total number of 
cells present in the proliferative zone.  
Our results showed that in WT growth plate, 11.4 % of chondrocytes were in proliferative 
activity. The number of BrdU positive cells detected in Col9a3Δex3 and Col9a3-/- growth plate 
proliferative zones were respectively 7.9 % and 6.7 %. Therefore, the proliferation of 
chondrocytes when compared to wild type littermates was significantly reduced of 31% in 







 WT  Col9a3Δex3 Col9a3-/- 
n. of BrdU 
positive 
cells ± SD 
113 ± 11 87 ± 9 85 ± 6 
n. of DAPI 
cells ± SD 
871 ± 144 1131 ± 125 1229 ± 115 
% of BrdU 
positive 
cells ± SD 
11.4 ±1.5  7.9±0.9* 6.7±1.0* 
 
Fig. 5.13 | Proliferation rate of chondrocytes in growth plate proliferative zones of 3-
week old WT, Col9a3Δex3 and Col9a3-/- mice. The level of chondrocytes undergoing mitosis into 
the proliferative zone of 3-week old tibial growth plates was analysed by BrdU labelling assay in 
Col9a3Δex3 and Col9a3-/- female mice and their wild type littermates. A. BrdU-labelled proliferative 
cells compared to Dapi-stained nuclei of 20X growth plate images (scale bar = 200 µm). B. Graph of 
BrdU–positive cells expressed as a percentage relative to the total number of cells in the proliferative 
zone. C. Table with numeric data used to generate “Chondrocytes Proliferation” graph. Two tailed T-






5.3 Transcriptomic analysis of Col9a3Δex3 and Col9a3-/- ribs cartilage. 
Transcriptomic analysis was performed to investigate transcriptional changes in 
homozygous mice for Col9a3Δex3 and Col9a3-/- mutations compared to their WT littermates. 
RNA sequencing was conducted using the RNA extracted from chondrocytes of ribs cartilage 
from 7-day old mice (N=4). After successfully passing the first integrity check (Appendix E, 
Fig. E.1), RNA was sequenced at Newcastle University Genomics Core Facility and Dr 
Kathleen Cheung kindly performed the subsequent transcriptomic analysis.  
Three females and one male coming from two different litters constituted the WT group of 
samples; Col9a3Δex3 mice were all male brothers and Col9a3-/- samples were from two 
females and two males from two different litters. To explore how the transcriptome compared 
across all the different samples, we performed a principal component analysis (PCA) (Fig. 
5.14). PCA showed distinct clustering of samples according to their genotype confirming that 
the transcriptome of each genotype was different. To determine the specific gene expression 
changes contributing to the distinct clustering in the three genotypes, we compared each 
mutant genotype with the WT gene set using DESeq2 (Love et al. 2014). The result 
demonstrated statistically significant alterations in expression levels within each group, as 
visualised by volcano plots (Fig. 5.15). Specifically, the expression of 424 genes resulted 
significantly upregulated and 271 genes significantly downregulated in Col9a3Δex3 mice 
compared to WT littermates. The first 15 most significant upregulated and downregulated 
genes are listed in Table 5.1. Among them was a significant increase in expression of 
fibroblast growth factor 13 (Fgf13) and decreased expression of fibroblast growth factor 
receptor 3 (Fgfr3) in Col9a3Δex3 chondrocytes.  
From the comparison of Col9a3-/- transcriptome profile with WT gene set, 259 genes and 185 
genes were respectively upregulated and downregulated in the mutant transcriptome. The first 
15 most significant upregulated and downregulated genes are listed in Table 5.1. Some of the 
genes most significantly upregulated in Col9a3-/- mice comprised Tensin1 (Tns1), Spondin 
1(Spon1), Versican (Vcan) and Cartilage intermediate layer protein (Cilp). A significant 
downregulation of genes such as Thrombospondin type 1 domain containing 4 (Thsd4) and 
Tolloidin like 1 (Tll1) was measured in Col9a3-/- mice. Subsequently we searched for 
commonalities in the gene expression profiles of the two mutant mice. By comparing the list 
of differentially expressed genes which exhibited a significant change in Col9a3Δex3 and 




downregulated between the two expression profiles (Fig. 5.15). On the lists of genes whose 
expression changes were found in common in the mutants, we subsequently performed 
pathway enrichment analysis to identify GO terms using the database for annotation, 
visualisation and integrated discovery (DAVID) functional annotation tool. When the list of 
commonly upregulated genes was interrogated, the analysis result displayed significant 
enriched gene ontology (GO) terms correlating with biological processes involving elastic 
fibre assembly (Fbln5, Lox, Mfap4, Tnxb), extracellular matrix (Postn), collagen fibril 
organisation (Dpt, etc..), cell adhesion (Col6a6, Mfap4, Spon1, Vcan, Svep1), regulation of 
cell growth (Igfbp4) and interestingly embryonic eye morphogenesis (Fbn2, Mfap2). In 
contrast, no significant GO terms were obtained using DAVID enrichment analysis out of the 
significantly downregulated genes shared by the two mutant mice.  
 
Fig. 5.14 | Principal component analysis of RNA-seq data. Gene expression changes were 
investigated at 7 days, in costal chondrocytes RNA from Col9a3Δex3 and Col9a3-/- mice versus WT 
(n=4 per genotype). The PCA was performed using normalised RNA-Seq data and results revealed 
separation of different biological replicates according to genotype, (WT animals in dark grey; 







Fig. 5.15 | Outline of significant up- and down-regulated genes (vs. WT) in Col9a3Δex3 
and Col9a3-/- transcriptomes. Volcano plot representation of differential expression analysis of 
genes in Col9a3Δex3 (A) and Col9a3-/- (B) mice versus wild-type. The x-axis shows log2fold-changes 
in expression and the y-axis the log10 of the false discovery rate (FDR) considered significant for 
values < 0.05.  C. Venn diagrams representing the number of genes significantly (padj value < 0.05) 







Table 5.1 | Significantly up- and down-regulated genes in Col9a3Δex3 and Col9a3-/- mice. 
List of the first 15 most significant up- and down-regulated genes. (Statistical significance padj value 





To further investigate putative gene expression programs able to contribute to the mutant 
mice phenotype, we compared and examined our mice expression profiles using Rank–rank 
Hypergeometric Overlap (RRHO) and Gene set Enrichment Analysis (GSEA) computational 
methods.  
The RRHO algorithm (Plaisier et al. 2010) was used to check through the two gene lists 
ranked according to the degree of differential expression exhibited by the two mutant mice, 
and to measure if the number of overlapping genes was statistically significant. The RRHO 
analysis output consists of a heatmap showing the overlap trend reflecting the relation 
between the two expression profiles. The highest intensity points depict the statistically 
strongest, or the least likely to randomly occur, overlap between the two profiles. The 
heatmap output of RRHO shows different colours based on the log10-transformed 
hypergeometric P-values. Therefore, the regions of highly significant overlap are denoted by 
red coloured high positive intensity areas, those regions where the overlap was lower than 
expected, are indicated by high negative intensity, purple coloured.  
The output map obtained from RRHO comparison of the ranked Col9a3Δex3 and obtained 
from WT versus Col9a3Δex3 and Col9a3-/- gene sets, revealed a strong red signal 
predominantly located at the bottom left quadrant of the map. (Fig. 5.16). This intensity 
pattern indicated that the highest overlap score was obtained only in the tops of the ranked 
genes lists. In other words, the strongly significant overlap trend suggested that the two 
mutant mice have related gene expression programs mostly involving their significant 
upregulated genes. Whereas not significant overlapping was reported in the downregulated 







Fig. 5.16 | RRHO heatmap. Heatmap generated by comparing the two ranked lists of transcripts 
that are differentially expressed in Col9a3Δex3 and Col9a3-/- using the rank-rank hypergeometric 
overlap (RRHO) algorithm.  High intensity signals (red lower corner) indicated that the highest 
overlap involved the top differentially expressed genes in Col9a3Δex3 and Col9a3-/- chondrocytes. The 






Along with the RRHO analysis, Gene Set Enrichment Analysis (Mootha et al. 2003, 
Subramanian et al. 2005) was applied as additional approach to compare different gene sets 
and to look for statistically enriched or depleted functional related genes in both mutant mice. 
GSEA significance was determined as a false discovery rate values (FDR) below 0.25.  
GSEA result showed 102 gene sets to be significantly enriched in Col9a3Δex3 mice when 
compared to WT expression profile. Some of the enriched biological processes in Col9a3Δex3 
(Fig. 5.17) comprised : “Cell cycle”, “DNA replication”, “Collagen formation” (Adamts14, 
Col23a1, Col4a2, Col12a1, P4hb, Col5a2, Col5a1, Bmp1, Col4a4, Col1a2, Col10a1, 
Col4a3, Pcolce, Col14a1, Ppib, Col3a1, Col4a1,  Plod1, Col15a1, Col5a3) and 
“Extracellular matrix organisation, sharing many genes with “Collagen formation” pathway 
plus some other additional genes  (Mmp14 , Cma1, Crtap, Elane, Timp1, Pcolce). Other 
resulting enriched pathways in Col9a3Δex3 were “Muscle contraction”, “Regulation of 
apoptosis”, “Wnt signalling pathway”. In Col9a3-/- mice none of the gene sets obtained by 
GSEA passed the significance threshold for positive enrichment. 
Eleven gene pathways were found to be significantly enriched for downregulated genes in 
Col9a3Δex3 and these included, “nonsense mediated decay enhanced by the exon junction 
complex”, “signalling by Fgfr mutants” (Fgfr3, Fgfr2, Fgfr1, Frs2) and “myogenesis” (Tcf4, 
Mef2a, Mef2d, Abl1). In Col9a3Δex3 it was worth noticing the downregulation of genes Gpc6, 
Gpc1 and Sdc4, involved in the “heparin sulphate glycosaminoglycan degradation pathway”, 
whose FDR was 0.26, therefore just above the significance threshold.  GSEA report for 
Col9a3-/- displayed significant depletion of 17 gene sets, which involved mainly the 
metabolism of RNA such as “3’UTR mediated translational regulation”, “ peptide chain 
elongation”,“ nonsense mediated decay enhanced by the exon junction complex”,  “activation 
of the mRNA upon binding of the cap binding complex and Eifs and subsequent binding to 
43s”. Interestingly, only the depletion of two gene sets directly related to ECM, resulted 
significant from GSEA applied on Col9a3-/-. They were “extracellular matrix organisation” 
and “collagen formation” pathways, which showed and shared the downregulation of only 






Fig. 5.17 | GSEA enrichment of Col9a3Δex3 and Col9a3-/- gene sets in mouse chondrocytes 
RNA-sequencing data. Plots providing a graphical view of the enrichment scores (ES) of some of 
the gene sets enriched in response to Col9a3Δex3 and Col9a3-/- mutations. The green peak represented 
in the top portion of the plot shows the running ES for the gene set as the analysis walks down the 
ranked list. The middle portion of the plot shows where the members of the gene set appear in the 
ranked list of genes. The bottom portion of the plot shows the value of the ranking metric as you 
move down the list of ranked genes and it measures a gene’s correlation with a phenotype. No plot 
related to upregulated genes in Col9a3-/- mice is shown as no gene set was found significantly 




































In this chapter the role of collagen type IX was explored by assessing the tissue 
pathology of the growth plate in our two mutant mice. Our investigation was carried out 
considering the crucial role of the epiphyseal growth plate in linear bone growth and the 
skeletal findings described in the previous chapter in Col9a3Δex3 and Col9a3-/- mice bones. 
The aim was to assess whether the putative collagen type IX role in bone formation was 
fulfilled by affecting cartilage growth plate stability.  
When localisation and abundance of collagen type IX was assessed in 3-week old tibial 
growth plates, Col9a3Δex3 mice showed a slightly reduced amount of the protein in the 
extracellular matrix but a more prominent accumulation around the pericellular space and 
more importantly its retention into chondrocytes. We can speculate a longer protein 
permanence inside the cell and subsequent delayed trafficking and secretion of it, probably 
caused by a defect in the correct triple helix formation due to the insertion of a mutated α3 
chain into the final protein. The same defect in the triple helix could then prevent or delay the 
correct integration of the mutated collagen type IX molecule in the inter-territorial ECM, 
which would explain the accumulation of the protein around the pericellular space as 
indicated by immunofluorescence localisation. Col9a3-/- mice showed very little staining for 
α1 of collagen type IX, which was predominantly cellular retained. This resulted in the 
absence of the whole protein into the matrix and therefore into a functional knockout of 
collagen type IX, as previously demonstrated in Col9a1-/- and Col9a2-/- mice 
(Balasubramanian et al. 2019, Dreier et al. 2008, Fassler et al. 1994, Hagg et al. 1997). 
We started investigating the consequences of Col9a3Δex3 and Col9a3-/- mutations, by assessing 
growth plate structure through basic histology using animals at 3-weeks of postnatal 
development. Microscopy images showed no obvious changes in Col9a3Δex3 chondrocyte 
morphology or arrangement; however, an alteration of the relative height of the different 
zones was measured. On the contrary, tissue analysis showed Col9a3-/- mutation to cause a 
more severe phenotype than Col9a3Δex3. The Col9a3-/- tibial growth plate was severely 
affected in its organisation, boundaries between the functional distinct zones were confused 
and chondrocyte morphology and arrangement were severely compromised. We observed 
alterations in chondrocytes predominantly in their proliferative state, which were visibly 
smaller, round-shaped and not anymore arranged in the typical columnar distribution. From 




the process of rotation and cell movement of chondrocytes during columnar arrangement in 
the proliferative zone. Although to our knowledge no evidence of this has been demonstrated 
in previous studies. Despite maintaining their morphology, hypertrophic chondrocytes 
appeared misaligned and less compactly distributed. Based on our observations, by 
reproducing the growth plate phenotype previously described in Col9a1-/- and Col9a2-/- mice, 
we further proved our Col9a3-/- mouse to be a functional knockout of collagen type IX.  
In a family affected by MED due to a mutation in the α3 chain of collagen type IX, electron 
micrographs of epiphyseal cartilage biopsies showed lamellar material retained in a dilated 
rER, organised in a hexagonal array of fibrils. The study authors suggested that this material 
was an accumulation of aberrant or not fully processed matrix proteins. (Bonnemann et al. 
2000). On the contrary, in another study involving MED patients affected by mutations in 
COL9A2 gene, articular cartilage biopsies appearance was similar to controls, not showing 
particular inclusions or variations in fibrils (van Mourik et al. 1998a). These discrepancies 
could be explained by probable differences in cartilage tissues analysed and their relative 
tissue- specific gene expression. In our study, TEM was performed on 1-week old tibial 
growth plates to confirm the findings observed through basic histology and to help 
visualisation of chondrocyte ultrastructure. A certain degree of ER enlargement was noted in 
chondrocytes along the different zones of both mutant growth plates. Based on previously 
described chondrodysplasia mouse models, we could speculate protein retention as the cause 
for ER enlargement. We speculated whether the dilated ER observed in mutant mice could 
lead to the activation of ER stress related pathways. However, RNA-seq analysis did not 
show significant enrichment of the pathways generally associated with ER stress. This could 
potentially be explained by the fact that RNA-seq was performed on costal chondrocytes and 
not on growth plate cartilage. The poorly packed chondrocytes observed in the early 
proliferative zone of both mutant mice, suggests a surrounding matrix with possibly changed 
mechanical properties. In fact, changes in the structural components of ECM could result in a 
no longer compact matrix meshwork, with reduced functional support to the encompassed 
cells. Therefore, the forces that usually help and guide the chondrocytes arrangement into 
chondrons might be less effective, leading to a loose or even completely impaired chondron 
structure. Further analysis on cartilage stability to better elucidate any change into the matrix 
induced by Col9a3Δex3 and Col9a3-/- mutations, will be explored in chapter 6 of this thesis. 
Despite the morphological abnormalities recognised in Col9a3-/- growth plate chondrocytes, 




normal physiological functioning of the cells, prior calcification steps. The distribution of 
glycogen particles indeed increases with the degree of differentiation and maturation of the 
chondrocytes, reaching the maximum level in hypertrophic chondrocytes. Glycogen in cells 
provides energy and substrates for protein synthesis. In particular glycolytic breakdown 
products of glycogen constitutes the necessary substrates for alkaline phosphatase or as 
source material for the production, or alteration, of cartilage prior to calcification (Daimon 
1977). 
In addition, TEM images identified an interesting tissue deformity in both 1-week old mutant 
growth plates, localised just in the central core area between resting and proliferative zone. In 
this highly disrupted area, the typical morphology of chondrocytes and matrix was lost, 
instead a confused pattern of poorly defined material was observed. In both mutant animals, 
the cells in this core region appeared in a state of necrosis, probably indicative of a 
generalised cell death event within the area. Moreover, in Col9a3-/- tissue, an ordered pattern 
of what appeared an array of collagen fibres was noted to be misplaced and detached from the 
rest of disordered material, indicating some remnants of a possible ECM. The fact that this 
acellular core was observed only from the two mutant mice, suggested a mutation related 
defect, rather than an artefact generated during tissue processing for TEM. However, in order 
to exclude the possibility of an artefact, we checked tibial growth plates at the same time 
point (1-week) through basic histology. Both H&E and Toluidine blue staining showed the 
presence of a region almost devoid of cells in the core region of the growth plate, starting 
from the resting zone and protruding down to the hypertrophic zone. This tissue defect was 
severe in Col9a3-/- mice, while attenuated in Col9a3Δex3, similar to the hypocellular region 
observed by TEM. Interestingly, the cell-free area was observed in both the proximal tibiae 
and distal femur, with femurs having a more dramatic change in both mutant growth plates. 
Thus through combined histology and TEM we could conclude, that this hypocellular region 
formed as consequence of the mutations. Surprisingly, the hypocellularity region was not 
detected in 3-week old growth plate sections, suggesting mechanisms were responsible for 
the recovery of the cartilage tissue structure during bone maturation. Similar hypocellular 
regions were previously described in mutant Col9a1-/- and Col9a2-/- mice, reinforcing the idea 
of the lack of collagen type IX causing the generation of these areas. However, interestingly, 
despite a lack of a significant growth phenotype (at least compared to Col9a3-/- or other 
collagen type IX null mice) also Col9a3Δex3 mice exhibit the hypocellular region 




solely due to the absence of collagen type IX, but perhaps it is sufficient its miss-localisation 
or altered function to trigger such changes, even though not dramatic as when it is absent. 
Notably, we noted lack of hypoxic, apoptotic or necrotic gene expression pathways in our 
costal RNA-seq on Col9a1-/- mice. This could be explained by the possibility that ribs are too 
small to develop such hypocellular regions. Alternatively, considering that RNA-seq is 
performed on a bulk of cells, it could be possible that the RNA coming from those few 
remaining cells of that area is lost in the total amount of RNA. Lastly, there is the possibility 
that a necrotic gene expression signature is not involved in the formation of such regions. 
Furthermore, delayed or disrupted secondary ossification centres were noticed in Col9a1-/- 
most likely due to the nearby hypocellularity. On the other hand, Col9a3Δex3 secondary 
ossification centres showed an early differentiation of chondrocytes into hypertrophic state. 
This observation was a confirmation on how the different collagen type IX mutations 
described, elicit different molecular changes reflecting then in the different skeletal 
phenotype observed in Col9a3Δex3 and Col9a3-/- mice. 
Based on our analysis, Col9a3Δex3 and Col9a3-/- mice expressed reduced chondrocyte 
proliferation rates at 3-weeks of age. This was perhaps to be expected given the highly 
disrupted growth plate organisation of Col9a3-/-, but surprising for Col9a3Δex3 mice, whose 
growth plate appeared relatively normal. We might hypothesise that the reduced proliferation 
seen in Col9a3-/- mice could contribute to the formation of the hypocellular area, usually 
predominantly involving the proliferative zone of the growth plate. 
For future analysis, assessing apoptosis rates along with proliferation, would provide insights 
on whether an increase in cell death could account for the generation of the hypocellularity 
regions, along with the reduced level of cell proliferation. However, previously, apoptosis 
seemed not to be involved in the generation of cell-free areas in a double deficient mouse 
model for collagen type IX and COMP (Col9a1-/-/COMP-/- ) (Blumbach et al. 2008).  
Collagen type IX represents an important structural component of ECM, deeply connected 
with its surrounding protein network. Direct interactions have been shown for collagen type 
IX through its collagenous and non-collagenous domains with the adapter protein matrilin-3 
and to COMP, respectively (Budde et al. 2005, Holden et al. 2001). Notably, no significant 
expression changes of the genes encoding for matrilin-3 and COMP proteins were observed 
in the transcriptome of Col9a3Δex3 or Col9a3-/- mice. However, using immunohistochemistry, 




Col9a3-/- mutations affected their deposition into the matrix. From our results, we did not 
detect obvious changes in matrilin-3 abundance in either of the two mutant growth plates. Its 
distribution though was affected in Col9a3Δex3 tibiae, which showed pericellular accumulation 
and potentially some cellular retention of matrilin-3, mainly in the proliferative zone cells. 
Surprisingly, in Col9a3-/- tibial epiphysis, no change in the staining for matrilin-3 was 
observed, but its distribution was altered although this could be simply due to the impaired 
growth plate organisation obvious for these animals. In addition, partial cellular retention of 
matrilin-3 was evident in the Col9a3-/- growth plate.   
COMP appeared less abundant in Col9a3Δex3 tibiae, which we could speculate to be due to a 
probable alteration of its binding site to the mutated collagen type IX, albeit its interaction is 
known to occur with non-collagenous domains of collagen type IX (Holden et al. 2001). 
From this, the expectation would have been further reduced staining of COMP in the Col9a3-
/- mice, however staining in these animals was similar, if not equal, to WT. It is worth 
noticing that COMP localisation was found unusually prominent in the hypertrophic zone of 
mice of all genotypes and we believe that this might have occurred because of some antigen-
retrieval artefact during the staining protocol. Earlier studies showed that the integration of 
matrilin-3 and COMP into the matrix was strongly reduced into the cartilage of vertebral 
bodies and ribs of Col9a1-/- mice. A defect in matrilin-3 anchorage to the matrix has also 
been observed when collagen type IX deficient chondrocytes were cultured (Budde et al. 
2005). Subsequently, Blumbach et al. showed that matrilin-3 was absent along with collagen 
type IX in Col9a1-/- tibial epiphysis (Blumbach et al. 2008). Furthermore, the A-domain of 
matrilin-3 was shown to interact with the COL3 domain of collagen type IX, since this 
binding was disrupted when collagen type IX contained a mutation leading to a deletion of 12 
amino acids (from exon 3) in its COL3 domain (Fresquet et al. 2007).  
Collagen type X distribution provided further confirmation of the morphometric analysis 
result of a more extended hypertrophic zone in Col9a3Δex3 growth plates compared to WT. 
However, the reason for an expanded hypertrophic zone in Col9a3Δex3 growth plates remained 
unclear. On the contrary, the reduction of collagen type X observed in Col9a3-/- hypertrophic 
regions, was in line with an overall highly disorganised growth plate with likely impaired 
matrix proteins deposition. 
As previously stated, a portion of collagen type IX molecule is covalently attached to the 




modulating the diameter of larger fibrils such as collagen II fibres (Blumbach et al. 2009). 
Therefore, we found essential the analysis of this other important collagen type IX interactor, 
collagen type II. However, when this was addressed in this thesis work, staining was 
unsuccessful. Nonetheless, investigating collagen type II will be one of the priorities in the 
future follow up of this project.  
When we searched for enrichment of genes and gene sets able to explain the alterations or the 
lack of alterations in our mutant mice phenotypes, we surprisingly observed shared 
expression profiles between the two mouse lines. Despite showing different phenotypes at the 
tissue level, the statistically significant overlap pointed out by RRHO analysis of RNA-seq 
data, indicated relating underlying upregulated gene expression programmes for Col9a3Δex3 
and Col9a3-/- mice. It was not a surprise to find pathways associated with collagen fibril 
organisation, cell adhesion and matrix organisation among the GO terms indicated by 
DAVID analysis for the communal enriched genes in the mutant mice. On another note, 
upregulation of gene such as Fgf13 and downregulation of Fgfr3 in Col9a3Δex3 as well as 
upregulation of Vcan and Cilp in Col9a3-/- drew our attention. These genes and relative gene 
sets will be the candidate for validation in follow-up experiments leading from this study. 
Additionally, it is important to highlight the fact that both Col9a3Δex3 and Col9a3-/- 
transcriptomes did not show significant expression changes of genes coding for proteins 
belonging to the collagen type IX interactome (Brachvogel et al. 2013). Same situation was 
for the other collagen type IX genes.   
Col9a3-/- mice, whose phenotype was confirmed to be more severe, showed only Col9a3 and 
Tll1 genes significantly depleted into the extracellular matrix organisation and collagen 
formation pathways.  
Surprisingly, in Col9a3Δex3 the muscle contraction pathway resulted enriched, whereas 
Col9a3-/- transcriptome had depletion of genes involved in myogenesis. This evidence was 
unusual considering that our analysis was conducted on chondrocytes transcriptome. On the 
other hand, the fact that MED has been previously also associated with mild myopathy 
(Jackson et al. 2010) gives the hint for further investigation on muscle associated genes in 
these mutant mice to verify if and how muscles could represent a secondary target for 




Furthermore, it was surprising to notice that gene sets such as DNA replication, regulation of 
apoptosis and Wnt signalling were upregulated only in Col9a3Δex3, albeit chondrocytes 
proliferation was reduced in both mutant growth plate.  
The nonsense-mediated decay enhanced by the exon junction complex pathway was reduced 
in both mutant mice, but intriguingly we were unable to detect a Col9a3 mRNA in Col9a3-/- 
mice.  
From the data observed so far, we collected very little evidence of the involvement of ER 
stress to the skeletal and cartilage phenotype observed into both mutant mice, however its 
contribution cannot be ruled out from the molecular mechanisms that cause collagen type IX-
MED.  In addition, taking into account the complex fibrillar network of which collagen type 
IX is an important constituent, we believe reasonable that Col9a3Δex3 and Col9a3-/- mutations 
might have altered cartilage stability by affecting the extracellular matrix organisation. This 
hypothesis will be addressed by the analysis described in the next chapter.  
In conclusion, RNA-seq provided important insights about the possible implications of the 
two collagen type IX mutations we have generated. However, when of interpreting these data, 
in relation to the histological observations, we should bear in mind the tissue origin of the 
material analysed. Distinct bone anatomical regions can express different gene expression 
programmes, resulting in their differential development. We therefore advice a cautious 
approach when comparing RNA-seq data obtained from costal cartilage, with tissue analysis 





- Collagen type IX mutations affect the skeletal phenotype by altering cartilage 
stability. 
- Severe cartilage tissue phenotype was observed in Col9a3-/- mice but not in 
Col9a3Δex3. 
- Consistent with other collagen type IX functional knockout mice, Col9a3-/- mice, and 
less severely Col9a3Δex3 mice, exhibited hypocellular regions in early stages of 
postnatal development, however the specific role of collagen type IX in the generation 
of this phenotype is not understood. 
- Significant reduced chondrocytes proliferation was measured in both mutant mice. 
- The cartilage defects observed seemed to be more matrix rather than cellular related, 
although we cannot exclude that the presence of hypocellular regions might be the 





Chapter 6.   






The results of Chapter 5 indicated that the skeletal abnormalities detected in Col9a3Δex3 
mice and in particular in Col9a3-/- mice might be induced by defects in the ECM stability 
affecting chondrocyte behaviour. The involvement of collagen type IX in the proper 
assembly of the fibrillar structure of ECM, and therefore in the complex interplay of its 
interacting factors, is well recognised. Hence, we hypothesised that the presence of a mutated 
collagen type IX molecule or its total absence from the ECM might have a negative influence 
on fibrillar structure assembly. These alterations eventually might change the mechanical 
properties of the tissue and the right chondrocyte-matrix interactions. In this chapter our aim 
was to determine whether our mutant mice exhibited an alteration of ECM stability as a result 
of their Col9a3 mutations. To assess matrix stability, we applied a multi-technique approach 
in order to assess various aspects of its integrity. To evaluate the collagen fibrils constituting 
the ECM we used transmission electron microscopy (TEM). To determine differences in the 
interaction strength of collagen type IX binding partners, we performed sequential protein 
extraction from cartilage. In addition, to better elucidate the nanostructure and mechanical 
properties of the growth plate cartilage, atomic force microscopy (AFM) allowed for 
simultaneous imaging and stiffness analysis on a nanometer scale of native cartilage samples.  
Amongst the clinical findings, patients diagnosed with MED resulting from collagen type IX 
defects, were reported to have knee joints showing osteochondritis dissecans and early-onset 
osteoarthritis (OA) (Bonnemann et al. 2000, Lohiniva et al. 2000, Jeong et al. 2014, 
Muragaki et al. 1996).  Moreover, in previous studies it was reported that mice deficient of 
collagen type IX (Col9a1−/−) develop early onset OA in their knee and temporomandibular 
joints (Hu et al. 2006, Fassler et al. 1994, Balasubramanian et al. 2019). These findings 
suggested a role for collagen type IX in the long-term maintenance of articular cartilage 
integrity.  Therefore, we further assessed the stability of ECM by evaluating articular 
cartilage integrity to investigate if our mutant mice developed an OA-like phenotype. As a 
comprehensive approach, we induced an accelerated cartilage degradation by stressing the 
articular cartilage of mice by performing destabilisation of the medial meniscus (DMM) 
surgery in young adult mice. In addition, we assessed articular cartilage integrity in aged 
mice. We focused our attention on the changes at the level of the medial side of the joint, as it 




6.2 Effect of Col9a3Δex3 and Col9a3-/- mutations on ECM ultrastructure. 
In order to visualise if Col9a3Δex3 and Col9a3-/- mutations affected ECM fibril structure, 
images of ECM were obtained by TEM from knee cartilage of 1-week old animals. Within 
the cartilage growth plate, chondrocytes are surrounded by a thin layer of matrix, the 
pericellular matrix (PCM). The PCM is usually rich in proteoglycans and characterised by the 
presence of thinner fibrils. Chondrocytes, and their relative PCM, are then enclosed into the 
territorial matrix (TM), which contains a network of heterotypic fibrils made of collagen 
types II, IX and XI. The usual arrangement of chondrocytes into columns together with the 
PCM and TM form the chondron within the proliferative zone of growth plate. In-between 
chondrons is the interterritorial matrix (ITM) which contains thick fibrils arranged parallel to 
each other. When the hypertrophic zone is approached, the separation between different 
compartments of the ECM is progressively less-well defined, and the PCM, TM and ITM 
space drastically reduces when chondrocyte enlargement occurs during the transition to 
hypertrophy.  
From TEM images of the PCM and TM, there was no evidence of a difference between WT 
and Col9a3Δex3 fibrils in the proliferative zones of growth plate sections (Fig. 6.1). However, 
an indication of thickened collagen fibrils was noted in Col9a3-/- TM (arrowheads in Fig. 
6.1). Progressing towards the pre-hypertrophic and hypertrophic zones, WT and Col9a3Δex3 
PCM and TM again displayed a similar pattern of fibrils. On the other hand, in Col9a3-/- 
cartilage micrographs, collagen fibrils appeared less dense although their orientation was 
comparable to WT. From an evaluation of ITM along the same regions of growth plate, a 
small reduction in the density of fibrils was observed in Col9a3-/- mice. This difference was 
more obvious in the hypertrophic ITM (Fig. 6.2).  WT fibrils appeared to be oriented on a 
different plane compared to both mutants in the ITM, which we attributed to the orientation 
of the cutting plane during tissue sectioning; however, we could observe that fibrils were 
sparser in the ECM of Col9a3Δex3 line. More remarkable was the variation in Col9a3-/- 
cartilage morphology in the hypertrophic zone.  The distribution of fibrils was uneven 
compared to the equivalent area in WT, with many regions characterised by a reduced density 
of fibrils alternating with areas where the fibrils appeared abnormally compactly clustered 






Fig. 6.1 | Electron micrographs of pericellular matrix (PCM) and territorial matrix 
(TM). Arrowheads indicate thicker fibrils. Scale bar = 400nm; PZ= Proliferative zone; PHZ= Pre-






Fig. 6.2 | Electron micrographs of interterritorial extracellular matrix (ITM). Scale bar = 





6.3 Effects of Col9a3Δex3 and Col9a3-/- mutations on cartilage protein 
extractability. 
Another approach applied to test ECM stability in our mutant mice involved the 
analysis of the extractability from the ECM of collagen type IX itself and two other matrix 
components known to interact directly with it, matrilin-3 and COMP (Budde et al. 2005, 
Holden et al. 2001). In our hypothesis, the integration of mutated collagen type IX molecules, 
or its total absence, would affect the incorporation and binding strength of other proteins in 
the ECM, resulting in changes in their extractability. To test our hypothesis, we collected 
cartilage from femoral heads of 3-week old mutants and WT mice and from it we 
sequentially extracted protein using a series of three increasing denaturant properties 
solutions. We then analysed the cartilage extracts for the presence/absence of collagen type 
IX, matrilin-3 and COMP proteins by Western blotting. 
The analysis of cartilage sequential extractions showed differences in the detection of 
collagen type IX in mice of different genotypes. Immunoblot for collagen type IX was 
performed using an antibody recognizing the NC4 domain of the α1 (IX) polypeptide since, 
as previously mentioned, no specific antibody for α3 (IX) was available. A strong band of 
around 150 kDa, corresponding to the collagen type IX heterotrimer, was observed in WT 
controls in all three extractions under reducing conditions. Only in harshest condition (buffer 
III) was a band corresponding to collagen type IX observed in Col9a3Δex3 extracts. For 
Col9a3-/-, as expected, no band corresponding to collagen type IX was observed. A series of 
bands whose molecular weight was between ~50 and ~37 kDa was consistently observed 
especially in mutant extracts from buffer III under reducing condition, however the identity 
of these proteins remained unclear.  The same pattern of extraction was visualised in all the 
mouse cartilage extracts analysed (Appendix E, Fig. E.2). Analysis of extractability of 
matrilin-3 revealed a higher quantity of the protein in both reduced and native extracts in 
buffer I when extracted from Col9a3-/- cartilage, although we could not detect a product of 50 
kDa, which we considered corresponded to matrilin-3 monomers, under non-reducing 
conditions (Fig. 6.3 A vs. B). Buffer II non-reduced extracts from Col9a3Δex3 showed an 
increase in matrilin-3 quantity compared to WT and Col9a3-/-. However, the same result was 
not observed in buffer II extracts of reduced proteins, where the quantity of matrilin-3 
monomers extracted was comparable to WT.  The extractability of matrilin-3 observed in the 




reduced extracts (Fig. 6.3 A-B). This pattern of extraction was consistent in buffer III extracts 
under reducing and non-reducing conditions in all the mice analysed (Appendix E, Fig. E.2). 
A similar extraction profile was noted when we analysed COMP extractability from cartilage. 
In the mild conditions of buffer I, no difference was noticed in the extraction of the protein 
from reduced and native extracts of the different genotypes. An increase of COMP 
extractability in both mutant extracts was noticed when buffer II extracts were resolved under 
reducing conditions.  However, when protein extracted with buffer II was analysed in non-
reducing conditions, a greater extractability of COMP was only observed for Col9a3-/- 
cartilage extracts (Fig.6.3B). Immunoblot of proteins extracted in the most stringent 
extraction buffer III, demonstrated a slightly higher COMP amount in Col9a3Δex3 compared 
to WT under both reducing and non-reducing conditions whereas, COMP level were lower in 
reduced and native Col9a3-/- cartilage extracts. This pattern of extractability was not 
consistent in other mice analysed (Appendix E, Fig. E.2), preventing the possibility of any 






Fig. 6.3 | Genotype dependent differences in the extractability of some ECM proteins. 
Femoral head cartilage was sequentially extracted from 3-week old WT and mutant Col9a3Δex3 and 
Col9a3-/- mice using a series of three buffers: Buffer I, II and III. Proteins were separated by SDS-
PAGE under reducing (A) and non-reducing (B) conditions and analysed by Western blotting using 
antibodies specific to the NC4 domain of collagen type IX α1 (Collagen Type IX-NC4), matrilin-3 
(Matn-3) and COMP. Images are indicative of the differences detected in protein extraction profiles 





6.4 Analysis of Col9a3Δex3 and Col9a3-/- matrix mechanical stiffness.  
Ultrastructural and biochemical properties of the altered ECM structure were assessed 
using AFM. Limbs from newborn and 6-week old mice of all genotypes, were collected and 
snap frozen in liquid nitrogen to preserve the cartilage. Samples were sent to the Centre for 
Applied Tissue Engineering and Regenerative Medicine in Munich, to Dr. Attila Aszodi’s 
laboratory where researcher Bastian Hartmann kindly performed the AFM. Indentation 
measurements were conducted on the right tibial growth plate in the interterritorial matrix 
(ITM) of the proliferative zone.  
ECM detailed images allowed us to visualise collagen fibrils in a 3 µm2 area of ITM as 
shown in Fig. 6.4. No apparent change in fibrils appearance was seen in both mutant newborn 
cartilage compared to WT. However, at 6 weeks of age, Col9a3-/- fibrils appeared thinner and 
less compact compared to fibrils of WT and Col9a3Δex3 ITM images.  
Mean values of nano-stiffness measurements from three animals per age and genotype (N=3) 
showed a bimodal distribution, as previously seen in studies on articular cartilage and for 
growth plate cartilage. The first peak in stiffness is generally assigned to proteoglycan phase 
(E1) and the second peak (E2) to the collagen phase (Loparic et al. 2010). In newborn WT 
mice, indentation measurements within the ITM gave such a bimodal stiffness distribution 
characterised by a first peak at 25.83 kPa and a second peak at 56.55 kPa. In Col9a3Δex3 
newborn mice peak values corresponded to 31.54 kPa and 58.70 kPa, for E1 and E2 
respectively, showing nanostiffness similar to WT newborns. However, when measurements 
at 6 weeks of age were compared, Col9a3Δex3 cartilage exhibited a tendency for softening 
compared to WT, with E1 values of 29.86 kPa vs. 65.35 kPa for the WT, and E2 values of 
61.26 kPa vs. 82.24 kPa for the WT (Fig. 6.5). By comparison, Col9a3-/- mice had a 
remarkably softer cartilage compared to both WT and Col9a3Δex3 mice.  Col9a3-/- peaks were 
E1= 12.95 kPa and E2=28.89 kPa in newborn mice, and E1=14.10 kPa and E2=22.28 kPa at 






Fig. 6.4 | AFM detailed images of ECM of ITM in the proliferative zone. ITM images of a 
3 µm2 region in the growth plate of newborn and 6-week old WT, Col9a3Δex3 and Col9a3-/- mice. No 
difference is noted in mutant matrices compared to WT in newborn mice, but thinner fibrils were 







Fig. 6.5 | Distribution of ITM stiffness in the ECM of proliferative zone at different time 
points. Nanostiffness measurements were performed on newborn and 6-week old WT, Col9a3Δex3 
and Col9a3-/- growth plate ITM. Histograms represent mean values of measurements (~10,000) on 
three slides per mouse and three animals per genotype. Solid line represents the sum of two Gaussian 
functions, which are represented separately by dashed lines. Calculation of standard deviation was not 
possible as we did not expect to find just one true value for the Young’s modulus since we observed a 
biological system with all its variations, so the width of the Gaussian distribution did not originate 
from any uncertainties of the measurement. The standard error would better describe how 
representing the peak values are with all the values measured. But since in the distributions are so 







6.5 Effect of Col9a3Δex3 and Col9a3-/- mutations on articular cartilage 
stability.  
To assess the involvement of mutant collagen type IX in the development of early-onset 
osteoarthritis (OA), as reported in some MED patients (Jeong et al. 2014, Nakashima et al. 
2005, Lohiniva et al. 2000, Holden et al. 1999), we analysed Col9a3 Δex3 knee joints 
histologically. Additionally, we searched for similar OA‐like changes in the knee joints of 
our mice deficient in collagen type IX as reported previously for Col9a1-/- mice (Hu et al. 
2006). We applied a double approach for the evaluation of OA changes in the knees of our 
animals. Our experimental strategy comprised the assessment of OA in mice after inducing a 
stress in the joint by surgical destabilisation of the medial meniscus (DMM). DMM surgery 
and post-surgery mice checks were performed by Dr Dimitra Tsompani and Hua Lin. In 
addition, we assessed for possible changes in the joints of aged mice to evaluate if a potential 
OA-like phenotype was triggered by naturally occurring ageing. Hua Lin kindly processed 
the tissue samples for Safranin-O-Fast Green staining. 
In the first part of our investigation, we performed DMM to induce OA in 10-week old WT 
(N= 5), Col9a3Δex3 (N= 10) and Col9a3-/- (N= 9) male animals following the procedure 
described in section 2.3.13. Eight weeks post-DMM, the mice were sacrificed to collect their 
right knee joints which had undergone surgery, these were then processed for histological 
examination and scoring as previously described (Glasson et al. 2010). Two experienced, 
independent and blinded scorers performed the scoring and data were combined to obtain 
average values. In this study cartilage degeneration was only scored in the medial femoral 
condyle (MFC), medial tibial plateau (MTP) (Fig. 6.6) and the severity of OA was indicated 
by the combination of the two parameters.  
At 8 weeks post-surgery, scores relative to the damage of MFC cartilage showed no 
significant variations amongst the different genotypes (Fig. 6.7 B), whose mean values were 
1.58±1.40, 1.71±1.09 and 1.18±1.25 for WT, Col9a3Δex3 and Col9a3-/- respectively. This 
indicated the presence of very mild lesions especially in WT and Col9a3Δex3 cartilage, but in 
Col9a3-/- no particular fibrillation of cartilage was apparent and only loss of proteoglycan 
content was noticed, indicated by partial loss of Safranin-O staining (Fig. 6.7A). Despite 
being the region where a more severe level of cartilage degeneration was observed, similar 
cartilage changes were observed in the MTP of Col9a3Δex3 and WT knees, whose scores were 




layer below the surface. In contrast, Col9a3-/- cartilage just showed a reduction in 
proteoglycan staining but overall good condition of the tissue hence the associated score was 
1.56±1.7.  When we combined MTP and MFC scores, both mutant mice did not show 
significant alterations in their OA phenotype compared to WT.  Therefore, we concluded that 
Col9a3Δex3 and Col9a3-/- mice exhibited extremely mild OA in their joints, which did not 
show evidence of increased severity compared to WT. However, the experimental procedure 
has not been consistent across all the mice. Accidentally, nine of the mice (four Col9a3Δex3 
mice and five Col9a3-/-  mice) did not have the clips removed after DMM surgery. We believe 
that this might have had an impact on their movement, consequently in the development of 
OA in their joints. When we excluded those mice whose clip were left on to verify their effect 
on the overall damage score (Fig. 6.7C), we noticed indeed that values for both mutants, 
despite still not significant, shifted towards more severe damage scores. In particular, for 
Col9a3Δex3 MFC and MTP, score values of 2.17 ± 0.72 and 3.95± 1.05 indicated vertical cleft 
and some loss of surface lamina in their articular cartilage. Similar situation, but less severe 
in Col9a3-/- MFC and MTP whose scores were 1.64±1.14 and 2.17 ± 1.87 respectively.  
Subsequently, we assessed the susceptibility to degradation of articular cartilage in both 
mutant mice due to ageing. Two female mice per genotype were kept until the age of 12 
months and then their right leg harvested for the same histological treatment used for DMM 
joints (Fig. 6.8A).  The damage score associated to MFC in both mutant mice was equal to 
0.56 ± 0.08 and was similar for the WT MFC (0.50±0.0). Similarly, in Col9a3Δex3 mice the 
MTP showed only partial loss of proteoglycan with limited tissue fibrillation whose damage 
score was 0.75 ± 0.35, similar to WT (0.87 ± 0.17). Col9a3-/- MTP cartilage appeared almost 
normal, with only a slight reduction in the proteoglycan content with a 0.25 ± 0.35 damage 
score. No difference was observed in the combined effect of the MFC and MTP damage in 
any of the genotypes (Fig.6.8B). Although for the ageing study the small number of animals 
available did not allow statistical analysis, our histological observation of cartilage damage 





Fig. 6.6 | Mouse knee joint after DMM surgery. Safranin-O staining of posterior view of 8-
week old knee joint following DMM procedure. A consistent feature of the DMM model is 
loss of Safranin-O, fibrillation and cartilage loss on the medial tibial plateau (arrowhead). 
MFC = medial femoral condyle; LFC = lateral femoral condyle; MTP = medial tibial plateau; 
LTP = lateral tibial plateau; MM indicates a medially displaced medial meniscus. Adapted 







Fig. 6.7 | Accelerated DMM-induced OA in mice. 10-week-old WT (N= 5), Col9a3Δex3 (N=10) 
and Col9a3-/- (N=9) male mice were subjected to DMM surgery and legs harvested 8 weeks post-
surgery and processed for histological staining. A. Representative coronal sections of the knee joint 
analysed by staining with Safranin O-Fast Green. Highlighted in a rectangle and magnified is the 
cartilage damage at the MFC and MTP Scale bars =100 µm. B. Graphs showing the results of 
histological scoring of OA (Glasson et al. 2010) for the three DMM operated groups. C. Graphs 
showing the same results as B without animals with unremoved clips. Scale bars =100 µm. Scoring 
was performed by two blind scorers on twenty sections from each mouse. Values are mean ± SD for 
the medial femoral condyle (MFC), the medial tibial plateau (MTP) and the sum of the medial 





Fig. 6.8 | OA evaluation in aged mice. Legs from 12-month old WT, Col9a3Δex3 and Col9a3-/- 
female mice (N=2) were harvested and processed for histological staining. A. Representative coronal 
sections of the knee joint from each mouse, analysed by staining with Safranin O-Fast Green. 
Highlighted in a rectangle and magnified is the cartilage damage at the MFC and MTP. Scale bars 
=100 µm. B. Graphs showing the results of histological scoring of OA (Glasson et al. 2010) for the 
three aged groups. Scoring was performed by two blind scorers on twenty sections from each mouse. 
Values are mean ± SD for the medial femoral condyle (MFC), the medial tibial plateau (MTP) and the 
sum of the medial femoral condyle and the tibial plateau (MFC+MTP) for each genotype group. The 





The aim of this chapter was to verify the effect of both collagen type IX mutations on 
ECM stability. Collagen type IX represents an important element in the ECM thanks to its 
ability to bind and stabilise other structural proteins. The hypothesis to be tested was 
therefore the possibility of deleterious changes in the stability of the heterotypic collagen type 
II/XI/IX fibrils in the mutant ECM as consequence of the two different collagen type IX 
mutations in our mice. Limited investigation of the cartilage ultrastructure is reported for 
EDM3 patients due to the lack of patient cartilage biopsies. Most observations predominantly 
report findings about chondrocyte morphology and speculative evidence of ER enlargement, 
likely to be due to protein retention (Bonnemann et al. 2000, Spayde et al. 2000). More 
detailed studies of the ultrastructure of cartilage from collagen type IX deficient mice have 
indicated that collagen fibril diameter is increased compared to WT or collagen type IX/ 
COMP double knockout animal fibrils (Blumbach et al. 2009, Budde et al. 2005).  From 
TEM images of our mutant mice growth plates, we could observe mild differences in their 
cartilage fibrils compared to WT. The alterations were more obvious in null mice, which 
showed both the TM and ITM with less densely arranged and sporadic unusual clustered 
fibrils, with an indication of increased thickness in the proliferative TM. On the contrary, 
Col9a3Δex3 fibrils were almost identical to WT, with a general less dense population of ITM 
fibrils.  
To assess the strength of incorporation into the ECM of collagen type IX and its direct 
interactor proteins matrilin-3 and COMP, we evaluated how readily these proteins can be 
extracted from the matrix of 3-week old animals using three solutions having increasing 
denaturant properties. This gave an indication of the level of cross-linking of these proteins 
within the ECM, since it is established that by 3 weeks of age collagen types II, IX and XI are 
highly cross-linked in mouse cartilage (Mendler et al. 1989). The experiment aim was to find 
genotype-specific profiles of extraction which gives indication of integration strength, but no 
actual quantification of protein extracted. Western blot analysis of sequentially extracted 
femoral head cartilage samples revealed genotype specific differences. Surprisingly, in anti-
NC4 α1(IX) immunoblots we were able to detect what we considered, according to its 
molecular weight, collagen type IX heterotrimer only in WT in all three extraction conditions 
and in Col9a3Δex3 extracts only in the final buffer. From the absence of protein detection in 




more tightly integrated within the ECM. Although it seems unlikely that mutated collagen 
type IX interaction with the surrounding environment can be stronger than WT protein, 
whose extracts showed collagen type IX band in all buffer conditions. Hence the reason why 
we did not detect any collagen type IX band in milder extraction conditions in Col9a3Δex3 
samples remains unclear. A possible explanation would be that the collagen type IX 
harbouring the mutated α3(IX) is less present and very unstably located in the ECM, which 
might have washed off during extraction steps, and the only protein visible was the one still 
retained intracellularly, which we could see when cells were lysate by the harsh conditions of 
buffer III. As anticipated Col9a3-/- mice lacked detectable collagen type IX when extracted 
with any solution.  
A reduction of matrilin-3 presence in buffer III Col9a3-/- cartilage extracts was consistent and 
could be due to loss of the protein during the earlier stages of extraction, indicating a possibly 
weaker integration of the protein within the mutant ECM. Conversely, the COMP extraction 
profile was more difficult to interpret with results less reproducible. More COMP was 
extractible from Col9a3-/- cartilage and on occasions from Col9a3Δex3 femoral cartilage. 
However, in other mice with the same genotype we encountered problems in reproducing a 
similar extraction profile. The extreme variability in the results obtained, prevented any 
reasonable conclusion. The findings obtained by µCT related to the bone microstructure 
pointed out a different status of ossification in Col9a3Δex3 and Col9a3-/- proximal femurs. 
While Col9a3Δex3 femoral head was characterised by a fully mature bone with no evidence of 
lower trabecular bone phenotype, Col9a3-/- femoral head was delayed in its ossification. This 
suggested a possible cause for such a variation observed in the extraction profiles in the 
femoral head cartilage of different mice.  
AFM results showed important changes in the mechanical properties of both mutant matrices. 
Cartilage ECM has a well-established double composition which confers different 
mechanical characteristics due to the two main molecule types, proteoglycans and collagen 
fibrils. Proteoglycans (PG), thanks to their negatively charged glycosaminoglycan (GAG) 
side chains, create an osmotic balance which leads to the formation of a PG gel able to 
deform and dissipate the energy under loading conditions. Meanwhile, collagen fibrils, by 
their extensive covalent cross-linking, form a three dimensional network which confers 
stability and elasticity to the matrix. Thus, cartilages mechanical propensity to counteract 
compressive and tensile stresses is provided by the combination of these components. From 




required to preserve matrix stability, because changes in this composite network will affect 
the overall tissue mechanical properties. Using AFM we were able to test these mechanical 
properties in order to have an indication about changes in the matrix composition.  Good 
evidence of the reliability of our measurements was the reproduction of a bimodal 
distribution of the nanostiffness, already described in studies where the structural and 
mechanical properties of the developing murine growth plate and the porcine articular 
cartilage were assessed by AFM (Prein et al. 2016, Loparic et al. 2010). In these studies, it 
was shown that nanoscale AFM was able to measure the local matrix nanostiffness by 
probing the elasticity of separate components, proteoglycan and collagen fibrils. This is 
reflected into a bimodal Gaussian distribution on the histograms constituted by a lower peak 
generally indicating the stiffness given by the proteoglycan content and a higher peak as a 
result of collagen fibril stiffness. In our study, WT newborn samples exhibited elastic moduli 
ranging in the typical interval reported previously for a young but well-established matrix, 
with clear peaks showing dense PG and collagen fibrils. In Col9a3Δex3 matrix the stiffness 
reported in newborn mice was similar to WT, whereas Col9a3-/- mice showed a shift towards 
lower values, indicating a decrease in nano-stiffness. However, despite being similar to WT 
during early post-natal stages, Col9a3Δex3 mice demonstrated a tendency to softening with 
time in both PG and collagen phases, as shown by 6-week old samples. Likewise, Col9a3-/- 
mice nano-stiffness did not improve with time and their elastic moduli were remarkably 
shifted towards low values also at 6 weeks of age. We can therefore imply that the absence of 
collagen type IX severely affects the mechanical properties of the matrix. Similar findings 
were shown in a study conducted on intervertebral discs of collagen type IX null mice 
(Col9a1-/-), where a less dense collagen network was identified by AFM in intervertebral 
endplates. Nanoindentention AFM measurement indicated a markedly softer ECM in the 
inner annulus and the articular region of vertebral endplate, consistent with our findings 
(Kamper et al. 2016). From our TEM analysis, an indication of collagen fibrils thicknening 
was noticed in Col9a3-/- cartilage, observation which was in contrast when Col9a3-/- fibrils 
were imaged from AFM detection. When the cartilage surface of Col9a3-/- ITM was 
visualised through AFM, collagen fibrils appeared thinner compared to WT cartilage surface 
images. Similar result was given by the observation of collagen fibrils diameter under 
polarised light after picrosirius red staining. Fibrils diameter was similar to WT in Col9a3Δex3 
but slightly reduced in Col9a3-/- as they appeared yellow and green under polarised light 
(Appendix E, Fig. E.3). In the attempt to elucidate these discrepancies about fibril diameter 




images of ITM surface. In a previous study, in 1-month old Col9a1-/- mice fibril thickening 
correlated with increased nanostiffness of articular cartilage, which then tended to soften by 
the age of 12 months (Stolz et al. 2009).  Our AFM data on newborn and 6-week old Col9a3-
/- mice contradicts the findings by Stolz et al. and did not correlate with our TEM observation. 
Differently from Stolz et al. which performed AFM on articular cartilage of Col9a1-/- femoral 
heads, in our study we analysed tibial growth plate cartilage. This could be accounted for the 
conflicting results, however further investigation on fibril diameter would contribute to 
unravel the origin of such discrepancies.   
Among the symptoms reported from patients diagnosed with MED caused by collagen type 
IX mutations, the appearance of early-onset OA was the most commonly mentioned. 
Moreover, collagen type IX has been frequently associated with OA changes, where its 
expression is increased in areas of the joint where cartilage defects were present, putatively as 
an attempt by the diseased cartilage tissue to stabilise and protect the remaining matrix from 
further destruction (Koelling et al. 2008). Degradation of collagen type IX was also observed 
in  primary stages of OA and rheumatoid arthritis (Diab 1993). In addition, both collagen 
type IX null mice (Col9a1-/- and Col9a2-/-) were described with early-onset joint 
degeneration. As consequence Col9a1-/- mice present behavioural changes, such as gait 
changes and impairment during exercise tasks, consistent with anatomic signs of OA and 
intervertebral disc degeneration (Allen et al. 2009). Findings of OA-like changes in the knee 
and temporomandibular joints during ageing were described in collagen type IX deficient 
mice (Col9a1-/-) (Hu et al. 2006). It was suggested that the proteoglycan depletion and loss of 
intact collagen II reported in the joints of these mice were caused by an increase of MMP-13 
expression due to induction of the discoidin domain receptor-2 (DDR-2). The increased 
MMP activity generates fragments of collagen type II and fibronectin which by binding to 
α2β1 and α5β1 respectively, induce more proteinases activity. Also cytokines such as IL-1 
further stimulate signalling pathways that induce MMP-13 expression (Li et al. 2007). We 
therefore decided to perform DMM surgery to induce a damage in the knee joints of our 
mutant mice which would accelerate the joint cartilage degeneration and progression of OA. 
The prevalence and clinical manifestation of OA is strongly affected by sex, with men 
showing higher prevalence of OA than women before the age of fifty (Srikanth et al. 2005). 
Similarly, also in different strains of mice which develop spontaneous OA, it has long been 
documented that male mice had a higher incidence of degenerative joint disease than females. 




model, with males having more severe OA than females. This seems to be due to the 
protective effect exercised by the ovarian-derived hormone on cartilage, whereas male 
hormones, such as testosterone, have a detrimental effect on the severity of OA (Ma et al. 
2007). Therefore, to be able to visualise a more dramatic OA phenotype we chose to perform 
DMM surgery on male mice. However, when we sought to determine the effect of both of our 
collagen type IX mutations on the articular cartilage of mice whose joints were stressed by 
DMM, we could not identify any difference in the damage scores when compared to WT. 
This observation would mean that the incorporation of a mutant collagen type IX as well as 
its absence does not affect the articular cartilage stability in this model. A similar observation 
was obtained when we assessed the tissue damage in articular cartilage of aged mutant mice. 
Although the very small sample size must be considered, no indication of worsening of 
articular cartilage was obtained from Col9a3Δex3 joints and more unexpectedly in Col9a3-/- 
joints. However, our study was greatly underpowered and despite it suggests that Col9a3Δex3 
mice do not reproduce the OA changes observed for EDM3 patients, this cannot be a certain 
conclusion. Moreover, our observations were in contrast with published evidence that the 
lack of collagen type IX contributes to OA-like changes in different mouse joints. We 
focused our attention only on knee joints, maybe missing other sites where possibly the effect 
of the mutations on cartilage degeneration is more prominent. We also recognise the sample 
size used in our analysis as a limitation and the possible explanation for the result, therefore 
increasing the number of animals in each arm of the study is required before a firm 
conclusion about role of Col9a3 in OA-like articular cartilage can be drawn.  
To summarise, we have explored the effect of Col9a3Δex3 and Col9a3-/- mutations on cartilage 
stability. Col9a3Δex3 mutation affects the growth plate cartilage stiffness in late stages of post-
natal development, but does not affect fibril appearance, the interactions with matrilin-3 and 
COMP, nor articular cartilage stability. The absence of collagen type IX has more severe 
consequences at least at the level of the growth plate cartilage, whose fibrils are less compact 
and dense. The binding strength of matrilin-3 resulted affected, as it showed to be more 
soluble in mild extraction conditions, while results obtained regarding COMP stability were 
inconclusive. The ageing related OA evaluation was inconclusive in both mice. Notably, 
ageing was evaluated only in females, but indication of sex related differences in the 
development of OA were noticed for example after DMM surgery, which affects 
predominantly males. In addition, we questioned if mice should have been kept longer than 




articular cartilage. Hence we think that implementing our experiment, by increasing the 
sample size, including male mice and possibly challenging them, will be imperative to fully 
conclude whether the lack of this fibre plays any role in OA-like disease development in 





- Col9a3Δex3 mice presented decreased cartilage nanostiffness in late post-natal 
development stages, despite retaining the stability of interaction of collagen type IX 
with matrilin-3 and COMP.  
- Col9a3-/- mice presented significant decreased cartilage nanostiffness, dispersed 
collagen fibrils with an indication of mild thickening and possibly weakly integrated 
matrilin-3 protein in the ECM. 
- Col9a3Δex3 did not phenocopy the OA observed by EDM3 patients.  
- Col9a3-/- mice did not present an osteoarthritic phenotype in knee joints, contrary to 













Multiple epiphyseal dysplasia (MED) is an autosomal skeletal disorder which when 
dominant is caused by mutations in structural components of ECM such as COMP, matrilin-3 
and the genes coding for the collagen type IX α-helices, COL9A1, COL9A2 and COL9A3. 
Patients belonging to the group of MED cases caused by mutations in the collagen type IX 
genes are found with the mildest form of symptoms such as irregular epiphysis and early 
onset OA mainly involving the hip and knee joints. Collagen type IX belongs to the FACIT 
collagen subfamily and constitutes an important element inside the ECM, as its role in 
controlling and stabilise the packing of collagen fibrils in the matrix has been suggested, 
along with its interactions with other collagenous and non-collagenous components within 
the ECM.  Intriguingly, the majority of collagen type IX genes mutations related to MED 
have been reported to be splice sites mutations in either acceptor or donor splice sites leading 
consistently to the skip of exon 3 and consequently to the deletion of 12 amino acids in the 
COL3 domain of the protein. The precise function of the COL3 domain is not understood, but 
we know that it protrudes together with the NC4 domain into the extracellular space where it 
reported to have a role in interacting with other ECM components. Because of its persistent 
association with MED, we believe that the COL3 domain represents a critical region for the 
pathogenicity of MED caused by collagen type IX mutations, however the pathological 
mechanism that links its mutations to the onset of MED is still unknown.  
The aim of this project was therefore to understand the pathological role of the deletion of 
exon3 in relation to MED. To do so, our strategy involved the induction in a murine model of 
the deletion of exon 3 from the Col9a3 gene to mimic the molecular consequence of splice 
sites mutations in COL9A3 (and COL9A2) of MED patients, being aware of the high degree 
of conservation of splicing between human and mouse (Thanaraj et al. 2003). Our aim was to 
reproduce in the mouse the human MED phenotype to generate a valuable tool for further 
molecular analysis of the disease mechanism.  
Firstly, we described our approach to generate the mutant mice. Using CRISPR/Cas9 gene 
editing we designed gRNAs targeting the intronic regions flanking the exon 3 of Col9a3 to 
induce deletion. We opted for this specific genome editing tool over the more conventional 
ones for site specific mutagenesis, mainly for its ease of design and use and for being 
extremely quick and efficient. Moreover, the specificity given by the simple design of the 
sgRNAs was sufficient to obtain the kind of mutation we were trying to induce, being a 




consequence of the error prone NHEJ repair mechanism triggered in the cell after Cas9 
double-strand cleavage, multiple different alleles carrying the desired deletion were 
generated. We therefore performed some initial characterisation of the F0 generation. After 
screening of all alleles, we selected two deletion mutations to be carried on in established 
mouse lines. One mutation, which we called Col9a3Δex3, caused the generation of a shorter 
Col9a3 mRNA lacking the 36 nucleotides of exon 3, proving that our strategy was successful 
in obtaining the desired consequence. From the Col9a3Δex3 mRNA a shorter α3 (IX) chain is 
generated, which did not affect the full collagen type IX formation or stability, as suggested 
by detection of α1 (IX) protein on Western blot analysis. The second mutation, which we 
termed Col9a3-/-, impaired Col9a3 mRNA stability, presumably due to aberrant splicing, and 
protein formation, resulting in a null mouse for collagen type IX. Aberrant splicing originates 
from different mechanistic models. It can arise from alterations in core spliceosomal 
components, leading to global splicing deregulation and resulting in a large number of 
aberrant products. Similarly, alterations in an accessory splicing factor can lead to 
deregulation or upregulation of splicing for the limited set of transcripts where the factor is 
required for accurate splicing. Alternatively, when the genomic mutations are in a critical 
splicing motif of a single gene, this will change the splicing pattern of just that transcript 
(Chen and Weiss 2015). We, therefore, consider unlikely that the phenotype we observed in 
Col9a3-/- mice could be caused by aberrant splicing induced stress rather than mutation in 
Col9a3 related changes.  
By fortuitously obtaining the Col9a3-/- mouse, we generated the first knockout mouse for 
Col9a3 and importantly we demonstrated that the α3 (IX) chain is indispensable for the 
formation of collagen type IX heterotrimer, as previously proved for α1 (IX) and α2 (IX) in 
Col9a1-/- and Col9a2-/- mice, respectively (Balasubramanian et al. 2019, Fassler et al. 1994, 
Hagg et al. 1997). Preceding studies on in vitro reassociation of the single collagen type IX α-
polypeptides, suggested the formation of homotrimeric or heterotrimeric molecules with 
different stoichiometry  (Jaalinoja et al. 2008, Pihlajamaa et al. 1999). However, as 
mentioned in this thesis work, any sort of compensation of the other two expressed α-helices 
can be excluded when one of the three is absent in vivo. In Col9a3-/- mice, despite the 
mRNAs for α1 (IX) and α2 (IX) chains are normally transcribed (data not shown), we could 
not detect α1 (IX) polypeptide when a specific antibody was used, and presumably the same 
result would be given by detection of α2 (IX). The reason for this is beyond the 




and α2 (IX) chains might be rapidly degraded or their production might be suppressed at the 
translational level, when normal collagen folding is not possible in the absence of α3 (IX) 
chain.  
The subsequent characterisation of the two mutant mice was driven by a new double purpose 
of our study.  Col9a3Δex3 mice were analysed to verify if phenotype commonalities with 
collagen type IX-MED patients were developed, to define these mice as valuable model for 
MED. Col9a3-/- mouse phenotype was analysed to determine its equivalence to the other 
collagen type IX functional knockout mice, but also used to verify if phenotype 
commonalities were shared with Stickler syndrome.  
We started the characterisation of the two mutant mouse lines from the analysis of their bone 
phenotype. Col9a3Δex3 mice did not show obvious skeletal abnormalities, but presented a low 
trabecular bone phenotype. On the contrary, Col9a3-/- mice showed hip dysplasia, short limbs 
with widening of tibial epiphysis reproducing the skeletal phenotype shown by other collagen 
type IX deficient mice, and features of Stickler syndrome patients. Our µCT analysis showed 
an increased bone volume in femurs and tibia of adult Col9a3-/- mice with an unexpected 
delayed ossification in their proximal femur. However, conflicting bone microstructure 
observations are reported in literature for mice deficient in collagen type IX, which suggest a 
variability in the bone phenotype observed probably influenced by different age, anatomical 
region or mouse background related variation.  
In Col9a3Δex3 mice µCT analysis gave evidence of a reduced trabecular bone phenotype and 
especially the indication of a “rod-like” structure of the cancellous bone, typical of conditions 
characterised by bone fragility and osteoporosis (Liu et al. 2010). Low bone mass, 
osteoporosis and increased incidence of fractures have been observed in several myopathies 
(Barzegar et al. 2018, van den Berg et al. 2010), neuromuscular disorders characterised by 
muscle weakness due to dysfunction of muscle fiber. Interestingly, in several skeletal 
dysplasia phenotypes, myopathy is a recognised neuromuscular complication of the disease. 
In particular, cases of mild myopathy have been reported for patients diagnosed with MED 
caused by mutations in COL9A2 and COL9A3 genes (Bonnemann et al. 2000, Jackson et al. 
2010). No evidence of collagen type IX expression in skeletal muscle have been reported so 
far (Irwin et al. 1985, Muller-Glauser et al. 1986), however its expression is found in 
fibrocartilaginous tissue in the enthesis, the attachment site at the tendon to bone interface. 




by the expression of a mutant collagen type IX, which might affect the musculoskeletal 
tissues. A similar myopathy condition analysed in a mouse model for MED resulting from 
Comp mutation (Pirog et al. 2010), helped to further explain this hypothesis. The enthesis site 
is responsible for transmitting the forces between the tendon and muscle fibers, so an altered 
structure of the tendon junction might disturb the mechanical forces transmitted to the muscle 
and therefore alter the ability of those tissues to remodel following stress. The bone is a 
dynamic tissue which is able to remodel in response to the mechanical load, such as an 
increase in loading, results in increased bone formation and decreased resorption whilst 
unloading of the bone has an opposite effect. Bone mineral density correlates directly with 
the mechanical forces applied by muscle strength, so that a reduced muscle tension on bone 
and consequent loss of muscular strength negatively affect the bone density. Taking into 
account these considerations, our finding of low trabecular and osteoporotic-like bone 
phenotype in Col9a3Δex3 mice could indicate a possible consequence of a form of muscle 
weakness in these mice, which would perfectly be in line with the myopathy reported for 
some colIX-MED patients. A follow-up study aiming at analyse the skeletal muscle and 
tendons will certainly add to the understanding of Col9a3Δex3  low trabecular bone phenotype 
and whether these mice represent a valid model for the study of MED related myopathy.  In 
addition, in the current study we did not undertake any analysis of bone deposition and 
resorption. An investigation on common bone turn over markers in both mutant mice, is 
advised as it will help understand if and how the mutations affect bone development and/or 
homeostasis.  
Subsequently, we explored the growth plate phenotype of the mice, by assessing its 
organisation, chondrocyte proliferation, and the presence and localisation of collagen type IX 
protein plus two of its binding partners, matrilin-3 and COMP. We investigated the growth 
plate of our mutant mice at similar time points already assessed previously in other mouse 
models of MED, to be able to better interpret our results in relation to the other MED models 
findings.  Col9a3Δex3 growth plate was not severely affected by the mutation in terms of 
morphology and chondrocytes appearance, although the relative height of the zones, was 
different from WT and more importantly they presented a significant reduction of 
chondrocyte proliferation. An indication of partial collagen type IX retention within 
chondrocytes was noted, but probably was not sufficient to trigger an ER stress response at 
least according to our transcriptome analysis. Conversely, Col9a3-/- growth plates were 




reporting some indication of enlarged ER by TEM. Interestingly similar changes of 
chondrocytes, appearing misaligned and misshapen were also detected in other mouse models 
of PSACH-MED harbouring mutations in matrilin-3 (moderate MED: Matn3 V194D) 
((Leighton et al. 2007) and COMP (mild PSACH: Comp T585M and severe PSACH: Comp 
DelD469) (Pirog-Garcia et al. 2007, Suleman et al. 2012) as well as in Col9a1-/- and Col9a2-/- 
mice (Balasubramanian et al. 2019, Fassler et al. 1994). These mouse models despite having 
different mutations resulting in different molecular changes responsible for the disease, 
presented some commonalities. All of them had short stature, misaligned and abnormal 
chondrocytes shape, decreased chondrocyte proliferation and some of them also had 
increased and spatially dysregulated apoptosis in the cartilage growth plate. In these previous 
studies it was hypothesised such changes in chondrocytes proliferation and apoptosis to be 
the cause of disrupted linear bone growth identifying these features as common disease 
signatures of these disorders. If this hypothesis can be applied to explain the short stature 
phenotype of Col9a3-/- mice, the same reasoning does not explain the absence of reduced 
bone growth in Col9a3Δex3 mice in light of the significant reduction of proliferation in their 
growth plate. This finding is the first evidence of reduced proliferation which does not affect 
bone growth, opening the question whether other mechanisms could compensate the 
detrimental effect of Col9a3Δex3 mutation on long bone growth or may signify that the reduce 
stature is not a direct consequence of it but of the interplay of several other factors with it. A 
phenotype similar to collagen type IX deficient mice was also observed in mice with a 
cartilage-specific deletion of β1-integrin gene.  Integrins mediate cell-matrix interactions and 
for this reason it is considered the insufficient adhesion of β1-null chondrocytes to be the 
cause of the change in the cellular morphology and alignment. Collagen type IX has unique 
cell adhesion properties thanks to its interaction with the cartilage integrins α1β1 and α2β1 
(Kapyla et al. 2004) and the importance of this interaction is also demonstrated by the 
changes of β1 localisation and intensity in Col9a1-/- mice (Dreier et al. 2008). We can think 
that even in our mice the absence of collagen type IX induces structural changes in the ECM 
which then have consequences on the signalling pathways based on integrins function, which 
affect chondrocytes morphology, division and survival.  
ER stress response has been considered another disease signature of some PSACH-MED, 
thanks to the study of knock-in models for the disease. A knock-in mouse model for mild 
PSACH, carrying the T585M mutation in COMP, developed a mid UPR stress without 




retention of the mutant protein in the ER with subsequent UPR response. A different 
mutation in COMP DelD469 causing severe PSACH was found to induce a novel cell stress 
response, independent from the conventional UPR (Leighton et al. 2007, Pirog-Garcia et al. 
2007, Suleman et al. 2012). The indication of ER enlargement in both collagen type IX 
mutant mice might suggest a molecular pathology similar to these mice, where we can 
speculate that the folding of a proper collagen type IX heterotrimer cannot be fulfilled 
because of either the absence of α3(IX) or the presence of a mutated α3(IX) chain. The 
consequence would be longer retention of the mutated collagen type IX molecules and delay 
of their secretion and insertion in Col9a3Δex3 ECM, probably explaining the pericellular 
localisation detected by immunostaining. Conversely, we suggest the retention and 
subsequent targeting for degradation of the other two (α1(IX) and α2(IX)) helices in Col9a3-/- 
ER, to be the reason for the ER enlargement and the lack of immunostaining signal observed. 
However, from our preliminary transcriptomic analysis did not emerge the activation in our 
mutant mice of specific ER stress pathways. For example, when we looked for expression 
changes of specific genes belonging to the ER stress and UPR associated genes such as 
Grp94, Grp78/BiP, Erp72/Pdia4, Calnexin, Calreticulin, CHOP, eIF2α, eIF2αP, none of them 
passed the threshold for significance in their relative expression in both mutant mice. In 
Col9a3Δex3 mice the genes Rgs5, Cdh5 which were associated to oxidative stress pathway in a 
previous study (Suleman et al. 2012), were significantly upregulated. Other genes such as 
Cilp involved in cell proliferation, and Srxn1 and Meox involved in NF-κB signalling 
(Suleman et al. 2012), were also significantly changed in Col9a3Δex3. Another significantly 
upregulated gene in Col9a3Δex3 was Smad2, coding for a protein that mediates the signal of 
the transforming growth factor (TGF)-beta, and thus regulates multiple cellular processes, 
such as cell proliferation, apoptosis, and differentiation (Eppert et al. 1996). Upregulated 
genes in Col9a3-/- included Cilp, Kera, Srxn1, Sox11, Agtr2, involved in cell survival and 
proliferation (Suleman et al. 2012). These observations pointed out that a more in-depth 
analysis of specific genes pertaining specific stress pathways, other than the classical UPR is 
needed to create a more comprehensive understanding of the consequences at the molecular 
level of these two mutations in collagen type IX.  
On another note, from RNAseq data we could notice the upregulation of the genes Lox (Lysyl 
oxidase), Loxl1(Lysyl oxidase-like 1) and Loxl2 (Lysyl oxidase-like 1) in both mutant mice 
(data not shown). These are members of the lysyl oxidase family of genes which encode 




collagen and elastin chains. This finding reminded of the involvement of LOXL3 mutations in 
the onset of Stickler syndrome (Chan et al. 2019). Moreover, biallelic mutations in COL9A1, 
COL9A2, and COL9A3 cause autosomal recessive Stickler syndrome. In this respect, 
previously described collagen type IX null mice were found with reduced auditory function, 
reproducing the hearing defects reported by patients affected by Stickler syndrome 
(Balasubramanian et al. 2019)(Asamura et al. 2005, Suzuki et al. 2005), which in addition to 
the other skeletal defects described, they represent good models of the disease. Notably the 
assessment of hearing impairment in our mutant mice was not addressed, but these findings 
suggest that it would be interesting to investigate the effect of Col9a3Δex3 and Col9a3-/- 
mutations also in the inner ear.  
As mentioned, no collagen type IX was present in Col9a3-/- growth plate, as expected, but 
surprisingly, matrilin-3 and COMP did not appear to be less abundant. This is in contrast with 
what reported previously in Col9a1-/- mice which showed an overall loss of matrilin-3 and re-
distribution of COMP in their growth plate (Blumbach et al. 2008). This observation made us 
question the reliability of the antibodies used, in particular for matrili-3 and in this regard, 
performing a positive control staining, which was not included initially, would be useful to 
ascertain the antibody specificity.  
The most striking observation was the presence of a hypocellular region, a nearly cell-free 
area in the centre of young developing tibial and femurs growth plate, in both mutant mice, 
but less severe in Col9a3Δex3. The hypocellular region was accompanied with a widening of 
the epiphysis, which was consistent with the findings reported previously in Col9a1-/- and 
Col9a2 -/- mice (Balasubramanian et al. 2019, Blumbach et al. 2008, Dreier et al. 2008). TEM 
also provided the first indication of this cell-free areas in both mutant mice, which we were 
able to confirm by histology. However, it has to be kept in mind that the observation through 
TEM came from analysis of only one mouse per genotype, which represents a risk of 
overinterpretation of results. Especially if we cannot exclude that those areas might also be a 
sectioning artefact or a cut through the edge of their secondary ossification centres. However, 
the histological findings and the absence of such area in TEM of WT growth plate make us 
consider the TEM observations reliable. Notably, mice carrying a targeted deletion of oxygen 
sensitive transcription factor HIF-1α presented acellular regions in the growth plate cartilage 
(Schipani et al. 2001) similar to those detected here in Col9a3-/-  and those of the other 
collagen type IX null mice.  HIF-1α transcription factor is one of the major regulators of the 




development, as the central regions of the growth plate become hypoxic and as a result cells 
express HIF-1α which mediates their survival in such condition. The hypothesis provided 
previously regarding the origin of such regions was considering that cartilage is an avascular 
tissue, and it is supplied with nutrients and oxygen only by diffusion. Therefore, the widening 
of the bones of collagen type IX null mice increases the diffusion distance, possibly leading 
to an undersupply with nutrients and/or hypoxia within the central region, despite no increase 
in cellular apoptosis was detected as possible explanation for such reduced cell density 
(Blumbach et al. 2008). On the contrary, considering that cell-free areas were found in both 
Col9a3Δex3 and Col9a3-/-  growth plates, but not widening of epiphysis was noticed in the mice 
carrying the exon 3 deletion, and taking into account the reduced proliferation detected in 
both mutant mice, we can speculate the lower cell density to be due to reduced cell division 
rather than a cell death induced by impaired diffusion of nutrients. Therefore we think that 
the analysis of cellular apoptosis in both mutant growth plates, which is lacking in this thesis 
work, will add to the understanding of the origin of these hypocellular areas. In addition, the 
localisation of other important ECM components and related collagen type IX interactors, 
could give new insights on the complex ECM network and how it affects important signalling 
pathways involved in cell viability. This could help understand if such a region is a 
consequence or the cause of the skeletal phenotype.  
From gene expression analysis, we could not detect possible compensatory effects of 
collagen type IX related proteins in Col9a3Δex3 and Col9a3-/- mice. Nonetheless, the 
observation of the upregulation of Fgf13 gene and downregulation of Fgfr3 in Col9a3Δex3 
suggested variations in the FGF growth factors signalling pathway, one of the major systems 
for cellular communication throughout development, life, and disease. More than eighteen 
different FGF ligands transmit extracellular signals through interaction with four receptor 
tyrosine kinases, FGFR1–4, which exert different physiological functions due to the 
differences in their temporal and spatial distribution of expression (Johnson and Williams 
1993). FGFR3 is expressed in different tissues, but its major physiological function seems to 
be the regulation of cartilage growth. In this regard, evidence showed FGFR3 to be a 
physiological negative regulator of skeletal growth, which restricts the length of long bones 
via inhibition of chondrocyte proliferation. Fgfr3 null mice have long bone overgrowth due to 
expanded zones of epiphyseal growth plate cartilage, caused by increased chondrocyte 
proliferation (Colvin et al. 1996). Gain of function mutations in FGFR3, resulting in its 




achondroplasia (Shiang et al. 1994). Moreover, the process of chondrocyte transition from 
proliferation to hypertrophy depends on the intricate cross-talk between the Ihh and PTHrP 
signalling pathways, and FGFR3 is known to mediate the downregulation of this pathway and 
inhibition of Ihh/PTHrP signalling due to aberrant activation of FGFR3 contributes to 
disrupted chondrocyte differentiation. Col9a3Δex3 mice presented enlarged hypertrophic zone, 
but their chondrocytes proliferation was reduced, therefore we could deduce that such 
enlargement is probably due to a decrease of the number of chondrocytes exiting the 
hypertrophic zone, rather than an increase of new proliferative chondrocytes entering it. For 
instance, Fgf2, which is a ligand for Fgfr3, has been reported to inhibit chondrocytes terminal 
differentiation (Kato and Iwamoto 1990). In addition, the early differentiation status detected 
in Col9a3Δex3 secondary ossification centres, offers ground for speculation about changes in 
Ihh and PTHrP cross-talk, possibly due to a reduction of the inhibitory effect of FGFR3 on 
the Ihh/PTHrP pathway. The link between collagen type IX and Ihh/PTHrP signalling was 
already reported in a study showing that during the embryonic development of the spine in 
collagen type IX null mice (Col9a1-/-) an imbalance in the Ihh-PTHrP signaling pathway 
leads to an accelerated hypertrophic differentiation. Researchers concluded that the changes 
of collagen fibril interactions and the matrix structure of collagen type IX null mice are the 
cause of a disturbance of signal molecule diffusion or presentation, creating for example an 
imbalanced Ihh–PTHrP feedback loop (Kamper et al. 2017). This finding would correlate 
with our observation of an earlier differentiation state of chondrocytes in the secondary 
ossification centre found in young Col9a3Δex3 growth plates. Although in the study it was 
hypothesised that the accelerated hypertrophic differentiation may result in a higher bone 
mineral density in the vertebral bodies of newborn Col9a1-/- mice and, give rise to the early 
onset of disc degeneration previously reported in these mice (Kamper et al. 2016). This 
would be in contrast with the lower trabecular bone phenotype found in tibia and femur of 
Col9a3Δex3mice, despite we are considering different tissues at different stages of 
development. 
Studies to unravel the role of FGF13 in the development of the skeletal muscle have shown 
that it plays a negative regulatory role in the process of myogenic differentiation (Lu et al. 
2015). The upregulation of the Fgf13 gene then might be the indication of an alteration of the 
correct skeletal muscle development in Col9a3Δex3 mice, leading to a possibly weaker and 
underdeveloped muscle in these mice, recalling the above considerations about myopathy and 




reduced expression of other two genes coding for important receptors involved in FGF 
signalling, Fgfr1 and Fgfr2 (data not shown).  In mice, targeted ablation of Fgfr2 impairs 
postnatal long bone growth, suggesting that Fgfr2 acts as a positive regulator of endochondral 
bone formation at the growth plate (Eswarakumar et al. 2002, Yu et al. 2003). In contrast, 
activating mutations in FGFR1 cause osteoglophonic dysplasia, another short-limbed skeletal 
dysplasia in humans, raising the possibility that FGFR1 acts as a negative regulator of 
skeletal growth (White et al. 2005). Recent studies have also demonstrated that mice 
conditionally deleted for FGFR1 in osteo-chondro-progenitor cells display an increased 
hypertrophic zone size, probably due to a decrease in the rate of cartilage resorption and 
ossification (Jacob et al. 2006). This would further contribute to the explanation of an 
enlarged hypertrophic zone in Col9a3Δex3 growth plate. 
Despite these findings, the fact that RNAseq was performed on isolated rib chondrocytes, 
rather than on cartilage of load-bearing anatomical regions, such as the knee, could be 
considered a limitation of our analysis. A histological analysis to verify if the ribs cartilage 
follows the same tissue pathology recognised in the growth plate, was not addressed during 
this work. Indeed, it is very probable that our analysis did not define the expression changes 
of genes and pathways that are a consequence of the mutations in a site-specific manner.  
When we assessed the ECM stability in our mutant mice we started from the hypothesis that 
the expression in Col9a3Δex3 mice of a collagen type IX molecule carrying a mutation in the 
COL3 domain, as well as the absence of the entire molecule in Col9a3-/-, would affect the 
stability of other direct interactors of collagen type IX present in the ECM of these mutant 
mice. In particular we investigated changes in the extractability of matrilin-3 and COMP, 
along with collagen type IX, as indication of alterations to their anchoring or associations and 
of the overall functional properties of the tissue. However, when we verified this hypothesis 
analysing the sequential extraction protein profiles of our mutant mice cartilage extracts, only 
in Col9a3-/- mice we noticed differences in the extractability of only matrilin-3. This 
confirmed the impact on cartilage stability of the absence of collagen type IX protein. Our 
analysis did not add information on the consequences of the insertion of collagen type IX 
with a mutant COL3 domain on matriln-3 and COMP anchoring, which we could not detect 
through this analytical method. Conversely, the same method resulted efficient when was 
used previously for similar purposes in other mouse models of PSACH-MED.  In this study, 
the cartilage protein extraction profile of the previously generated targeted mouse models of 




COMP (Comp T585M and Comp DelD469) (Pirog-Garcia et al. 2007, Suleman et al. 2012) 
was investigated. Their Western blot analysis of sequentially extracted knee cartilage 
revealed genotype-specific differences in the extraction of a number of proteins that are all 
known to interact with each other. Among these, they were able to demonstrate that collagen 
type IX was more easily extractable from Comp DelD469 and Comp T585M cartilage, 
suggesting that it may be less tightly integrated into the ECM of these animals, implying an 
effect on overall integrity of their cartilage. In the same study they detected increased 
extractability of matrilin-3 and COMP, with some variability of extraction in different 
conditions and of their molecular forms, giving insights on protein processing and 
detrimental molecular mechanisms which might be responsible for the disease. 
Demonstrating indeed that the mutation of matrilin3 or COMP can induce changes to the 
extractability of other cartilage proteins, confirmed a close functional relationship between 
matrilin-3 and COMP and FACIT collagens, in particular collagen type IX, in the 
chondrocyte pericellular matrix and that disruptions to this network might be a key disease 
trigger in cartilage degradation (Bell et al. 2013). The conclusions obtained in that study were 
the result of an integrated approach involving also analysis of protein from isolated 
chondrocytes and semi-quantitative proteomic analysis, which defines our investigation 
incomplete and suggests that a similar approach could help elucidate the results obtained by 
sequential extraction. 
Consistently with the results obtained by sequential protein extraction and proteomic 
analysis, the visualization by electron microscopy of the cartilage from the same three mouse 
models has previously demonstrated changes in the morphology of the ECM (Leighton et al. 
2007, Pirog-Garcia et al. 2007, Suleman et al. 2012). In particular, the collagen fibrils were 
more clearly visible, suggesting that lower levels of fibril surface-associated proteins were 
decorating individual collagen fibrils. 
When we assessed the matrix stability of Col9a3Δex3 mice, such trait was not observed, as we 
did not detect any striking difference in the collagen fibrils, the protein extraction profile of 
matrilin-3 and COMP, or any worsening of OA-like cartilage damage due to DMM or ageing. 
Despite this, taking into account all the weak points of our methods, we cannot fully conclude 
that Col9a3Δex3 joints do not replicate the early onset OA trait often diagnosed in MED 
patients. Likewise, Col9a3-/- mice displayed less abnormalities than expected, in terms of 
collagen fibril appearance. We did not observe on TEM more exposed collagen fibrils, but 




with previously reported evidence of collagen type IX role in limiting fibrils diameter, which 
then tends to increase in its absence (Blumbach et al. 2009), was not supported by AFM 
observations, implying the risk of overinterpretation of TEM findings only based on n=1 
biological replicate. An OA-like phenotype is well recognised in the joints of other functional 
collagen type IX knockouts, with Col9a1-/- knee joints developing OA changes already at 3 
months of age, which then become severe by 12 months of age. Surprisingly, in Col9a3-/- 
knee joints we could not detect a similar OA phenotype in either DMM stressed 18-week old 
or in unchallenged aged 12-month old knee joints. However, our analysis was limited to only 
one tissue joint, and is probably missing changes in cartilage damage in other joints. In 
addition, no real conclusions about the ageing effect on development of OA could come from 
an underpower study, as no power analysis was performed to identify the correct number of 
animals needed to reach a significant result. AFM indentation test revealed reduced 
nanostiffness in both mutants, which was particularly pronounced in Col9a3-/-. This result 
demonstrated that the mutation of collagen type IX and more importantly its absence, has a 
severe effect on the mechanical properties of the cartilage tissue, probably realised by 
affecting the distribution and interaction of other matrix components as well as collagen type 
II fibril diameter. It remains unclear why DMM, ageing or sequential protein extraction 
showed little effect while the mechanical stiffness of the Col9a3-/-cartilage was profoundly 
affected by the mutation. 
To conclude, we have generated and described the first mouse model for MED caused by 
splice sites mutations in Col9a3 gene. These mice, despite genetically reproducing the 
patients’ mutations molecular result, present very little phenotypic abnormalities which 
partially, but not completely, mimic patients’ phenotype, at least based on our current 
analysis.  Considering that collagen type IX mutations cause a very mild form of MED in 
humans, we questioned if using mice to replicate such disease is the appropriate approach to 
undertake. The phenotype expressed by collagen type IX null mice further confirmed the 
importance of this protein for the stability of cartilage. In addition, their phenotype resembles 
some features of patients null for collagen type IX who experience Stickler syndrome. This 
suggested that a mutant collagen type IX protein retains many of the functions of the wild-
type protein within the ECM, explaining the limited phenotype observed in the Col9a3Δex3 
mice. Both these mice represented novel tools to gain insights on collagen type IX structure 
and function, however we were unable to sufficiently expand our understanding of MED 






Appendix A: Buffers 
0.5 % Acid alcohol:  
0.5% v/v Hydrochloric acid in 70% ethanol 
Tris-Acetate-EDTA Buffer (TAE):  
0.04M Tris (pH8), 5.7% (v/v) glacial acetic acid and 0.001M Methylenediaminetetraacetic 
acid (EDTA) 
Loading Buffer: 
(Tris 0.125M (pH 6.8), 10% (v/v) glycerol and 0.001% (w/v) bromophenol blue) 
Tris buffered saline -Tween (TBS-T):  
150mM NaCl, 10mM Tris Base pH7.4, 0.1% (v/v) Tween-20) 
5X Laemmli sample buffer: 
0.1M Tris-HCl, pH 6.8, 0.35M SDS, 20% (v/v) glycerol, 0.01% bromophenol blue and 10% 
(v/v) β-mercaptoethanol 
Towbin transfer buffer: 
25mM Tris Base, 192mM Glycine, 20% Methanol 
Toluidine blue:  
0.04% (w/v) Toluidine Blue, 0.1M sodium acetate buffer pH 3.75 
5X 0.1M Borate Buffer (pH 8.5): 





Appendix B: PCR Programs 
 
Table. B.1 | PCR program for generation of sgRNA mRNA. 
Step Temperature Time 
n˚ of 
cycles 
Initial denaturation 98 ˚C 30 seconds 1 
Denaturation 98 ˚C 7 seconds 
25 Primer annealing 50-72 ˚C 15 seconds 
Elongation 72 ˚C 50 seconds 
Final elongation 72 ˚C 2 minutes 1 
Hold 10 ˚C ∞ 1 
 
 
Table. B.2 | PCR program for mice genotyping and cDNA amplification. 
Step Temperature Time 
n˚ of 
cycles 
Initial denaturation 98 ˚C 30 seconds 1 









Elongation 72 ˚C 10 seconds 







Appendix C: Antibodies 
 

























































Thermo Fisher Scientific A11073 Goat 1:200 
Anti-goat IgG H+L 
(AlexaFluor® 594) 




Thermo Fisher Scientific A11037 Goat 1:200 
Anti-rat IgG H+L 
(AlexaFluor® 488) 










Appendix D: Tissue processing programme 
 
















Step  Solution Time 
1. 70 % Ethanol 6 hours 
2. 90 % Ethanol 45 minutes 
3. 95 % Ethanol 45 minutes 
4. 100 % Ethanol 45 minutes 
5. 100 % Ethanol 45 minutes 
6. 100 % Ethanol 45 minutes 
7. Xylene 30 minutes 
8. Xylene 30 minutes 
9. Xylene 30 minutes 
10. Paraffin wax 1 hour 




Appendix E: Supplementary material  
 
RNA quality determination for RNA sequencing 
Before proceeding with RNA sequencing and generating reliable gene expression profiles, 
the quality of the RNA provided by each sample was verified by analysis using an Agilent 
Technologies 2100 Bioanalyzer. This analysis provides an RNA integrity number (RIN) 
value indicative of RNA quality (and the degree of degradation). Samples with RIN > 8 were 
recommended for following RNA sequencing.  
The electropherograms and gel images provided by the Bioanalyzer showed that all samples 
and controls were of good quality. One peak corresponding to the marker and other two 
peaks, of 18S and 28S RNA, were detected for all samples, and no other peaks (indicative of 
RNA degradation) were observed. All RINs assigned were then higher than 9 and all samples 
passed the quality control check and were subsequently processed for sequencing.  
  
 
Fig. E.1 | Results of RNA integrity analysis from ribs chondrocytes. 
RNA samples (n=4 per genotype) quality was checked before sequencing. Two bands 
denoting the 18S and 28S ribosomal subunits were detected on the Agilent 2100 Bioanalyzer 
gel images in all RNA samples and no other bands corresponding to degraded RNA were 
observed. All samples RINs were above 8 and passed quality control. All samples were 








Fig. E.2 | Extractability of some ECM proteins in other mice. Femoral head cartilage was 
sequentially extracted from 3-week old WT and mutant Col9a3Δex3 and Col9a3-/- mice using a series of 
three buffers: Buffer I, II and III. Proteins were separated by SDS-PAGE under reducing and non-
reducing conditions and analysed by Western blotting using antibodies specific to the NC4 domain of 
α1(IX) (Collagen Type IX-NC4), Matrilin-3 (Matn-3) and COMP denotes differences detected in 
protein extraction profiles between mice of different genotypes; Each blot represents one biological 








Fig. E.3 | Collagen fibrils thickness. Under polarised light collagen fibrils stained with 
picrosirius red appear red, orange yellow or green depending on the thickness of the fibril, decreasing 
in thickness from red to green. Fibrils diameter is similar to WT in Col9a3Δex3 but slightly reduced in 








Fig. E4 | Western blot of cartilage protein probed with antibody against α1 (IX). Image 
showing full blot of results section 3.7 Fig. 3.9. MW= molecular weight. Blot repeated four times 
using four different biological replicates and no indication of lower protein amount was noticed in 
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